




Bone-resident mesenchymal stromal cells in 
healthy ageing and osteoarthritis: enumeration 





Submitted in accordance with the requirements for the 
degree of 
Doctor of Philosophy 
 
 
The University of Leeds 
 















The candidate confirms that the work submitted is her own, except where work which 
has formed part of jointly authored publications has been included. The contribution of 
the candidate and the other authors to this work has been explicitly indicated below. 
The candidate confirms that appropriate credit has been given within the thesis where 
reference has been made to the work of others. 
 
The work in Chapter 3 and 4 of the thesis have appeared in publication as follows: 
 
The analysis of in vivo aging in human bone marrow mesenchymal stromal cells 
using colony-forming unit-fibroblast assay and the CD45lowCD271+ phenotype 
Stem Cells International, August 2019  
 
Authors: Payal Ganguly, Jehan J El-Jawhari, Agata N Burska, Frederique Ponchel, 
Peter V Giannoudis and Elena A Jones 
 
I was responsible for: Experimental design, sample collection, performing experiments, 
analysis of data and manuscript writing. 
 
Work attributed to others: study conception and design (JEJ, ANB, FP, and EAJ); 
sample collection (PVG), analysis and interpretation of data (JEJ, ANB and EAJ), 
manuscript preparation and final draft (EAJ), response to reviewers and revisions 
following peer review (EAJ). 
 
 
This copy has been supplied on the understanding that it is copyright material and that 
no quotation from the thesis may be published without proper acknowledgement. 
 



















I would like to begin with a big thank you to my main supervisor Dr Elena A Jones not 
only for giving me the opportunity to work on such a globally relevant project but also 
for guiding, encouraging, criticising, appreciating and understanding my approach at 
different stages of the project. Apart from being a thoroughly professional and an 
extremely efficient scientist, I wish to thank Elena for her commendable leadership 
qualities that has maintained a successful research group of PhDs, postdocs, 
consultants and experts from across the globe. She is one of those very rare bosses 
who have the right mix of compassion, strength, vision and motivation and the world 
desperately needs more of people like her, more leaders like her.  
 
I am very grateful to Leeds Institute of rheumatic and musculoskeletal medicine 
(LIRMM) for offering me the scholarship and the opportunity to work with people who 
are best in the field and also with people who will undoubtedly, be the best in the field, 
in  the coming years (contemporary PhD students). A big thank you to University of 
Leeds (UOL) for being among the most accepting and inviting Universities I have been 
a part of. UOL pride themselves on their diversity of students and my personal 
experience will vouch for that. I have met some of the most brilliant minds of the future 
pursuing a PhD in subjects varying from literature to molecular medicine, from 
childhood studies to chemical engineering, from water law to plant genetics and many, 
many more. May this diversity of knowledge keep growing every year! 
 
I would like to extend a big thank you to my postdoctoral supervisors Dr Jehan J El-
Jawhari and Dr Agata N. Burska for their unending patience during my laboratory work, 
analysis and writing phase and for supporting me through and through during the 
difficult phases of the PhD. Jehan also played a significant role in my understanding of 
flow cytometry and Agata’s inputs were vital for the gene expression and the novel type 
1 interferon based chapter. None of this work would have been possible without 
Professor Peter V. Giannoudis, his patients and the team of surgeons and nurses in 
Leeds General Infirmary (LGI).  
 
Next, I want to thank the entire MSC research group for being my 4th, but easily, the 
best research group I have worked with till date. Dr Dennis McGonagle, Dr Thomas 
Baboolal, Dr Richard Cuthbert,  Dr Ala Altaie, Dr Weichao Rachel Zhai, Dr Clara 
Sanjurjo-Rodriguez and Dr Charlie Bridgewood, Dr Yasser-El-Sherbiny for constructive 
criticism during lab meetings. My colleagues (and friends) Dr Heather Owston, Dr  




Thomas Scambler, Dr. Devon Smith, Mr Samuel Lara Reyna, Mr Jonathan Holbrook, 
Mr Georgi Georgiev and Dr.Katrina Moisely. Dr Heledd Haf Jarosz-Griffith, Dr Emily 
Caseley, Miss Zoe Wigston, Miss Chen Xia-Dong, Miss Rujiraporn Pitaksalee, Mrs 
Rekha Parmar and Dr Chi Wong for being very friendly and helpful and co-workers. 
Miss Priyanka Dutta for her encouragement and warmth and Miss Shelly Pathak, Miss 
Tejal Bhatt and Mrs Rekha Parmar for all the times they have pampered me, 
introduced me to the lovely members of their families and have been there to listen and 
counsel me through difficult situations. 
 
I wish to thank my colleagues from the haematology department for encouragement, 
guidance, support and help at every stage needed. Dr Sophie Stephenson, Dr Amel 
Saadi, Dr Marjorie Davison, Dr Katie Holmes,  Dr Rebecca Ross, Dr Adewonoula 
Alase, Dr Mario Cocco, Dr Claire Mckinley, Dr Ruth Kennedy, Dr Jorge Jimenez 
Lucias, Miss Naomi Gibson, Miss April Baral, Miss Bethany Kuszlewicz, Miss Emma 
Adams, Mr Nate Lee, Mr Fraser Thomas, Miss Nicole McDermott and Mr Kieran 
Walker, it has been an absolute pleasure knowing them. I want to convey a huge thank 
you to the flow cytometry facility in-charge Miss Liz Strszynski and Dr Adam Craig 
Davison, Dr Claire Taylor for very patiently going through the intense process of using 
a new equipment and guiding Dr Raechel Barlow for carrying out the enormous task of 
a laboratory manager for a busy floor as ours. Mrs Angela Greenbank for being very 
patient and always helping us out with reimbursement forms, meeting room bookings 
and for always greeting everyone with a bright smile. 
 
Outside of work, I owe a generous thank you to Prof Claire Chambers not only for her 
insights on PhD life in general but also for introducing the benefits of Zumba in my life. 
It helped me keep sane through the entire PhD process and today, I cannot imagine 
my life without it. She has also played a vital role in talking me through the difficult 
times of the PhD. I would like to thank Dr Kathleen Wright, Dr Amrisha Pandey, Dr 
Lana Lai and Dr Rohit Thakur for their constant inspiration and motivation. Miss Kamla 
for her warmth, monthly supply of hand-made desserts and for introducing me to so 
many people, whom I now call friends. Miss Ambika Kapoor, Miss Richa Yeshevekar, 
and Miss Arththi Sathnanthar for all the regular catch-ups.  Dr Kanhu Charan 
Pattnayak, his wife Lipsa and their daughter Samvidha for keeping me in their prayers 
and for looking out for me during the PhD. Dr Wei Goh and Mr Joey Mark Diaz, Dr 
Gnosi Michiladou and Miss Shuang Wang for their friendship. 
 
Apart from the friends at University, I owe a generous thank you to all my house mates 




Ingram and Mr. Dominic Flower , Miss Lorienne-Doyle Maw, Miss Aysha Panter and 
Miss Sophie Roche for being very considerate housemates. It is going to be very hard 
to find housemates like all the people mentioned above. 
 
Miss Shelly Pathak for keeping up with nearly every phase of my PhD, for introducing 
me to her lovely family, offering help of every possible kind and for ensuring I had a 
home away from home in Leeds, especially during the festive seasons. I am very 
grateful for her friendship. Dr Akhil Krishnan, Miss Manasi Inamdar, Miss Nanda Rohra, 
Mr Saurabh Patil and Miss Tejal Pant for the continuous flow of care and positivity, for 
the warmth and love, for ensuring that we caught up every month, for being the source 
of laughter and for being a guardian angel since 2014, respectively, even from 4,528 
miles away! Dr Susmita Basak for her unconditional support and Miss Anusha 
Sundaram for being in touch nearly every week in good and bad times. 
 
Finally, my family back in Mumbai without whom this would have in no way, been 
possible. My father, Mr Ramkrishna Ganguly for believing in me even when I did not, 
for being a constant source of motivation, inspiration, critique and for giving my sister 
and me the best life lessons on hard work and not giving up. My mother, Mrs Sumana 
Ganguly for her never ending strength, resilience, and unconditional love. Her 
dedication for dance inspires anyone and everyone who knows her and I cannot thank 
both my parents enough for putting up with me for nearly 3 decades now. Last, but not 
the least, a very big thank you to my younger sister, Miss Bitan Ganguly for being the 
light of my life, my strength during my weakness and my dose of good thoughts when 
situations were not the best. Her ability to comprehend situations at her tender age and 
her passion towards things she believes in, have always pleasantly surprised me. I 


















Ageing considerably reduces the quality of life with osteoarthritis (OA) being the most 
common age-related degenerative disorder. Whilst majority investigations have 
focussed on cartilage changes in OA, damage in the bone preceding cartilage damage, 
is increasingly being acknowledged. Bone and cartilage arise from progenitor cells 
called mesenchymal stromal cells (MSCs) resident in the bone marrow (BM). It was 
hypothesised that changes in BM MSCs contribute to OA development. It was aimed to 
investigate changes in BM MSCs in healthy ageing and then explore if these changes 
were aggravated in OA using flow cytometry for the CD45lowCD271+ phenotype and 
gene expression. 
 
Minimally-expanded/uncultured MSCs were used to avoid effects of in vitro ageing due 
to culture expansion. BM aspirates from 51 healthy donors (19-89 years old) were 
processed for MSC quantification using colony forming unit fibroblast (CFU-F) assay. 
For OA investigations, MSCs from donors with hip OA (56-83 years old) were recruited. 
Gene expression of MSC multipotentiality genes, genes associated with cell 
senescence and type 1 interferon (IFN1) pathway genes was compared between 
CD45lowCD271+ MSCs and donor-matched control CD45+CD271- haematopoietic 
lineage cells (HLCs).  
 
MSC numbers declined with advancing age as measured by both assays but a more 
prominent decline was noted using CFU-F assay. Colony size and integrated density 
significantly reduced in old donor MSCs indicating age-related decline in MSC 
proliferation. When cultured in media with old donor serum, young and old donor MSCs 
displayed lower proliferation. IL6 expression from old donors displayed 4-fold increase 
in both MSCs and HLCs. IFN1 genes displayed strikingly high expression but no age-
related changes in MSCs. In OA, number of genes displayed significant differences 
including LepR, CXCL12 and IL6 as compared to healthy old donor MSCs. Surface 
marker expression of CD106 and CD295 were found to decline significantly in MSCs 
and a similar trend for CD295 decline was observed in HLCs. Age-related increase in 
IL6 expression was aggravated more notably in MSCs.  
 
In summary, age-related decline was observed in MSC number and proliferative 
capacity while gene and surface marker expression displayed non-significant 
differences as compared to donor-matched HLCs. These data indicate that BM MSCs 
are potentially more resistant to ageing stimuli in vivo compared to other BM resident 
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Chapter 1 Introduction 
1.1 Ageing 
Ageing in simple terms, is the process of growing old. This process however has been 
found to be a result of complex changes within an individual. Growing old has 
increasingly been associated with decline in strength, loss of physical fitness and 
increased vulnerability to diseases, all of which eventually lead to a gradual 
deterioration in the quality of life (QOL) (1). Diet, lifestyle, physical activities, heredity, 
epigenetics and environment, all of these factors are believed to contribute to this 
decline in QOL (2, 3). World Health Organisation (WHO) reported in 2018 that the 
“proportion of the world’s population over 60 years old will nearly double from 12% to 
22%” within a span of three decades (4). The report also outlines that by 2020, the 
number of people aged over 60 will outnumber children below the age of 5, suggesting 
a huge shift in the global demographics. The United Nations (UN) estimates over 3 

















Figure 1.1 Projections of global ageing 
Increase in number of people aged over 60 over the next few decades until 2100, 






In mid-2014, the United Kingdom (UK) was identified as having an ‘ageing population’ 
when the average population age exceeded 40 years old (6). Age UK also points out 
that 37% of the carers for old people are themselves old and over 72% of them have 
reported pain or discomfort while providing care (7). The office of national statistics 
(ONS) predicted in 2017 that by 2039, nearly 74 million of UK population will be over 
the age of 60 (8). The office for budget responsibility predicts that the public spending 
between 2019/20 and 2064/65 will increase by £79 billion to meet the needs of the 
ageing population. 
 
The fact that increasing age has been associated with increased frailty (an elevated 
risk of decline in health and function (6)) has led to an increased interest in 
understanding the mechanisms of age-related changes in the past few decades. In 
2013, a pioneering paper ‘the hallmarks of ageing’ was published summarising nine 
major age-related changes at the cellular and sub-cellular levels. These were grouped 
into main three themes: cellular senescence, genetic instability and stem cell 
exhaustion (9). In combination, all these factors caused an increase in individual’s 
vulnerability towards diseases, loss of control over daily activities and overall increased 
time period in recovering from physical injury.  
 
Considering that increasing age has been linked with several types of cancers, 
cardiovascular and musculoskeletal diseases, loss in cognitive functions and neuro-
degenerative diseases, healthcare experts have introduced a concept of ‘healthy 
ageing’ (10), which WHO experts have defined as ‘the process of developing and 
maintaining the functional ability that enables well-being in older age’ (1). In other 
words, even though ageing has been associated with a number of diseases, it is not a 
disease by itself. It is the natural progression of one’s life. Hence, to understand any 
age-related disease, it is vital to first understand the age-related changes in ‘healthy 
ageing’. 
1.1.1 Theories of ageing 
In biological terms, ageing is a complex process of gradual build-up of numerous 
molecular and cellular damages over time. To better understand the process, a number 
of theories have been postulated over the years to explain different aspects of age-
related differences.  
 
The theory of stem cell exhaustion (SCE) outlines the role of stem cells that drive 
tissue regeneration over an individual’s lifetime. It suggests that there is an age-related 




eventually leads to a reduction in body’s ability to regenerate tissues or heal when 
damaged by injury or a disease (9, 11). Stem cells are undifferentiated cells that have 
the potential to differentiate either into any lineage (have total potency or are 
‘totipotent’) or into multiple lineages (‘multipotent’). Most adult stem cells are 
multipotent stem cells (12). Stem cells can be of different origin depending upon the 
tissue source and species they belong to. They can also be categorised as embryonic, 
if sourced from an embryo (ES cells); adult, if sourced from an adult (adult stem cells) 
or can also be induced by reprogramming from mature adult cells to an ES-like state 
(induced pluripotent stem cells, iPSCs) (13). SCE theory of ageing pertains to age-
related changes in adult stem cells. 
 
An age-related decline in the proliferation and regeneration capacities of stem cells has 
been established in the last decade (14) and a number of factors have been proposed 
as contributors. These include deoxyribonucleic acid (DNA) damage and, accumulation 
of toxic metabolites (harmful free radicals) in stem cells themselves and a notable loss 
in the balance between damage and regeneration signals in the surrounding 
microenvironment. Interestingly, one of the main current debates revolves around the 
preferential roles of intrinsic (intracellular) or extrinsic (extracellular) factors on the 
number and basic functions of stem cells. Research focusing on the impact of the 
extrinsic factors within in the stem cell niches (specific anatomies and 
microenvironments within which the stem cells reside) has gained  an increased 
interest owing to parabiosys experiments showing that stem cells in old mice can 
potentially be reversed to be as functional as stem cells in young mice, using systemic 
factors from young mice (15, 16). However, this concept dates back to 1913 when 
Carrel performed experiments to understand ageing of organs with the aim of life 
extension (17). The concept has now gained importance potentially due to an 
increasing ageing population, worldwide. 
 
Damage to the DNA of stem cells is one of intrinsic factors that have been proposed to 
lead to SCE. The theory of DNA damage response (DDR) is among the oldest theories 
aimed at understanding age-related changes at the sub-cellular levels (9, 18, 19). It 
refers to the accumulation of damage in the DNA over time. The structure and integrity 
of DNA continuously gets challenged from both intrinsic factors (for example, 
replication errors and mutations) and extrinsic factors (for example, background 
radiation, cellular microenvironment and reactive oxygen species or ROS), which play 
the role of causative agents of DDR (9). In young people, all the cellular damage/debris 
is automatically eliminated by our body by means of autophagy (engulfment of 




lysosomes (20)), which in older age is shown to becomes less efficient (21). Telomere 
attrition, irreversible arrest in cell cycle (senescence), inadequate response to cellular 
stress are also key factors contributing to DNA damage (22). Interestingly, ROS acts a 
major source of formation of DDR which brings us to the next theory of ageing. 
 
The ROS or the free radical theory was first proposed in 1955 by Harman where he 
suggested that accumulation of cellular damage along with declining integrity of cellular 
components lead to oxidative stress owing to impaired metabolic cycles in old age (23). 
The free radical theory of ageing suggests that damages at the cellular and sub-cellular 
levels are caused by ROS. ROS are generated continuously during regular metabolism 
but are scavenged due to the presence of naturally occurring anti-oxidant molecules 
within our bodies (24). The theory outlines that the accumulation of ROS increases with 
age and overwhelms the ability of protective anti-oxidant molecules to scavenge ROS, 
thus increasing cellular damage and eventually leading to inability of cells to 
regenerate. However, the exact mechanisms that govern age-related changes in 
humans due to ROS are still unknown. Until now, levels of free radicals and anti-
oxidants have been used to estimate the balance between ROS levels and the 
potential anti-oxidant scavengers of ROS but only in culture expanded stem cells (25, 
26).  
 
Recently, ROS, DNA damage and SCE theories have been combined leading to 
various studies investigating age-related changes in hematopoietic stem cells (HSCs) 
within the bone marrow (BM) niche (27, 28). In independent studies, type 1 interferon 
(IFN1) was found to play a role in the clearing of senescent cells (29, 30) and IFN1 
pathway was found to potentially be the link between DNA damage, ROS and ageing 
of HSCs (31). Bone and joint cells are produced and maintained by another type of 
BM-resident adult stem cells (mesenchymal stem/stromal cells (MSCs)) where they co-
exist with HSCs in the same microenvironment. However, the roles of various factors 
like ROS and IFN1, on these stem cells in healthy ageing and age-related 
musculoskeletal conditions, remain unknown and require further investigation.  
 
1.1.2 Age-related conditions – clinical need to understand healthy ageing 
Age-related conditions are a global health burden and combating them is now the 
driving force for many scientists and economists alike. Section 1.1.1 above outlined the 
theories of ageing and potential causes of the age-related damaging effects. In this 
section, some age-related conditions will be discussed in more depth, primarily to 




believe, the co-existence of the numerous theories about the process of ageing, in 
reality, indicates a gap in knowledge on the complexity of ageing and its link to age-
related diseases. However, there is a possibility that in fact, all the theories are 
complementary and/or collectively responsible for the different levels of damages 
(subcellular, cellular and organismal). 
 
There is growing body of evidence that connects different diseases to the process of 
growing old. For example, accumulation of damage over time, via ROS acting at the 
sub cellular and cellular levels have been found to be common between healthy ageing 
and many disease conditions including cancer (18, 32, 33), cardiovascular diseases 
(34-36), neurodegenerative disease (37-39),  as well as diseases of the 
musculoskeletal system (40-42). Figure 1.2 shows how the known factors for age-
related changes can transition to distinct disease conditions, but the main drivers for 









Figure 1.2 Unclear transition from ageing to diseases  
Shared features of ageing and age-related diseases with an unclear path towards 
disease transition (adapted from (43)) 
 
Old age has been linked with many diseases along with the reduction in the QOL of 
older people. Thus, there are scientists who not only consider ageing to be a 
degenerative disease (44), but also propose that ageing must officially be classified as 
a disease by the International classification of disease (ICD) (43, 45). The ICD is the 
classification used by WHO for epidemiology studies and health care management 
globally, the 11th revision being the most updated version (ICD-11). It is a tool that aids 
the monitoring of occurrence of diseases to better understand the healthcare condition 




ICD-11 and rightly so, as the concept of ‘ageing is a disease’ is controversial owing to 
the fact that it is a natural progression of every living being.  
 
In fact, some scientists believe that we begin to ‘age’ right from our conception, even 
before birth. The process is simply broken down into phases of birth, growth, 
maturation, adulthood and old age. This idea has been further promoted by Allison et. 
al who found that pregnant rodents that were treated with anti-oxidants, had off-springs 
that grew old slower than those whose mothers were not given any anti-oxidants (46), 
suggesting that ageing begins from the moment we are conceived. While advanced 
age leads to considerable frailty, not every old person is frail. These variations are due 
to the different environmental factors, genetic make-up and life styles that individuals 
lead.  
 
Among the diseases associated with old age, diseases of the musculo-skeletal system 
impacting the bones and joints may be considered the most incapacitating diseases 
worldwide. The WHO reports that osteoarthritis (OA) is the most common degenerative 
disease in older population (47). While the disease has primarily been described as the 
degeneration of cartilage with negative impact on the other joint tissues, recent 
evidence suggests that the damage to bone plays a key role in the disease progression 
(48). The disease has largely been identified by degenerating cartilage, stiffness and 
pain. Increasingly along with these, subchondral bone sclerosis, bone marrow lesions, 
increase in bone volume but low mineralisation due abnormal bone remodelling 
(explained in section 1.1.4) have gained recognition as hallmarks of the disease (49, 
50), even though the debate as to if these hallmarks are the causes or the effects, are 
still active. 
1.1.3 Bone and bone marrow  
The skeletal system consists of bones, cartilage, tendons, ligaments and connective 
tissues. It forms the framework of our bodies and provides us with basic structure and 
support. Apart from protecting our internal organs, it is also responsible for our 
locomotion in daily lives. Bones in particular perform mechanical functions along with 
serving as the reservoir for the hematopoietic marrow and a reserve for calcium. At this 
given point of time there are 16,334 active clinical trials globally that are aimed to 
restore bone and bone related conditions (51).  
 
Structurally, the bone contains inorganic mineral depot and organic extracellular matrix, 
lipids and water. The organic components include abundant quantities of collagen, 




bone is majorly hydroxyapatite (Ca10(PO4)6(OH2)) (52). The composition involving both, 
the organic and inorganic components enable the bone to have both, mechanical 
strength as well as flexibility for movement. The inside of the bone is a very dynamic 
environment with various types of cells residing and interacting with one another. The 
bone marrow (BM) within the bone is also where stem cells reside, making it one of the 
most important organs in the body.  
 
The BM exists within the trabecular spaces in the cancellous bones (such as the iliac 
crest or IC) and in the medullary cavities of the long (cortical) bones. It is contained by 
the exterior (cortex) of the bone and includes a complex mesh of blood vessels, cells 
and fatty tissue. This micro-environment within the bone forms the ‘niche’, where BM 
stem cells reside (53). As mentioned, the BM houses two types of adult stem cells and 
their progenies: HSCs and MSCs. HSCs originate in the aorta-gonad-mesonephors 
(AGM) region in the embryo and migrate to the liver and then to BM  (54-56), where 
they reside and self-renew for the rest of the adult life. BM HSCs give rise to progenitor 
cells of both lymphoid as well as myeloid lineages. Lymphoid progenitor cells further 
give rise to natural killer (NK) cells, T lymphocytes and B lymphocytes. Myeloid 
progenitor cells on the other hand, give rise to monocytes/macrophages, eosinophils, 
basophils, neutrophils, erythrocytes and platelets. 
 
HSCs residing in their BM niche replenish billions of cells every day while maintaining 
themselves over decades, a process known as haematopoiesis (57). The BM or the 
stem cell niche is the microenvironment within which these stem cells reside. The niche 
is known to provide the appropriate conditions, growth factors, temperature, oxygen 
levels to enhance and maintain the cells and their functions within the BM, making it an 
important factor for stem cell formation, function and survival (56). Within the BM or the 
stem cell niche, MSCs also exist which originate from the mesoderm and the neural 
crest, which is a transient embryonic tissue (58).  
 
It has been reported that neural crest cells would migrate to different locations through 
the blood stream including the BM where their arrival would coincide with the arrival of 
HSCs. They continued to be there until adulthood and supported HSCs. There have 
also been reports of these neural crest cells travelling through developing nerves rather 
than via bloodstream. What is definitely known is that regardless of their embryonic 
origins, BM resident MSCs can give rise to bone, fat and cartilage lineages. For MSCs 
specifically, the BM niche can be divided into endosteal and perivascular based on the 
anatomical location within the microenvironment. Endosteal niche is located around the 




perivascular niche is located near the sinusoidal vessel within the BM cavity (59, 60).  
In mice, MSCs have been also topographically linked to CXC motif chemokine 12 
(CXCL12) abundant reticular (CAR) cells that form a network of stromal cells 
connecting endosteal and perivascular niches. MSCs residing at the endosteal niche 
are most likely to be directly involved in the process of bone remodelling (58). 
1.1.4 Bone remodelling and age-related bone loss 
To maintain the integrity of the bone, about 10% of the bone is believed to be 
remodelled each year (61). The process of bone remodelling involves a balance 
between old bone removal and new bone formation. However, with increasing age, the 
rate of new bone formation has been found to fall behind the rate of old bone removal 
leading to the eventual decline in bone formation and reduced functionalities of the 
bone (62). The mechanisms underlying bone remodelling have been extensively 
studied and have revealed the involvement of the RANKL (Receptor activator of 
nuclear factor kΒ ligand)/OPG (Osteoprotegerin) pathway (63). 
 
The cells directly involved in bone remodelling process are osteoblasts (the bone 
forming cells), osteoclasts (the bone resorption cells) and osteocytes, which are fully 
mature  bone cells  embedded within the mineralised matrix (64). Osteoblasts are 
derived from MSCs and are the effector cells largely known for their ability to produce 
bone matrix by the secretion of alkaline phosphatase, type 1 collagen, proteoglycans, 
osteocalcin and osteopontin. They are short-lived and exist and function in clusters 
along the bone surface. Some of the osteoblasts mature over time and get embedded 
within the matrix of the bone to eventually become osteocytes (64). Over the years, 
osteoblasts have been extensively studied in relation to their contribution to age-related 
bone loss and age-related bone diseases (65, 66).  
 
Osteocytes are the most abundant cells embedded deep inside the bone matrix and 
their half-life is estimated to be around 25 years (67). Owing to their deep seated 
location (Figure 1.3), isolation and investigation of these cells pose technical 
challenges. Thus, most of the osteocyte investigations in humans have largely been 
based on histology of stained and fixed specimens or using gene expression for 
osteocyte-specific transcripts. Osteocytes are considered to be the final differentiated 
cells of the osteoblast lineage that eventually perish as a result of apoptosis/necrosis or 
autophagy (68). By gene expression, osteocytes have classically been identified by the 
expression of sclerostin (SOST), matrix extracellular phosphogylcoprotein (MEPE), 
dentin matric acidic phosphoprotein 1 (DMP1) and phosphate regulating neutral 




‘mechanostat’ of the bone that sense and respond to mechanical stress by sending 
signals to osteoblasts and osteoclasts, as well as MSCs, on the bone surface and 
modulate bone remodelling (70). 
 
Osteoclasts are the cells that are responsible for the process of resorption of bone. 
These are multinucleated cells that are derived from the mononuclear progenitors of 
the myeloid lineage from HSCs, that also give rise to macrophages. Discovered back in 
1837, they possess a unique ‘ruffled border’ that is formed by complex finger-like 
projections from the cytoplasmic membrane, which isolate area under the cells to 
release high concentration of acid to dissolve bone mineral (71). The acidic 
environment is achieved by the transfer of H+ and Cl- ions across the borders of the 
ruffles to ensure the dissolution of the non-organic component of the bone to bring 
about bone resorption (72). They are typically identified due to the presence of tartrate 
resistant acid phosphatase (TRAP) by immunohistochemistry (71).  
 
Dysregulation of osteoclast activity can lead to both increased bone mass (if there is 
reduced development or function of osteoclasts) or decreased bone mass (in case of 
their increased development or function). For the purpose of bone remodelling, the 
progenitors of osteoclasts are recruited to the surface of the bone, where they mature 
to form a multinucleated osteoclast, then perform resorption functions and eventually 
die via apoptosis (73).  
 
The process of bone remodelling is brought about by a number of soluble factors that 
recruit the above mentioned cells for executing the process. The key players of this 
process are RANKL, RANK and OPG. RANKL is a protein produced by the osteoblasts 
as well as MSCs, which binds to its receptor RANK on the surface of osteoclast 
progenitors. The binding of RANKL to RANK is essential for the formation and function 
of osteoclasts (71). The formed osteoclasts then begin to resorb the old bone leaving 
behind a portion of the bone pit known as ‘howship’s lacunae’ exposed. Osteoclasts 
eventually undergo apoptosis to end resorption (74). Osteoblasts, then form new bone 
in the bone pit left behind by the osteoclasts for bone formation. OPG, the natural 
decoy receptor for RANKL is also expressed by osteoblasts and MSCs (69). When 
OPG binds to RANKL, the latter is no longer available for binding to RANK on 







Figure 1.3 Bone remodelling  
Figure indicating the different cells involved in the process of bone remodelling. Green 
spindle shaped cells are MSCs that develop into osteoblasts (shown in orange cells 
with blue nucleus) that are associated with bone formation.  Osteoclast precursors give 
rise to osteoclasts (shown in orange multinucleated cells with ruffled borders) that are 
involved with bone resorption. RANK-RANKL binding brings about the process of 
osteoclast formation which will be stopped if OPG (Decoy receptor of RANKL) binds to 
RANK instead (adapted from (75) ) 
 
Bone-remodelling process is therefore tightly regulated and balanced. However, with 
increasing age, this balance appears to be lost and the rate of bone resorption seems 
to exceed the rate of new bone formation leading to age-related bone loss (65). Why 
bone formation rate is reduced in old age remains unclear but it can be speculated that 
it can be due to a decrease in the number or function of osteoblast progenitors, the 
MSCs. 
 
Age-related bone loss comprises of a gradual decline in bone mass and strength in 




fractures in people of older age, especially over the age of 60. Bone loss can be 
measured as lower bone mineral density (BMD), bone volume (BV) and bone thickness 
(BT) on quantitative computed tomography (QCT) and in dual energy X-ray 
absorptiometry (DXA) scans. Of note, age-related bone loss is higher in women after 
menopause as compared to age-matched men (76, 77). It is also believed that women 
begin to lose bone earlier than men and at a greater rate as compared to men, 
potentially due to the role of sex hormones (78, 79). 
 
The age-related bone loss has also been observed parallel to an increase in the 
adipose content within the BM. In fact, age-related shift from bone formation to fat 
formation is potentially the best known age-related change in the BM associated with 
bone loss (80). With the knowledge that bone is a very complex and dynamic organ, it 
can be said that these age-related changes in bone are potentially a combination of 
changes in many cells inside the bone, as well as soluble factors they produce. The 
reduction of growth factors like insulin growth factor (IGF) which is an important 
regulator of osteoblast proliferation and differentiation in the bone matrix in older age 
suggests that the BM microenvironment too plays a part in age-related bone loss (81). 
The bone cells directly involved in the bone remodelling process are mature and fully-
differentiated cells. However, the progenitors of osteoblasts (MSCs) are interestingly, 
also the progenitors of the fat cells within the BM. Thus, a better understanding of age-
related changes in BM MSCs is essential for uncovering the cellular mechanisms of 
age-related bone loss and their contribution to age-related skeletal diseases such as 
OA. 
1.2 MSCs 
1.2.1 Definition, characterisation and CD45-CD271+ phenotype  
Mesenchymal stromal cells primarily originate from the mesodermal lineage in the 
embryo and in the neural crest as outlined in section 1.1.3. MSCs are plastic adherent, 
give rise to bone, fat and cartilage tissues (tri-lineage differentiation potential) and are 
positive for cell surface cluster of differentiation (CD) markers of CD73, CD90 and 
CD105 (82). They were first discovered by Friedenstein et. al in 1970s when he found 
a population of cells within the BM that was highly proliferative, adherent to plastic and 
formed colonies of fibroblasts when seeded at low density (83). Hence, due to the 
growth of these cells as colonies of fibroblasts, they came to be known initially as 
colony forming unit-fibroblasts (CFU-F). The CFU-F assay remains to date, the most 
accepted method for MSC quantification. Since their discovery, MSCs gained a lot of 




abilities (84). MSCs have been subsequently isolated from other tissue sources 
including bone marrow, adipose tissue, synovial tissue and fluid and umbilical cord (85, 
86), but these MSCs remain outside the scope of this thesis.  
 
As of now there are globally over 1150 clinical trials that utilise  MSCs for applications 
varying from the regeneration of the liver (GCT no: 0101062750) to the treatment of 
broncho-pulmonary dysplasia (GCT no:0103683935) (51). Among all the potential 
sources of MSCs, BM remains the most preferred choice for in vitro expansion and 
further application in clinical settings. This is possibly because the BM is the first and 
most reliable described MSC source, even though the frequency of MSCs in the BM is 
very low and ranges between 0.01-0.001% of total nucleated cells (87). Thus they 
usually need to be enriched and cultured in vitro for separating them from other cells 
and in order to obtain sufficient number of MSCs for clinical applications.  
 
In spite of the growing interest in MSCs, there remain discrepancies in the definition of 
these cells. The source of the MSCs, the technique used for their isolation, laboratory 
conditions and many other factors add to this discrepancy. As lack of uniformity can 
give different results for the same experiments in different laboratories or clinical trials, 
there is a need to identify key factors to help define MSCs better. 
 
In 2006, the International society for cellular therapy (ISCT) outlined three minimal 
criteria for defining MSCs in culture. First, MSCs should adhere to plastic, second they 
should be positive for the expression of CD73, CD90 and CD105 and not expressing 
CD45 (pan–leukocyte marker), CD34 (common HSC marker), CD14, CD11b, CD79a, 
CD19 and human leukocyte antigen (HLA) class II. The final criteria for MSCs is their 
tri-lineage differentiation capacity in vitro. For these differentiation assays, plastic 
adherent cells are grown in culture in medium containing factors for osteogenic, 
adipogenic and chondrogenic differentiation for 2-3 weeks. For osteogenic 
differentiation, the level of the enzyme alkaline phosphatase (ALP) found in high 
quantities in bone and Von Kossa or alizarin red stains indicative of calcium deposition 
from developing osteoblasts is quantified (82). For adipogenic assay, the level of oil red 
stain (that stains fat) is measured and for chondrogenic assay, a pellet is formed which 
is then weighed and the amount of glycosaminoglycans (GAGs, indicative of 
chondrocytes) is quantified (88). 
 
While the criteria specified by ISCT have significantly contributed to ensuring the 
uniformity for defining MSCs, there are many factors that were not clearly addressed by 




adhere to plastic. MSCs are not the only plastic adherent cells – fibroblasts, epithelial 
cells, endothelial cells and many others - are also adherent to plastic. The next criteria 
includes the expression of CD73, CD90 and CD105. Even though the ISCT panel has 
long been used for the characterisation of MSCs (82, 89) and they (CD73, CD90 and 
CD105) remain largely stable through in vitro cultures, it has often been criticised due 
to the lack of their cell specificity and due to their presence on other types of cells. For 
example, CD73 and CD105 were found to be expressed by dermal fibroblasts (90, 91)  
and in umbilical vein endothelial cells (92, 93). CD90 too has been found to be 
expressed on many other cell types in the BM, hence paving way for the need of a 
more suitable BM MSC marker. CD90 (Thy 1) is known to mediate cell to cell adhesion 
and is involved in the adhesion of monocytes and leucocytes to endothelial cells and 
fibroblasts (94). Also, it is a recognised marker for embryonic stem cells (95). Thus, 
simply combining the first two criteria, the test for ensuring that cells are MSC is 
unreliable. While some of these markers have been known to decline with in vitro 
culture expansion (96, 97), the investigations of age-related differences of these 
surface markers have not provided any conclusive results. 
 
The final criterion is MSC tri-lineage differentiation ability, in vitro. While this criterion 
focusses on the differentiating ability in vitro, it critically misses out on the quantitative 
evaluation of native or uncultured MSC. Also, culturing MSCs have been shown to alter 
their properties, even at passage zero (P0, cultured but not yet passaged). If the 
criteria have been assigned to cells that adhere to plastic, it automatically means that 
they do not define native MSC that are freshly obtained and are uncultured. Changes in 
cell size, granularity and morphology (98, 99), surface marker expression (97) and 
gene expression (99) have been shown to alter as a result of in vitro culturing. These 
changes have been referred to MSC ‘in vitro ageing’ or ageing induced by culturing 
cells in non-physiological conditions (100), and are further discusses below in section 
1.2.2.  
 
Schneider and Mitsui were first to investigate ‘in vitro ageing’ using cultured fibroblasts 
from young and old donors (101). They found significant difference between fibroblasts 
from young and old donors with respect to cell proliferation, in vitro life span and 
senescence. They concluded that using cultured cells from young and old donors is a 
suitable model for investigating age-related changes in cells prior to culture. While the 
cells used were cultured therefore not devoid of manipulation, their study indicated that 
in vitro culture expansion sensitises cells to two-dimensional (2D) conditions therefore 
early stages of culture expansion better represent the state of cells in vivo compared to 





Owing to lack of clarity in defining uncultured BM MSCs using ISCT criteria, several 
attempts have been made to investigate surface markers that reliably define them and 
can be used for their isolation prior to culturing. Mesenchymal stem cell antigen 1 
(MSCA-1) and CD271 have been proposed to be positive specific markers of MSCs 
(94, 102). Historically, Stro-1 was the first surface marker found to be specific for BM 
MSCs (103).  However, Stro-1 was found to be cross reactive with erythroblasts (103)  
and thus it was used to enrich/identify MSCs in combination with other molecules such 
as CD106 and CD146 (104) or with platelet derived growth factor receptors alpha and 
beta (PDGFR and (105, 106) 
 
CD271 or Low-affinity nerve growth factor receptor (LNGFR) belongs to the tumour 
necrosis factor receptor super family and has been used as a  marker for BM MSCs by 
several independent research groups in the last two decades. CD271 is also known by 
the name of p75 neurotrophin receptor and was among the first receptors of its family 
to be characterised. It has also been suggested to be involved with the functions of cell 
survival and is suggested to be present in abundance during the growth phase (107). 
The phenotype CD45lowCD271+ has been shown to provide best specificity for BM 
MSCs compared to other candidate markers or their combinations (108, 109). In 
contrast to CD73, CD105 or CD90, CD271 is absent on fibroblasts indicating its least 
cross-reactivity with non-MSC adherent cells.  
 
The CD45lowCD271+ phenotype has also shown to fulfil all the three ISCT criteria 
needed to define an MSC, that is, the in vivo expression of CD73, CD90 and CD105, 
plastic adhesion and formation of colonies, as well as tri-lineage differentiation 
following minimal cultivation (110, 111). CD271 has thus become a marker of choice 
for phenotyping BM MSCs. However, using CD45 as a negative marker or using other 
known markers like CD106, CD146 along with CD271 provides better characterisation 
of BM MSCs (112).  
 
1.2.2 Age-related changes in MSCs  
Age-related changes in cultured cells are measured using various techniques as large 
numbers of cells are available for investigation. Quantification of cell numbers (96, 
113), telomere length (114), cell proliferative capacity (115), senescence (116), 
resistance to oxidative stress (117), metabolism (118), alterations in differentiation 
potential (80, 119) are some of the methods that have commonly been employed for 




investigations have been most commonly performed using cultured MSCs from young 
and old human donors. However, the effect of passaging on cells’ behaviour have not 
been commonly considered.  
 
Amongst animal models, Caenorhabditis Elegans or C.Elegans (phylum nematode, 
round worms with simple/non existing organ systems) has been widely studied owing 
to its primitive organ system, ease of use and short life-span which enables 
investigation of age-related changes in the organism during the whole course of its life 
span (120). However, to understand ageing in humans better, physiologically advanced 
animals like mice, naked mole rats, rhesus macques (primates) as well as dogs and 
cats have been used as models (121). Studies like these have immensely contributed 
to our understanding of age-related differences. Nevertheless, due to ethical 
considerations, similar experiments cannot be performed in healthy, functional humans. 
Thus, investigations involving age-related differences in young and old donors remain 
limited to use of (majorly) culture expanded and rarely, uncultured cells. Next sections 
will outline the main considerations for the study of age-related changes in human BM 
MSCs using cultured and uncultured cells.  
1.2.2.1 MSC ageing in vitro (passage dependent) 
As mentioned, age-related changes in human BM MSCs have been historically studied 
using culture expanded MSCs. However, it hasn’t been commonly considered that all 
primary cultured and plastic adherent cells ‘age’ in vitro as a result of rapid cell division 
(98, 101). As MSCs are plastic adherent cells, their in vitro ageing on tissue culture 
flasks and similar consumables is relatively well understood and has been studied 
using proliferation, migration and differentiation assays (98, 122), as well as telomere 
length (114), senescence assays (99) and gene transcripts measurements (99). A 
decline in the proliferative capacities of serially-passaged BM MSCs has been 
observed in various studies (114, 123) along with a change in the expression of certain 
surface markers with in vitro ageing (97). CD106 and CD146 have been associated 
with young or aged MSCs based on culture expansion in vitro. CD106 has been shown 
to either decline in expression (124), increase in expression (125) or to have random 
oscillations (123) with in vitro passaging. CD146 has been shown to decline in serial 
passages with culture expansion (124). CD295 has been shown to be higher in cells 
expanded in culture along with higher levels of Annexin-V indicating increased 
apoptosis in MSCs of later passages (126). Morphologically, MSCs have been reported 
to increase in size, appear more flattened and granulated when expanded in vitro. 




stages with cells in the initial stages of culture expansion (127) along with an increase 
in cell granularity (99) indicative of in vitro ageing and replicative senescence.  
 
Cells in the later passages are known to show greater positivity for senescence, 
indicated by assays like SA--gal (128, 129). Senescence is generally defined as an 
irreversible arrest of cell proliferation (130) and over the years various methods have 
been used to identify senescent MSCs in culture (131).Apart from all of the differences 
mentioned above, the shift towards adipogenic differentiation from osteogenic 
differentiation has also been shown when MSCs were cultured in vitro. Bonab et al. in 
2006 have shown that when donor MSCs are cultured over time in vitro, then both, 
their osteogenic and adipogenic potential decline after 5-8 passages (98).  
 
This clearly suggests that in vitro differentiation studies are more indicative of 
replicative senescence that has accumulated over time rather than resembling the 
actual differentiation capacity of MSCs in vivo towards any lineage. The compromised 
ability of MSCs in later passages to undergo osteogenic differentiation was also 
recently shown by Yang et al. by gene expression (123) and by other researchers 
using in vitro differentiation assays (132, 133). Even though there are reports that have 
shown a decline in in vitro adipogenic potential with increasing MSC culture (99), the 
presence of a ‘fatty marrow’ with advancing age (134) suggests toward an increasing 
adipogenic differentiation of BM MSCs in vivo. 
1.2.2.2 MSC ageing in vitro: donor age dependent 
Summarised evidence from literature outlined in the previous section were performed 
using BM MSCs from early and late passages. The loss of surface some markers or an 
increase in cell size that have been observed during this exaggerated ageing process, 
lead to a hypothesis that similar changes may occur in older donor MSCs in vivo.    
 
This section focuses on studies that were performed on BM MSCs from young and old 
human donors at the same passage, in order to mimic their age-related changes in 
vivo, a little better. A number of studies observed a decline in osteogenic potential 
(135, 136) and telomere lengths in MSCs from older donors compared to younger 
donors  from the same ‘culture age’ (114). With respect to surface markers, an up-
regulation CD264 (137), CD106 (138) and CD295 (126) has been reported from 
cultured cells of older donors when compared to cultured cells of young donors. 
Increased production of ROS along with an increase in the proportion of senescent 
cells was also observed in cultured cells of older donors as opposed to the cultured 





Stenderup et al. examined the various aspects of MSC ageing using cultured cells from 
young (18-29 years old) and (68-81 years old) donors and found an age-related decline 
in the life span of MSCs from older donors (129). Another age-related difference 
observed when MSCs were cultured was the decline in number of MSCs with 
advancing age, potentially indicating that higher proportion of MSCs in older donors 
were senescent (139). These findings suggested that there might be an age-related 
decline in the number of MSCs in vivo potentially due to increased ROS levels, which 
should also be quantified in uncultured cells.   
1.2.2.3 MSC ageing in vivo: animal models 
Our understanding of age-related changes in uncultured MSCs majorly comes from 
animal studies. A number of species have been used to understand broader ageing 
processes in vivo using Caenorhabditis elegans (or C.elegans due to short life-span) 
(140), rodents, naked mole rats and primates (121). Investigations specifically 
regarding the ageing of MSCs have most commonly been restricted to rodents owing to 
feasibility and ease of handling (141). Among these, the shift from osteogenic to 
adipogenic differentiation was shown in the 1990s in senescence-accelerated mice–P6 
(SAMP6) by Takahashi et al. (142). These mice developed osteoporosis within a few 
months after birth suggesting that MSC senescence could lead to the imbalance 
between bone and fat differentiation. 
 
In earlier studies using cultured MSCs, BM MSCs of old C57BL/6 mice (20-26 months 
old) were found to produce higher amount of fat compared to younger (6-8 months old) 
mice (143). BM MSCs from the old female Wistar rats (56 weeks) had increased 
senescence and apoptosis, reduction in proliferative capacity and a decline in bone 
markers as compared to young (3 weeks) rats (144). Interestingly, the authors did not 
find any increase in MSC adipogenesis in the old rats when compared to young rats. 
They found lower number of CFU-Fs in old rats, which was also observed by Katsara 
and co-workers in adult mice (>3 months) in comparison to young (<1 month) mice 
(145) and by Josephson and colleagues in old (52 weeks) mice compared to young (12 
weeks) and old (146). Studies investigating BM MSCs from young (4 months) and old 
(15 months) Sprague Dawley rats, found lower tri-differentiation potential in old rat BM 
MSCs compared to BM MSCs from young rats. The study also observed an age-
related decline in the presence of Connexin43 (Cx43) in BM MSCs, (147) which is the 





In another extensive study, rat BM MSCs were culture expanded to passage 100 and 
various experiments were carried out to understand the link between in vitro ageing 
and chronological ageing of these animals.  BM MSCs from old (12 months) Sprague 
Dawley rats were compared to young (3 weeks) rats (149) and the results showed that 
the MSC migration potential and anti-oxidant capacity were the only parameters that 
decline in both, in vitro and chronological ageing. The osteogenic differentiation 
potential, cell morphology, senescence markers and the expression of genes 
associated with MSC differentiation showed significant changes only in in vitro ageing. 
Authors concluded that chronological ageing and in vitro MSC ageing are distinct 
processes (149). However, based on accumulated evidence from all presented animal 
studies, it is possible to hypothesise that in vitro MSC ageing (passage dependent) 
represents an exaggerated ageing process, some features of which (for example, a 
loss of some surface markers) can be detected in MSCs in vivo. Animal studies have 
also indicated towards a decline in the number and proliferative capacity of BM MSCs, 
mainly in rodents. 
1.3 Osteoarthritis 
1.3.1 Epidemiology 
Osteoarthritis (OA) is among the most incapacitating degenerative diseases in the 
world. In the United States, it is the most common joint disorder and 10% of men and 
13% of women over the age of 60 suffer from OA (150). It is also cited as the most 
common rheumatic condition with a huge impact on population and demographics, 
worldwide (151). Of the 291 conditions examined in the global burden of diseases 
(GBD) study, hip and knee OA are ranked the 11th major contributor, just after diabetes 
and falls (151).  Incidentally, it is also the most common reason for total hip and knee 
replacement (152).  
 
The global cost of OA has been estimated to be very high.  Chen et al., described total 
costs as direct costs (medication, surgery), indirect costs (loss of productivity, absence 
from work) and intangible losses (suffering, decreased QOL and depression). In 2012 
in the UK  alone, just the direct OA costs were recorded as 168 million for drug 
therapies and 872 million for joint replacement surgeries (153). The direct and indirect 
costs of other studies in America and Europe have also revealed considerable amount 
of cost incurred due to OA. As for intangible loss, the level of anxiety, depression and 
loss in personal morale along with decline in QOL is unimaginable (154). And, this 
impacts not only the patient suffering from OA, but also  close family members and the 





Considering the global burden OA imposes, it has been classified under the diseases 
of the musculoskeletal system in four further subparts in the ICD by the WHO. The four 
major categories of OA in the ICD-11 include OA of the hip, OA of the knee, OA of the 
wrist and hand and OA of other joints. Each of these categories are then further 
subdivided on the basis of the cause/origin. These are primary, post traumatic, 
secondary and unspecified causes. 
 
Unfortunately, by the time a patient is diagnosed with the disease, the condition has 
usually progressed considerably. This means, that by the time, the patient has come to 
the doctor with complaints of pain and stiffness, chances are, the patient will certainly 
be given pain relief drugs for pain management and suggested lifestyle changes with 
immediate effect. The other outcome is that the patient will need surgery. Tissue 
engineering applications have seen an increased interest owing to the possibility of 
minimal invasion for joint repair and many biomaterial scaffolds are now available in the 
market (155); however, the attempts are far from becoming the first choice of therapy 
on a global scale. The diamond concept (156) of tissue regeneration requiring a 
scaffold, cells, growth factors and mechanical strength of a given tissue engineering 
platform often faces challenges to be translated from ‘bench to bed’ successfully (157).  
1.3.2 Current understanding of OA 
OA is a degenerative disease that may have several underlying causes. Pain in joints 
is the key symptom for medical attention. WHO’s scientific group on rheumatic 
diseases estimates that 10% of the world’s population aged 60 years or older have 
significant clinical problems that could be attributed to OA (158). 
 
Commonly recognised by stiffness and pain in joints, on pain persistence, radiological 
examination involves measuring joint space narrowing and the presence of 
osteophytes., thinner cartilage lining and inflammation in the area of pain. While there 
are different techniques for imaging in OA, the technique of magnetic resonance 
imaging (MRI) has become a very useful method owing to its ability to evaluate the 
pathology in structures that are not easily visible in traditional radiographies (159). Due 
to these observations, initially, OA was approached as the disease of the cartilage. 
However, it has been recognised as a degenerative disease of the joint owing to the 
involvement of the cartilage, bone, synovium as well as meniscus and ligaments (160). 
 
In a study in 2008 by Quintana and Azkarte, the authors found the prevalence of hip 




stress (165), physical trauma and age (166), all have been associated with the 
progression of the disease. While it is understood that over 45% of men and 55% of 
women over the age of 60 are likely to face OA, it is also established that factors like 
diet, lifestyle, physical exercise, genetics and environment also play an important role. 
A number of common factors have been suggested to link old age and OA. These 
include loss of normal bone structure and increased stiffness in joints (167), oxidative 
stress due to ROS (168), cellular senescence (169) and reduced QOL (170) outlining 
that OA is complex and multifactorial. However, majority of these links have been found 
using cultured chondrocytes and investigations using bone cells remain minimal. 
Considering OA is multifactorial and the number of links found between ageing and 
OA, one may hypothesise that these age-related factors are potentially exacerbated in 












Figure 1.4 Age-related factors that can potentially contribute to OA 
 
 
The most common way to define OA radiographically is by the use of Kellgren-
Lawrence (K/L) radiographic scoring method that defines OA ranging from grades 0-4 
depending on the level of severity, presence of osteophytes and joint deformity in 
general. While a school of thought believes that it is the secretion of pro-inflammatory 
factors that leads to the degradation of the ECM in cartilage and eventually leads to 
bone remodelling in OA; another school of thought supports the hypothesis that 
subchondral bone remodelling and joint inflammation precedes the articular 
degeneration in OA (171). Another fact supporting our lack of understanding of OA 
pathophysiology is the presence of over a million scientific publications on 




across the globe with pain management and surgery as the last medical interventions 
available to patients.  
 
Due to the fact that OA is a multi-factorial disease involving articular cartilage, the 
subchondral bone as well as the synovium and synovial fluid, the exact mechanisms of 
the degradative events up to now have been difficult to dissect. Largely, the 
development of OA may be segregated as ageing dependent processes and ageing 
independent processes. Ageing dependent processes include the wear and tear 
mechanisms, such as age-related changes in cartilage matrix, loss of viable 
chondrocytes due to apoptosis and increase in age-related chondrocyte senescence. 
As mentioned, age-related process within OA subchondral bone, including MSCs 
however, remain poorly understood (172). Ageing independent processes include the 
processes of mechanical load and physical injury, genetic and environmental factors 
along with stress on lifestyle and obesity which impact individuals, irrespective of their 
age.  
 
Current approaches for treatment of OA include pharmacological approaches using 
medication for pain relief like non-steroidal anti-inflammatory drugs (NSAIDs) and 
others (173) and non-pharmacological approaches. These include surgeries, physical 
alternatives like orthosis, insoles and foot wear (174), changes in lifestyle (175), use of 
physiotherapy (176) and an increase in the use of tissue engineering with MSCs (155) 
for the treatment of OA. Lifestyle changes have also been shown to prevent and 
potentially reduce the occurrence of OA (177). OA of the hip is the leading cause of the 
hip replacements in the elderly (178) and with projections of an ageing population 
worldwide, the incidence of hip replacement in only expected to increase. Thus to 
investigate the factors in ageing that may be aggravated in OA, samples of hip OA 
patients were investigated in this thesis.  
 
This project first aimed at investigating changes in number, gene and surface marker 
expression of BM MSCs in healthy ageing. The same parameters would then be 
examined in MSCs from donors with hip OA to appreciate any trends in healthy ageing 
that would be further aggravated in OA. 
 
1.4 Hypotheses and objectives 
Hypotheses: 
 




2) There are age-related differences in the levels of expression of multipotentiality 
genes, genes associated with senescence and IFN1 pathway in uncultured old 
donor MSCs compared to young donor MSCs. 
3) These age-related differences are further aggravated in uncultured MSCs of 




1) To quantify the number of BM MSCs across the broad age range (19-89 years 
old) and between  young (19-40 years old), intermediate group (41-59 years 
old) and old (60-89 years old) donors, using the CFU-F assay and the 
CD45lowCD271+ phenotype. 
2) To investigate the level of expression multipotentiality genes, genes associated 
with senescence and IFN1 pathway in uncultured BM MSCs (CD45lowCD271+) 
from young (19-40 years old) and old (60-89 years old)  donors. 
3) To investigate the level of expression of multipotentiality genes, genes 
associated with senescence and IFN1 pathway in uncultured BM MSCs 






















Chapter 2 Materials and methods 
The methods described in this chapter were performed in experiments presented in 
more than one results chapter. The methods specific to a result chapter have been 
described in the respective methods section of that chapter. List of reagents, 
consumables, equipments, softwares used, prepared solutions are listed in Appendix 2 
Table 1, 2, 3, 4, 5 respectively. 
2.1 Age groups distribution 
The term ageing or defining at what age someone can be called old is more than often, 
subjective. While many references focussed on ageing refer to ‘old’ as the age of 60 
and above (Figure 1.1) globally (5), skeletal ageing become noticeable around the fifth 
decade of life (62, 96). In both cases, there are individuals, whose biological age 
(defined as how young their bodies are, how physically active their organs are) do not 
match their chronological age (actual age in years) (179). Thus to examine age-related 
changes in BM MSCs in human adults, in this project, three age groups were 
investigated: young (19-40 years old); intermediate age group (41-59 years old) and 
old (60-89 years old).  
 
In order to investigate and understand differences in old donors relative to young, this 
PhD included donors beginning from adulthood (>18 years old). Paediatric donors (<18 
years old) were excluded from this study as they are in early stages of growth which 
includes elongation of bones, sexual development and reaching skeletal maturity (180). 
Considering this, an obvious difference would be expected in factors like the number of 
MSCs and gene expression of osteogenic differentiations in old (>60 years old) donors 
when compared to young, eventually leading to a bias. While an adult over the age of 
18 is considered to have attained skeletal maturity, the age of 40 has been suggested 
to start displaying a decline in BMD (62). Incidence of fractures and bone associated 
conditions become prevalent around the age of 60 and thus 60 and above was chosen 
as the cut-off for old donors (1, 181). 
 
Based on the evidence presented above, it can be proposed that in order to 
understand the process of ageing in BM MSCs that is relevant to their in vivo biological 
ageing, MSCs from human donors must be used prior to any culture expansion. This 
will avoid the changes in the cells induced artificially through passaging and cultivation-
induced replicative senescence. When cultivation cannot be avoided (such as in CFU-F 




or minimally-cultured MSCs will be used in this thesis for the purpose of investigating 
age-related changes in human BM MSCs in vivo. 
 
2.2  Ethical approval  
Ethical approval for the collection of human tissue samples was obtained from 
Yorkshire and Humberside National Research Ethics Committee (ethics reference 
06/Q1206/127 for bone marrow aspirate (BMA) collection, 14/YH/0087 for femoral 
head (FH) collection and 04/Q1206/107 for the collection of blood from healthy 
volunteers (Appendix 5). Participants’ details and sample distribution across different 
study arms are presented in separate tables outlined in Appendix 1.   
2.3 Donor selection and sample processing 
The age range for the three groups were as follows: 19-40 years old were referred to 
as the young age group, 41-59 years old were indicated as donors of the intermediate 
age, and 60-89 years old were referred to as the old age group. The ages of recruited 
OA donors were between 56-83 years old. 
 
Human BM aspirates (BMA) were collected in 4ml Ethylenediaminetetraacetic acid 
(EDTA) tubes from the iliac crest (IC) of patients undergoing surgeries for fracture 
fixation or for removal of metal work in Leeds General Infirmary, Major Trauma Unit. 
The patients were reported as otherwise healthy. BMA was collected from n=58 
donors; 30 males and 28 females with the age range of 19 to 89 years old, median age 
of 47.5 years old. BMA median volume was 8 ml (range 4-24ml). 
 
In the laboratory, BMA was first passed through a sterile nylon mesh 70m cell strainer 
to exclude small clots, if any. The total aspirate volume was recorded and collected in a 
50ml sterile falcon tube. Enumeration of MSCs was performed using CFU-F assay 
explained in Chapter 3 (Appendix 1, Table 1) and flow cytometry (Appendix 1, Table 2) 
on fresh samples (n=51 and n=32, respectively) followed by experiment for testing 
resistance to oxidative stress (Appendix 1 Table 2) the next day. The remaining sample 
was then processed for freezing (section 2.3) for testing MSC proliferation in the 
presence of human serum (Appendix 1, Table 1) explained in Chapter 3 or for use in 
cell sorting followed by gene expression (Appendix 1, Tables 2 and 3).  
 
FHs from OA donors (Appendix 1, Table 4)  was collected, processed and frozen by 




the femoral head were defrosted, stained and then processed for cell sorting as 
explained in section 2.3  and 2.5 below. 
 
2.4 Cell freezing and defrosting 
For freezing of the nucleated cells (NCs), BMA was treated with ammonium chloride 
(NH4Cl) solution (BMA: NH4Cl=1:8, v/v) for 10 minutes at room temperature (RT) for 
the lysis of erythrocytes and then centrifuged at 650g for 5 minutes at RT to pellet NCs. 
The supernatant was discarded and the cell pellet was washed twice with PBS to 
remove any remaining traces of NH4Cl. The pellet was then re-suspended in 5-10ml of 
Dulbecco’s minimum essential medium (DMEM) supplemented with 10% Fetal calf 
serum (FCS).  
 
The number of NCs were counted using a haemocytometer by mixing 10l of cell 
suspension with 10l of trypan blue dye. At least 2 large squares with 16 grids each 
were counted and the average count was multiplied by 104, the dilution factor for trypan 
blue and the total volume of cell suspension (for example, 56x104 x 2 (dilution factor for 
trypan blue) x 5ml (total volume of suspension)). The cells were centrifuged again at 
650g for 5 minutes at RT. The supernatant was discarded and the cells were re-
suspended in the required volume of freezing medium (FM) (Appendix 2, Table 5). 10-
20x106 cells were frozen in each cryovial in 1ml of FM, labelled and first stored in -80℃ 
freezer for at least 24 hours followed by transfer into liquid nitrogen for future use. 
 
To revive frozen cells for future experiments, vials were defrosted in water bath (37C) 
and the cell suspension was added to 15ml falcon tubes. Thawing medium (TM) was 
prepared by adding 20l DNAse to 20ml of complete medium to prevent accumulation 
of cells into clumps due to released DNA from damaged cells. 5ml TM was added for 
every ml of defrosted cell suspension drop by drop. Cells were pelleted at 600g for 5 
minutes at RT to remove DMSO and were slowly re-suspended in TM up to desired 
volume. For any study using these cells, if a clump was observed at any given point of 
time, the cell suspension was filtered using 70m cell strainer to obtain a homogenous 
cell suspension. 
2.5 MSC Enrichment using Anti-Fibroblast microbeads 
MSCs are a rare population in the BMA (87, 108) and the MSC enrichment step is 
needed prior to fluorescent activated cell sorting (FACS) to pre-enrich MSC thus saving 
time and cost of cell sorting. Enrichment of MSCs was performed by three different 




(LNGFR) beads and RosetteSep cocktail, and owing to no differences in the 
proportions and absolute numbers of enriched MSCs obtained, the most feasible 
method of using Anti-Fibroblast (A-Fib) microbeads was chosen for future experiments. 
A-Fib beads are magnetically conjugated to anti-D7-Fib antibody allowing MSCs as D7-
Fib positive cells (108) to be retained in the column during separation and hence 
isolating them from D7-Fib negative cells. 
 
For this, defrosted NCs were pelleted at 650g for 5 minutes at RT and were re-
suspended in 500l to 1ml of MACS buffer (Appendix 2, Table 5) to achieve average 
concentration of 1x107 cells/ml as per the manufacturer’s instructions. 40l of A-Fib 
beads per 107 cells was added to the cell suspension, mixed well and incubated at RT 
for 30 minutes. The cell-bead suspension was next washed with 1-2ml of MACS buffer 
and centrifuged at 650g for 5 minutes at RT. The supernatant was carefully removed 
and the cells were re-suspended in1.5-2ml of MACS buffer. The cell suspension was 
passed through a cell strainer to ensure that there were no clumps. 
 
MACS column was positioned in multi-stand with the MACS Separators attached, 
these are powerful magnets and MACS columns amplify the magnetic field by nearly 
10,000 folds. MACS buffer alone was first run through the column to prime the column 
before adding the cell suspension carefully. The fraction of cells retained in the column 
included the magnetically labelled cells while the cells leaving the column (negative 
fraction) did not contain the magnetic beads. The column was washed with 2-4ml of 
MACS buffer to wash out residual negative cells and the negative fraction was 
collected in a 15ml sterile tube.  
 
Once the negative fraction had been collected, the column was removed from the 
magnetic field and placed on top of a separate 15ml sterile tube. 2-3 ml of MACS buffer 
was added into the column and the bead-labelled cells (positive fraction) were collected 
by firmly pushing the plunger into the column.  
2.6 Flow cytometry and Fluorescence activated cell sorting (FACS) 
2.6.1 Principle of flow cytometry 
 
Flow cytometry is the technique that uses fluid dynamics (flow) to study and quantify or 
measure (metry) the different properties of cells (cyto) within a heterogeneous cell 
population (184). It has five key components that include the sample, fluidics, optics, 




flow chamber with sheath fluid and pressurised lines, both of which are responsible for 
the transportation of the particles, or in this thesis, cells (185). Excitation optics include 
lenses which help to direct and focus the other segment of the excitation optics, the 
lasers. The lasers produce light using high voltage electricity. The point at which the 
stream of cells interacts with the laser is known as the interrogation point. It is also the 
point where the optics detect the light scattering (186). At the interrogation point, the 
light emitted by cells is collected by the collection lens and passed through dichoric 
mirrors (mirrors with separate reflection/transmission property at two different 
wavelengths) and filters that ensure the wavelengths of specific lights to be detected by 
their respective detectors.  
 
The light that travels along the path of the laser is in the forward direction and is 
assembled by collecting lens as ‘forwards scatter’ or FSC. FSC is indicative of the cell 
size or surface area and is the result of diffraction of light. The light then travels to the 
photodiodes which is responsible for the conversion of light into electronic signals to be 
recorded by the computer system (185). When light comes in contact with cells and 
refracts or reflects and is collected at 90 degrees to the laser, the scattering pattern is 
called ‘side scatter’ or SSC. SSC is indicative of granularity and the internal complexity 
of cells. (185). The light signals captured by both photo diodes and photomultiplier are 
converted to electronic currents which travel to the amplifier to be converted into 
voltage pulse. This analogue measure is further amplified by linear and logarithmic 
amplifiers, converted into digital signals by digital converters which may then be used 
to produce histograms or plots for data representation (185). 
2.6.2 FACS 
This is where the use of fluorescent labelling comes in, which combines the 
functionality of the flow cytometers with fluorescent labelled antibodies used to stain 
cells. These florescence labelled antibodies can bind to specific cell types and help in 
distinguishing different types of cells from a heterogeneous mixture of cells. The 
distance between the absorption and emission maxima (peak) in the spectra of a 
fluorochrome is known as ‘Stoke’s shift’. The higher the Stoke’s shift, the greater is the 
separation between the absorbance and the emission of a given fluorochrome (187). 
 
The total photons being absorbed by a fluorochrome are associated with the excitation 
wavelength. Thus, while FITC is known to absorb light at 400-550 nm, its highest 
absorbance is usually at 490nm at which it absorbs more photons ensuring that the 
emission will be more intense (187). Using the fluorochromes and the principle of 




heterogeneous cell population. This is referred to as cell sorting.  When fluorochrome 
labelled cells pass the laser beam, they are excited by the correct wavelength of the 
laser light. After excitation, the emitted light is directed towards emission filters allowing 
for the detection of multiple fluorochromes emitted by a cell. 
 
The fluorochromes used are usually for cell surface staining or for intracellular staining. 
Selection of the appropriate fluorochromes for a given study is essential and the panel 
of fluorochromes to be used is dependent upon the aims of the study. In this thesis, 
different fluorochromes were used to identify and enumerate MSCs using the 
CD45lowCD271+ phenotype (Table 2.1). The same phenotype formed the base of cell 
sorting into two separate populations of MSCs (CD45lowCD271+) and HLCs 
(CD45+CD271-). Studies investigating levels of potential age-related surface markers 
and for detecting oxidative stress in young and old donor uncultured BM MSCs were 
performed using fluorescent antibodies and dyes listed in table 2.1. 
2.6.3 Sample preparation and cell staining for cell sorting 
Vial containing FH digest was defrosted in TM, cells were counted and distributed in 10 
tubes to be used for cell sorter instrument settings (8 tubes) and cell sorting (2 tubes). 
Owing to significantly smaller numbers of MSCs in BMA compared to FH digests (182), 
FH cells were used for setting of the machine for unstained cells, isotype controls and 
spectral compensation. These procedures were performed by the technical staff of the 
Flow Cytometry and Imaging Facility in St.James’s University Hospital. Cell sorting was 
usually performed using two BMA samples (from one young and one old donor) on a 
single day, in addition to a FH sample.  
 
For sorting, the enriched cells from BM samples were counted and distributed equally 
into 2 tubes, one to be stained with CD271 PEVio770, CD45 V450, CD106 PE and 
CD295 APC combination and another one for CD271 PEVio770, CD45 V450, CD146 
PE and Cx43 APC (Table 2.1). Violet laser (405 nm excitation) was used for the V450 
fluorochrome, blue laser (488 nm excitation) was used for PE, PECy7 and PEVio770 
and PerCP fluorochromes and the red laser (633 or 640 nm excitation) was used for 
APC as indicated below in table 2.1.  
 
Average cell numbers for isotype controls were 3x105 while for tubes with cells for 
sorting, contained up to 3x106 cells. Both, FH and BM cells were centrifuged to form a 
pellet. The supernatant was discarded and the cells were re-suspended in 100l of 






The cells were subsequently incubated with the antibodies in dark for 15 minutes. After 
staining, the cells were washed in FACS buffer, re-suspended in 500l of the same 
buffer and passed through the filtered-cap flow cytometry tubes to remove the 
presence of any cellular clumps. Finally, 10l 7-aminoactinomycin D (7-AAD) was 
added to all tubes containing cells (except unstained) to distinguish between live and 
dead cells and run through the FACS machine. The list of antibodies and their 

































MSCs CD271 APC  650 633 660 IgG1 20 
MSCs CD45 PECy7 LSR II 496 488 785 IgG1 20 
MSCs 7-AAD PerCP  482 488 647 NA  10 
ROS 
production* 
MSCs CD271 PEVio770  488 488 775 IgG1 20 
MSCs CD45 V450 LSR II 404 405 448 IgG1 20 
MSCs CellROX FITC  508 488 525  NA 2 
MSCs Sytox APC  640 633 658  NA 2 
FACS*,# 
MSCs and HLCs CD271 PEVio770  488 488 775 IgG1 20 
MSCs and HLCs CD45 V450  404 405 448 IgG1 20 
MSCs and HLCs CD106 PE BD Cell sorter 565 488 575 IgG1 20 
MSCs and HLCs CD295 APC  650 640 660 IgG2a 10 
MSCs and HLCs CD146 PE  565 488 575 IgG1 10 
MSCs and HLCs Cx43 APC  650 640 660 IgG2b 10 
MSCs and HLCs 7-AAD PerCP  482 488 647 NA  10 
 
2.6.4 FACS and sample collection 
Once instrument settings were adjusted, stained samples were sorted to collect 
CD45lowCD271+ cells (MSCs) and CD45+CD271low cells (HLCs) which would be the 
control population for the population of interest (MSCs) (188). While sorting, data was 
simultaneously acquired for the selected surface markers of interest – CD106/Vascular 
Cell Adhesion Molecule (VCAM-1), CD295/Leptin receptor (LepR), CD146/ Melanoma 
Cell Adhesion Molecule (MCAM) and Connexin43/ gap junction- (Cx43/GJA-1). Sorted 
cells were collected into 1.5ml eppendorf tubes containing 350l Buffer RL (Appendix 
2, Table 1) that has guanidinium salts for lysing cells and exposing the genomic 
contents (189). The salts also ensure the inhibition of RNAse to prevent the 
degradation of RNA into smaller components. The eppendorfs were frozen at -80C 
until further use. 
2.6.5 FACS data analysis  
Data from FACS was analysed using FlowJo software (version 10). The gating strategy 
and the histograms for each of the surface markers are shown in the respective 
chapters. First, the raw files were loaded on to the workspace and each tube within a 
given experiment was analysed in detail. Dot plot display was chosen to better 
visualise the cells of interest. 7-AAD negative cells were gated as live cells. Using this 
live cell gate, the cells with the phenotypes CD45lowCD271+ (MSC) and CD45+CD271low 
(HLC) were identified. On each of these cell phenotypes, the expression of surface 
markers (CD106, CD295, Cx43 and CD146) was analysed using respective histogram 
displays. MFI was recorded for each of the surface markers for MSCs and HLCs for all 
samples. The MFI values were then compared and analysed for any differences in 
relation to donor age or the presence of OA, as described in Chapter 4 and Chapter 6, 
respectively. 
2.7 Gene expression 
Genes are the fundamental unit of heredity and information about a person at the 
genetic level. Measurement of the expression of genes have long been used to identify 
differentially expressed genes in diseases or other anomalies. To understand if there 
are any differentially expressed genes in old donor MSCs as compared to young donor 
MSCs, or in OA, gene expression experiments were carried out using sorted 






2.7.1 Principle  
Polymerase chain reaction (PCR) may be defined as a chain reaction that occurs to 
increase the final product exponentially with the help of an enzyme polymerase. Thus 
the reaction enables the production of billions of copies of DNA from a single copy of 
DNA. The essential components needed for the production of billions of copies from a 
single reaction include the enzyme, primers, DNA template and nucleotides. Initially, 
the technique was developed for DNA but was soon applied to RNA as well. However, 
the technique is qualitative, consumes time for the preparation of gels using hazardous 
chemicals, is limited in terms of number of samples and allows the detection of the 
amplified product only after the end of all the cycles. 
 
Quantitative PCR (qPCR) technique is built on the same basic principles of PCR but 
has several advantages. Not only is the method quantitative but the reaction can be 
quantified at every step of amplification. This is achieved by the use of fluorescence 
labelled probes (in this thesis, TaqMan probes). The fluorescent labelled probes have a 
fluorophore that is not active in the beginning of the reaction as it is attached with a 
quencher. As the reaction proceeds, the fluorochrome on the 5’ end and the quencher 
on the 3’ end of the TaqMan assay (in this thesis FAM-MGB respectively) are 
separated by taq DNA polymerase. This separation activates the fluorochrome which is 
now fluorescent ensuring the amplification dependent increase in the fluorescence is 
tracked and measured by the amplification curve. The sample preparation does not 
involve the assembly of gels using hazardous materials and allows a large number of 
sample reactions at the same time (generally up to 386 samples). These factors make 
qPCR a preferred technique to quantify gene expression over normal PCR. 
2.7.2 Fluidigm and Integrated fluid circuits (IFCs) 
Due to the population of interest MSCs being a rare population, it was vital to use a 
method for gene expression that would allow high quality and consistent outputs even 
with input of sample with low cDNA concentration. Gene expression analysis in sorted 
MSCs and HLCs were performed using integrated fluid circuits (IFC) chip technology 
which is based on the principles of microfluidics. These devices are based on the 
principle of qPCR but allow further miniaturization and integration of liquid handling 
components on a single chip. Such microfluidic devices utilise technology that 
combines networks of channels (fluid lines of extremely small dimension (10-6m)), 
chambers (holding extremely small volumes of liquids (10-9l)) and Nanoflex valves (that 
can withstand very high pressure (175mmHg)) in a single chip (190). IFC chips allow 
reactions with small quantities of cDNA and TaqMan primers carrying out numerous 




of the chip, all at once. These chips are aimed at high throughput data collection and 
analysis of biological samples with low concentration of starting materials.  
 
Two types of IFC chips were used in this thesis based on the number of genes 
investigated. The Flex SixTM  chip (Section 4.2) was used for performing gene 
expression in Chapter 4 which investigated 12 genes, owing to the 12 segments in 
each of the 6 compartments of the chip. For investigation of genes in Chapter 5, 2 of 
48.48 chips (Section 5.2) were used to examine 96 genes. At one time in one 48.48 
chip, 2,304 reactions were carried out. The difference between the two chips used lies 
in the number of assays and samples that may be run and the final volume of reaction 
mixtures. The concept, principle and application remains the same. A simple flowchart 
(Figure 2.1) shows the steps that were followed from the sample preparation to the 

















Figure 2.1 Flow-diagram indicating the steps followed for obtaining gene 
expression data throughout the thesis 
2.7.3 Sample preparation 
As indicated in section 2.3, frozen NCs from young and old donor cohorts (Appendix 1, 
Tables 2 and 3) were defrosted and then subjected to cell sorting based on 
CD45lowCD271+ and CD45+CD271- phenotypes for MSCs and HLCs, respectively. HLC 
fraction included BMA cells of the hematopoietic lineage and served as a control to 




each population fraction. The cells were collected in the RL buffer (lysis buffer) in an 
eppendorf and the cell lysates were then kept at -80 until further use. 
2.7.4 RNA extraction 
To minimise the degradation of RNA, the working bench was wiped with RNAse away. 
RNA extraction was performed using Norgen single cells RNA isolation kit (Appendix 2, 
Table 1) which uses the column technique for better yield owing to the low number of 
cells in the fraction of interest (range: 647–22,229 with a median of 4,694 
CD45lowCD271+ MSC). The technique essentially utilises spin column chromatography 
using resins as the separation matrix which ensures the purification of RNA without the 
use of phenol or chloroform (189). 
 
Frozen cell lysates were defrosted on ice and 200l of 100% ethanol was added to 
each lysate for every 350l of the sample volume. The mix of cell lysate and ethanol 
was then gently mixed by vortexing for 10 seconds. The mix was added to a column 
contained inside a collection tube and centrifuged for 2 minutes at a speed 3,500g at 
15C. This ensures the binding of the RNA to the resin column while proteins are 
eliminated in the flow-through liquid (189). The flow-through was discarded and the 
column was washed with 400l of wash solution by centrifugation for 1 minute at 
14,000g to ensure the removal of any remaining impurities. 
 
Genomic DNA digestion ensures the removal of any DNA contamination that was not 
eliminated in the previous steps and could lead to false positives and lower detection 
sensitivity in samples. It was performed by adding 100l of DNAse I digestion mix 
(DNAse I and DNAse I reaction buffer) to the column containing the RNA and 
centrifuged for 1 minute at 14,000g ensuring the entire volume had passed through the 
column. The flow-through was added back onto the column and the column was 
incubated for 15 minutes at RT. Following incubation, the column was washed twice 
with 400l of wash solution by centrifuging for 1 minute at maximum speed. The flow-
through was discarded and the column was centrifuged twice to thoroughly dry the 
resin.  
 
The dry column was placed in a new elution tube and 12l of elution solution was 
carefully added (drop-wise) to the centre of the column and incubated for 2-3 minutes 
to allow the hydration of RNA attached to the column. The column was centrifuged for 
1 minute at 200g followed by 1 minute at 14,000g to ensure that the elution solution 
had passed through pulling the purified RNA along with it. The column was then 




Nanodrop measures the amount of a variety of molecules including nucleic acids based 
on the principle that different molecules can absorb lights at different wavelengths 
(spectrophotometry). Proteins were measured at 280nm, nucleic acids (sample of 
interest) at 260nm and organic compounds at 230mn. The eluted RNA was quantified 
by recording the generated concentration of the RNA in ng/l by the 
spectrophotometer. The purity of the RNA samples was checked using the 260/230 
ratio indicative of presence of impurities belonging to organic compounds for values 
below 2 and the 260/280 ratio indicative of protein impurities in the RNA sample below 
1.8. The extracted and quantified RNA was then placed in -80C until further use. 
2.7.5 Reverse transcription (Rt) for cDNA preparation 
Rt is needed to convert single stranded RNA to cDNA. The Rt component mix was 
prepared by mixing 14l of Rt master mix and 28l of nuclease free water. Rt master 
mix contains all the components required to prepare cDNA which include 
deoxyribonucleotide triphosphates (dNTPs), mix of oligo-dTs and random primers, 
RNAse inhibitor and reverse transcriptase along with buffers. The dNTPs act as the 
building blocks for the new strand being built, the primers direct the synthesis of the 
strand, RNAse inhibitor prevents the degradation of RNA in the process and reverse 
transcriptase is the enzyme that is needed for Rt for cDNA preparation. 3l of the Rt 
mix was added to each well in a 96-well plate followed by 2l RNA sample to each well 
making the total volume 5l. The plate was sealed, mixed by vortexing, centrifuged and 
placed in the thermocycler for the reverse transcription using following the settings: 5 
minutes at 25C, 30 minutes at 42C, 5 minutes at 85C and then hold at 4C, for 
approximately 50 minutes. The produced cDNA (5l) was then stored at -20C for 
future use. 
2.7.6 Pre-amplification 
As  BM MSCs are a rare population, the number of cells (CD45lowCD271+) obtained 
after cell sorting were relatively low (section 2.6.4) and so was the concentration of the 
RNA from these cells (5.6-32.5 ng/l with a median of 11.55ng/l). Limited quantities of 
RNA and cDNA often restrict gene expression analysis, ultimately generating no results 
(191). Thus to ensure detectable levels of starting material (cDNA), pre-amplification 
(PA) step was needed. This is basically a qPCR with limited cycles before the actual 
qPCR begins (192). The limited number of cycles (usually 10-18) ensure the 
amplification of cDNA without significant bias. PA allows for amplification for up to 96 
target genes and a pool of primers is prepared form the same gene expression assays 
that are to be used for the qPCR (191). PA is an established method and is 





TaqMan assays used in different study arms are indicated in respective chapters. For 
PA, pooled TaqMan assay mix was prepared by mixing 2l of each TaqMan assay 
(indicated in respective chapters) and the final volume was made up to 200l using 
nuclease-free water. Next, 1l of PA master mix was added to 1.25l of the prepared 
pooled TaqMan assay, 1.5l of nuclease-free water and 1.25l of cDNA prepared 
(section 2.6.5). Total volume of 5l was transferred to individual wells in a 96-well plate 
in a pre-determined sequence. The plate was carefully sealed and the samples were 
pre-amplified on the thermocycler using 18-cycle protocol (2 minutes at 95C, 15 
seconds at 95C, 4 minutes at 60C and then hold at 4C). The sample were then 
prepared for qPCR in Fluidigm. 18-cycle PA is the recommended number of cycles for 
samples with a concentration range of 5-20ng of RNA (193). The PA samples were 
diluted with 15l Tris-EDTA (TE) buffer and then loaded on the IFC chip for qPCR on 
the same day. 
2.7.7 Sample run 
qPCR was performed using Fluidigm Flexsix™ IFC and 48.48 IFC. Flex SixTM chip has 
6 independent compartments. Each compartment has 12 assay and 12 sample inlets. 
Each compartment can be run independently as a separate experimental run or 
simultaneously. Before the first run on the chip, the complete volume (150l) control 
line fluid was carefully added to the accumulator region only, pushing past the spring 
for the purpose of priming the chip. The 48.48 chip is a single-use chip and needs to 
primed using the control fluid just as in the Flex SixTM chip. For both the chips during 
priming, the barrier plugs were kept on and the chip was placed in their respective 
priming instrument and the prime script was run for 15 minutes.  
 
After priming, the chip was removed from the machine and the barrier plugs of the 
compartments intended for use were removed. For the assays, 2l of each TaqMan 
assay and 2l of assay loading buffer were mixed and 3l from this mix was added to 
the 12 wells in the assay compartment in a pre-determined sequence. Similarly, the 
sample mix was prepared by adding 28l of TaqMan universal master mix, 2.8l of 
sample loading buffer and 1.8l of pre-amplified cDNA, and 3l of the sample mix was 
added to each well in the sample side of the compartment. The volumes used for 48.48 







2.7.8 Data collection, analysis and presentation 
The qPCR run was performed on the BioMark™ HD System with the ‘Data collection’ 
software and GE Flex SixTM Standard cycling protocol (35-40 cycles) for approximately 
60 minutes cycles. Owing to the large number of reactions that can occur 
simultaneously within extremely small volume (10-9 l) in a single run, it surpasses the 
other quantitative assays for qPCR (193).  After completion of the run, IFC was 
removed from the Biomark and the post run script was run for 5 minutes on IFC 
Controller HX to relax the valves. This allows the unused compartments to be used in 
further experiments within a span of 3 months. ‘Biomark Real-Time PCR Analysis’ 
software was used for the analysis of the data. First, the cycle threshold (Ct values) 
were generated for each gene using the software for analysis and the data was 
exported to Microsoft excel for further calculations. The data were then normalised with 
hypoxanthine-guanine phosphoribosyl transferase 1 (HPRT1) as the housekeeping 
gene to generate the Ct values for each gene using the formula [Ct target gene - Ct 
housekeeping gene]. Finally, the Ct values were converted to ‘relative expression’ for each 
gene using the formula [2-Ct] and the values were compared between young and old 
donor cohorts, or in OA cells and age-matched controls, in both MSC and HLC 
populations.  
 
Cluster and Treeview softwares were used to generate clusters of gene expression for 
the samples and observe any trends between the expression of genes in 
CD45lowCD271+ MSCs and CD45highCD271- HLCs. The softwares were also used to 
get an overview of gene expression data distribution across the entire donor cohort. 
Grey squares in clusters represent data that was below detection. Comparative 
investigations between young and old donors or old donors and OA patients were 
analysed using GraphPad Prism software (version7.0a).  
2.8 Data presentation and Statistical analysis 
Various data representation techniques were used for displaying the results obtained. 
Cluster analysis was used to observe any differences in gene expression across the 
entire donor cohorts. Dot plots were used to indicate individual values, frequency 
distribution curves were used to display the data frequency across a range. Bar graphs 
were used to indicate the results of a subgroup, histograms were used to indicate MFI 
generated using flow cytometry. 
 
Statistical analysis and graphs preparation were performed using GraphPad Prism 
software. The distribution of the data was assessed using the Shapiro-Wilk and 




and unpaired, Mann-Whitney U test was used to compare data between young and old 
donor groups, or between MSC and HLC fractions. The tests used for each experiment 
are specified in the respective chapters. For all data, p value of <0.05 was considered 




































Chapter 3 Proliferative capacity of human BM MSC from using 
colony the forming unit-fibroblast (CFU-F) assay  
3.1 Introduction 
As stated in the general introduction (section 1.2.1), BM aspirate from the iliac crest 
(IC) is a reliable source for MSCs but they exist as a rare population with a frequency 
between 0.01-0.001% of nucleated cells (87, 108). CFU-F assay has been the oldest 
method for counting the number of MSCs ever since its discovery by Friedenstein and 
colleagues (194). MSCs are enumerated by counting the number of single cell derived 
colonies that are formed on petri dishes based on first, their ability of adhering to plastic 
and second, their ability to proliferate into a complete colony. Each colony is 
representative of a single MSC and it takes up to two weeks before the colonies can be 
visualised. In spite of it being a time consuming method, it is still performed today and 
remains the most feasible way to enumerate MSCs based on plastic adhesion. Flow 
cytometry based methods and phenotypes used for enumeration of MSCs will be 
discussed in Chapter 4. The plastic adherent cells that are not proliferative, either do 
not form a colony or will form a colony with very few cells. To ensure that a single MSC 
derived colony that was counted as a colony was a true representation of its 
proliferative capacity, a group of at least 50 cells was considered a colony in this 
project (195). Thus, each colony from the CFU-F assay represented a single MSC. 
 
3.1.1 Previous studies investigating age-related changes in number of human 
BM MSCs based on CFU-F assay 
Several groups have performed CFU-F experiments to examine the age-related 
changes in number of MSCs. These experiments have yielded inconclusive results with 
some of them showing a decline (96, 114, 132) while some not showing any age-
related difference (113, 196, 197) in the number of colonies. This can be due to the 
lack of uniformity in laboratory protocols used for the CFU-F assay. Table 3.1 lists 
investigations in the number of MSCs as observed in cultured cells and in uncultured 
cells. From Table 3.1, it can be seen that many of the studies for investigating the age-
related changes in number of MSCs using CFU-F assay have been performed on 
cultured cells. When grown in cultures, in vitro ageing sets in within the MSCs (98, 
114), as stated in section 1.2.2, which is not representative of uncultured cells in vivo 
(100). Thus, the actual biological age-related difference in number of native MSCs 
















BM: Bone marrow, BMA: Bone marrow aspirate, O: Old, Y: Young, PA: Plastic adhesion, DC: Density centrifugation -MEM: Alpha – Minimum 
essential medium, DMEM: Dulbecco’s minimum essential medium, FCS: Foetal calf serum, ND: Not defined, NS: Non significant 
 
 
When uncultured cells have been used, different methods in extraction of BMA, further processing of the aspirate for MSC isolation, and using 
different media, culture conditions as well as colony definition and scoring criteria can all explain the variation in the results (Table 3.1). 
 
 
MSC source Age (years) Isolation Media Colony 
definition 
CFU-F  Ref 
Trabecular BM  14-87;              
no groups 
PA -MEM+      
10%FCS 
> 1mm  in 
diameter 
No change (113) 
BM from iliac 
crest 
Y: 22-44;           
O: 66-74 
DC -MEM+      
10%FCS 
>16 cells No change (197) 
BM from iliac 
crest 




ND Decline (114) 
BM from iliac 
crest 




>50 cells Decline (96) 
BM Y: 6m-16y;      
O: 29-76 
PA -MEM+      
20%FCS  
ND NS decline (198) 
BMA 1-52; no groups DC DMEM+ 
20%FCS 






3.1.2 Previous studies investigating age-related changes in colony area and 
density in human BM MSCs based on CFU-F assay 
While CFU-F assay has commonly been used to count MSCs, few studies have also 
analysed the colony area and fewer studies have evaluated the colony density as a 
measurement of proliferative capacity of MSCs. Ultimately, the number of studies 
correlating colony area and density to donor age are sparse (listed below in Table 3.2). 
Colony area measures how big a colony is and larger colony areas have been 
associated with younger donor samples (132). However, the variations in the methods 
adapted in independent laboratories and donor variation, make it difficult to come to a 
consensus with respect to age-related changes in colony area.  
 
Even though colony area measures how big the colony is, it does not take into account 
the density of cells within a colony. The denser a colony, the more the number of cells 
that will be closely packed within a colony, indicating higher proliferative rates of colony 
initiating MSCs. As per my knowledge, there has been only one study that has 
mentioned colony density in relation to donor age in uncultured BM MSCs (Table 3.2). 
The study used uncultured cells that observed no change in colony density (200) but 
they did not present the data for the same.  
 
Quantification of colony size has either been performed by comparing diameters of the 
colonies or by comparing the area of colonies in millimetre square (mm2) or related 
units (132, 201). Quantification of density of a colony is relatively more challenging 
considering the variation in sizes of the colonies, the patterns of cells in which they may 
overlap making it difficult to calculate the density. This is potentially why, only 2 studies 
have mentioned density of colonies in their studies and only one of them reported 
qualitative observations (Table 3.2). This indicates that a study of BM MSC colony area 








Table 3.2 List of previous studies investigating age-related changes in colony 
area and density of human BM MSCs 
 
BM: Bone marrow, Y: Young, O: Old, UC: uncultured, NR: Not reported, NC: No 
change 
 
3.1.3 Significance of microenvironment in MSC proliferation 
As mentioned previously (in section 3.1.2) CFU-F assay can not only directly measure 
the number of MSCs from a donor, but it also gives  information about the proliferative 
capacity of these MSCs. MSCs from BMA in vivo exist within a complex matrix 
composed of other types of cells and various other soluble and extracellular matrix 
factors forming its own micro-environment (Figure 1.3). Stenderup et al. investigated 
the in vivo bone forming capacity of human MSCs obtained from 5 young (24-30 years 
old) and 5 old (71-81 years old) donors in immuno-deficient mice. Interestingly, they 
found that the bone forming capacity was maintained even in the MSCs obtained from 
old donors (202). This could be due to the fact that mouse microenvironment was able 
to boost the function of human MSCs from old donors. 
 
Microenvironment includes various factors that guide the cells to their fates. Factors 
like extracellular matrix (ECM), other non-cellular components like soluble proteins, 
growth factors present in the serum have all known to influence the direction of adult 
stem cells. Presence of growth factors, conditioned media from older donors (139) as 
well as serum from older donors (203) have been shown to have an inhibitory effect on 
culture of MSCs as compared to the effect of growth factors, conditioned media and 
serum from young donors. These investigations suggested that the microenvironment 
of old donors also contribute to age-related effects in the cells of older donors. These 
components play an important role in MSC fate decisions with respect to proliferation, 
differentiation, migration as well as molecular interactions with other cells.  However, 
the investigation of how these factors influence the area or density of an MSC colony 
MSC 
source 

















UC NR Decline 










O- 8.23 mm2  






Y- 7.2mm2;              
O- 6.1 mm2  




and thus the proliferative capacity of MSCs within the CFU-F assay, remains 
unexplored. 
 
Autologous serum flows from blood vessels to the BM where MSCs reside, therefore in 
vivo MSCs from older donors are continuously exposed to ‘old donor’ serum and vice 
versa for young donors. Keeping this in mind, several studies have investigated the 
effect of autologous serum on the proliferative capacity of MSCs, but this has been 
performed only on culture expanded MSCs (203, 204). Furthermore, such studies have 
been performed for various aims primarily, finding a human alternative to foetal calf 
serum for supporting MSC expansion, differentiation and proliferation (205, 206). Only 
limited studies have used human serum aimed at investigating age-related changes 
(203), and none in CFU-F assays from uncultured BM MSCs. 
 
This chapter aimed at investigating the age-related changes in the number of BM 
MSCs using the CFU-F assay. The same assay would be used to investigate the 
proliferative capacity of BM MSCs from young and old donors by further dissecting the 
CFU-F assay. The proliferative capacities of BM MSCs from young and old donors 
would also be investigated when exposed to young and old serum to understand the 
role of microenvironment (serum) in MSc proliferation. 
3.1.4 Hypotheses and objectives 
Hypotheses: 
 
1. The number of MSCs measured by CFU-F assay declines with donor age. 
2. The proliferative capacity of MSCs measured by colony area and density 
declines with donor age. 
3. The proliferative capacity of MSCs measured by colony area and density is 
lower when exposed to serum from older donors. 
4. Subjecting old donor MSCs to media supplemented with young donor serum 




1. To enumerate BM MSCs by CFU-F assay. 
2. To investigate the proliferative capacity of MSCs using CFU-F assay. 
3. To test the proliferative capacity of MSCs grown in media supplemented with 
young and old human serum. 
4. To compare the proliferative capacity of old donor MSCs grown in young and 





3.2.1 Donor selection 
BMA was collected from donors undergoing surgeries for fracture fixation or for 
removal of metal work in Leeds General Infirmary, Major Trauma Unit in 4ml EDTA 
tubes as outlined in section 2.2.2. Donors were reported as otherwise healthy and were 
aged between 19-89 years old (median age=48) with n=27 males and n=24 females 
with a total of n=51 donors. 
3.2.2 Enumeration of MSCs using CFU-F assay 
CFU-F assay was performed as previously optimised in our laboratory (111, 207). To 
perform CFU-F assay, 80l of freshly collected and filtered BMA was added into 
duplicate 60mm petri dishes containing 4ml of StemMACS (SM) MSC expansion 
medium. It was later adapted to 200l of BMA in duplicate 100mm petri dishes 
containing 10ml of SM medium to obtain more colonies per dish. Following BMA and 
SM medium mixing, dishes were placed in the incubator in 37C and 5%CO2 and 
maintained in culture for two weeks. After 48 hours, the dishes were gently washed 
twice with 10ml of Phosphate buffer saline (PBS) using sterile stripette and 10ml of 
fresh SM medium was added. Half medium change was performed for these dishes 
twice a week and the dishes were checked for the growth of colonies under the 
inverted microscope. On the 14th day, the medium was aspirated completely and the 
cells were fixed for an hour using 10ml of 3.7% formaldehyde prepared previously 
(Appendix 2). The dishes were then stained with methylene blue stain for one hour and 
washed carefully to visualize the colonies. The stained dishes were allowed to air dry, 
then scanned using the Infinity scanner at 1200dpi resolution. Images of the cells within 
the colonies were captured using microscope equipped with the Infinity Analyze 
software. A colony was defined as consisting of at least 50 cells (207). The colonies in 
each duplicate dishes were manually counted (Figure 3.1) and CFU-F/ml was 
calculated according to the formula ((1000l x average number of colonies from 2 
dishes)/200l) and then averaged.  
 
Figure 3.1 illustrates duplicate CFU-F dishes with colonies grown from BM aspirates 
from representative donors from each age group as outlined in section 1.2.3. ImageJ 
software was used to investigate the colony area and density which are together 


















Figure 3.1 Duplicate dishes containing colonies from each age group. 
The dishes in the figure illustrate colonies after staining with methylene blue on day 14. 




3.2.3 Colony area analysis 
To investigate age-related differences in MSC colony area, dishes were chosen from 
the young and old donor groups. Initially, CFU-F dishes from 10 young and 10 old 
donors were selected for analysis using ImageJ. Visually, colonies of various sizes 
were observed in CFU-F dishes from both young and old donors (Figure 3.1), and 
there was no clear evidence for separate groups of large or small colonies, as 
categorised by Gothard et al. (201).  
 
The images of scanned dishes were converted to ‘grey-scale’ to be recognized by 
ImageJ software and then measurements for colony area was performed. By default, 
ImageJ measures area in (pixel)2. The measurement was then calibrated for millimeter2 
(mm2) and the software generated an outline for each of the colonies. To avoid the 
influence of the background disturbances and to minimize software error (for example, 
by counting two close colonies as one), the colonies on the edges of the dish and two 
or more colonies that almost merged as one, were given an outline manually. This 
enabled the measurement of colony areas for each individual colony. Details about the 
samples, on which colony area analysis was performed can be found in Table 1, 





Upon initial analysis of colony area, it was observed that the data for colony area was 
not normally distributed (Figure 3.2). In some donors, dishes contained numerous 
colonies including very large colonies (for example; donors: 31/F and 62/M). It was 
decided that selection of CFU-F dishes with low number of colonies would potentially 
miss out on these rare large colonies leading to a biased analysis of colony areas. 
Thus, dishes with a minimum of 25 colonies were chosen for the final analysis of 
colony area and density (Figure 3.2). 
 
 
Figure 3.2 Initial studies to evaluate difference in colony area in 10 young and old 
donors. 
 
Dots indicate individual colonies and horizontal lines indicate median values from 
young donors (top panel) and old donors (bottom panel). Age/Sex of the donors is 
indicated within brackets. 
 
The final colony area studies were performed on dishes from n=7 young and n=7 old 
donors that had generated 25-60 colonies per dish. The results  were analysed for 


















































3.2.4 Colony integrated density (ID) analysis 
The data for colony ID was generated along with the data for colony area for all 
colonies from the same 7 young and 7 old donors, for which the colony area had been 
calculated. The ID was measured by the software (area * mean grey value) for each of 
the colonies. The value of ID was always generated by the software, irrespective of the 
outline for areas done automatically or manually. The values for colony area and ID 
were generated simultaneously.  Once the data for colony area and ID were recorded, 
the data were compared between young and old donor groups. 
 
3.2.5 Serum collection and preparation of medium with human serum 
To generate human serum, 30 ml of blood was collected in 6 ml serum clot activator 
tubes from 4 young and 4 old healthy donors after obtaining their consent. The tubes 
contain silica micro particles coated along the inside of the tubes that activate clotting 
of blood. Once the blood was collected, the tubes were agitated for 5 seconds to allow 
the homogenous mixing of the blood with the coated silica micro particles. The mix was 
allowed to stand for 30 minutes and then centrifuged at 2000g for 15 minutes. This 
allowed the separation of the serum from the cells which was seen as a clear bilayer. 
The serum from the upper segment of the separated mix was collected carefully to 
avoid extraction of cells. However, if a small quantity of cells was extracted due to the 
proximity of the two liquids at the separating junction, the mix was further centrifuged in 
1.5ml eppendorfs to ensure complete separation of serum from the cells. This was 
done for blood from each donor. Subsequently sera from four young donors (equal 
volumes) were pooled together to generate stocks of ‘young’ serum (YS). Similarly, 
‘old’ serum (OS) was also prepared and both YS and OS were then aliquoted in 1ml 
vials and frozen at -20o. Media containing either 10%YS or 10%OS were prepared 
fresh using DMEM as the basal media and supplemented with 1% Penicillin-
Streptomycin for each experiment. Optimisation experiments were performed using 
serum from a single young donor for the ease of availability of young healthy donors.  
 
3.2.6 Experimental design for investigating MSC colony formation in human 
serum   
The aim of these experiments was to investigate how young and old donor MSCs 
responded to young and old donor microenvironment (represented by YS and OS), in 
comparison to SM, as well as how their colony numbers, areas and densities were 




(YS). These experiments were performed using frozen cells (for freezing and thawing, 
refer to section 2.2) from 6 and 4 donors from ‘young’ and ‘old’ groups, respectively 
(Appendix 1, Table 1).  
3.2.6.1 Medium optimisation 
To test the effect of ‘young’ and ‘old’ human serum on MSCs, it was important to 
ensure the right controls for the experiments. The first medium chosen as a positive 
control was SM medium that is industrially optimised for isolation, adhesion and growth 
of MSCs from BMA. However, the serum in SM is foetal calf serum (FCS) but it does 
not specify the type of basal media used.  
 
As the aim of this experiment was to test the effect of human serum on the colony-
forming capacity of BM MSCs, it was important to have a positive control with human 
serum supplement added to a known basal media. Mesencult supplement or Mcult is a 
human serum supplement that is optimized for isolation of MSCs in vitro. Thus, it was 
chosen as another positive control added at a concentration of 10% in basal 
Dulbecco’s minimum essential medium (DMEM). DMEM with standard FCS (not 
optimised for MSCs growth) was used as negative control. All the media were 
supplemented with respective serum and 1% penicillin/streptomycin antibiotic. 
3.2.6.2 Experimental design for control media evaluation 
Frozen NCs (predicted to generate approximately 25-30 colonies based on the initial 
CFU-F assays, (Figure 3.2) were defrosted at 37C in thawing medium (TM, Appendix 
2). The cell suspension was centrifuged to remove the DMSO from the suspension and 
was re-suspended in TM. The cells were then equally divided into 12 60-mm dishes (3 
for each of the medium of choice, Figure 3.3) containing 4 ml SM for an initial 48-hour 
attachment period.  
 
Subsequently, the media was removed, the non-adherent cells were washed with PBS 
and complete media changes were performed as follows: 3 dishes were supplemented 
with  4 ml SM (control), 3 other dishes with 4 ml DMEM/10%YS, 3 other dishes with 
DMEM+10%Mcult and 3 final dishes with 4ml of DMEM/10%FCS. The dishes were 
then placed at 37C and 5%CO2 for 2 weeks, and half medium changes were 
performed using the respective media twice a week. On day 14, all media were 
aspirated and for each condition, two dishes were stained with methylene blue to 
visualise the colonies, while the adherent cells from the third dish were lifted off using 
trypsin (Appendix 2) and counted. The stained dishes were allowed to air dry and then 




involved in selection of appropriate donors and the criteria in testing the effect of MSC 
colony formation in human serum are shown in a flowchart format in Figure 3.3 


















Figure 3.3 Flowchart demonstrating the steps and crucial parameters involved in 
the selection of donors for testing MSC colony formation in human serum. 
Steps have been written as a flow chart to simplify the complexity of factors that were 
involved in executing the plan of the experiment with human serum. NCs: nucleated 
cells, TM: thawing medium, SM: StemMACS media, DMEM: Dulbecco’s minimum 












Figure 3.4 Optimisation of controls for testing the proliferation of MSCs in human 
serum 
Equal number of defrosted MSCs were plated in 60mm petri dishes for 48 hours in SM 
medium to ensure uniform adhesion of MSCs in all dishes. After 48 hours, SM medium 
was aspirated and the corresponding medium was added (shown in the coloured 
panel). Half medium change was peformed twice in a week and on day 14, 2 dishes 
from each medium condition were stained and one was trypsinised for obtaining cell 
counts. 
 
3.2.6.3 Final experimental design 
The final experimental design included pooled YS and OS from n=4 donors from each 
group. As the optimisation experiments were performed from a single young donor, 
serum for final experiments were pooled to avoid bias. Observation from results from 
optimisation experiments (discussed further and shown in Figure 3.10) lead to 
finalisation of 3 serum conditions for the experiments shown in Figure 3.5. This 
























Figure 3.5 Optimised conditions and medium controls for testing MSC colony-
forming capacity in human serum. 
 
3.2.7 Statistical tests 
Statistical analysis and graphics were performed using GraphPad Prism software 
(version 7.0a). The normal distribution of the data was assessed using the Shapiro-
Wilk and Kolmogorov-Smirnov tests for normality. As no data were found to be 
normally distributed, Mann-Whitney test and Kruskal-Wallis test with Dunn’s correction 
for multiple comparisons were used to compare two and three groups, respectively. 
Spearman test was used to analyse correlations. The results were considered 
significant at p value of <0.05. 
 
3.3 Results 
3.3.1 Age-related changes in number of CFU-F 
As mentioned in section 3.2.2, the colonies were visualised after staining the cells with 
methylene blue solution on day 14. Initial observation included scanning the petri 
dishes for images and manual counting of the colonies. There was no age-related 




indicating different types of colonies existed even within the duplicate dishes of a single 
donor (Figure 3.1).  
 
Once all the colonies were visualised and counted, the data for n=51 donors (n=27 
males, n=24 females), was compiled and then correlated with donor age (Figure 3.6A). 
There was a significant age-related decline (p=0.0153) in the number of colonies. 
While there were donors with a relatively higher number of colonies among the older 
donors, an overall decline in the number of colonies (indicative of MSCs) was evident 









Figure 3.6 Age-related changes in number of CFU-F 
(A) Age-related change in the number of CFU-F per ml of BMA across entire donor age 
range (n=51) and (B) in between age groups. Each dot indicates individual donor, 
black dots represent male donors and empty circles represent female donors. The 
black line on the left indicates the slope and the on the right, the median values. 
Spearman non-parametric test was performed for A and Kruskal-wallis test with Dunn’s 
correction was performed for B, *p<0.05. 
 
When the number of colonies was segregated based on the donor age groups (Figure 
3.6B), a decline of over 3-folds (p=0.0245) was found between young donors 
(median=163 CFU-F/ml) and donors of intermediate age group (median=53 CFU-F/ml). 
When young and old donors (median=38 CFU-F/ml) were compared, a decline of over 
4-folds (p=0.0512) was observed. It must be noted that while the overall median was 
the lowest in the older donors, the decline was the steepest between young donors and 
donors of intermediate age group. This indicted towards the considerable decline in the 
number of MSCs in the donors who are over the age of 40. The decline in the number 
of colonies continued after 60s as well, however, some of the donors over the age of 
60 were also observed to have relatively large number of CFU-Fs suggesting young 




To understand if there were age-related changes with respect to gender, male and 
female donors were split and analysed separately for age-related correlations 
(Appendix 3, supplementary Figure 3.1A and C). There was a significant decline found 
in males (p=0.0319; r=-0.41) and a non-significant decline in females (p=0.128; r=-
0.32). To understand the variation in each gender, they were further split into three age 
groups (Appendix 3, supplementary Figure 3.1B and D). The trend for decline in males 
and females was found to be similar to  3.6A above. However, owing to the limited 
number of donors in old males and intermediate group females, it was decided to keep 
the focus on age-related changes without segregating data for males and females 
further in the thesis.  
3.3.2 Age-related changes in colony area  
Until now, data from this chapter has established that there is significant decline in the 
number of colonies (indicative of number of MSCs) with increased donor age. While 
counting colonies and analysing them, colonies of different sizes were observed 
(Figure 3.7A). From literature, it was known that each colony is indicative of a single 
MSC and that colony area and colony morphology has the potential to indicate the 
proliferative capacity of MSCs (201, 208). However, none of these studies had 
measured the colony area on uncultured MSCs in relation to age ranging from 20-89 
years old or quantified colony density. While the general idea related to the decline in 
sizes of MSC colonies has been linked with lower MSC proliferation in aged donors 
(132, 144), investigations on age-related differences in colony density have not been 
performed. 
 
CFU-F dishes from 14 donors (n=7 young and n=7 old) containing a minimum of 25 
colonies each were scanned. The scanned images of the dishes were analysed for 
colony area as described in section 3.2.3 and all colonies from each age group were 
combined to increase the statistical power of the analysis. The comparison of colony 
area between all colonies from young donors (n=321) and all colonies from old donors 
(n=266) suggested that the area of colonies in old donors (median=10.3 mm2) was 
significantly 10% lower (p=0.0289) than the area of colonies in young donors 
(median=11.2 mm2) (Figure 3.7 B). However, it was not clear if the decline in the 
colony area was due to a predominant loss of the larger colonies or due to a shift from 





























Figure 3.7 Age-related changes in colony area 
(A) Presence of different sizes of colonies from a single donor CFU-F dish (B) 
Comparison of colony areas between all colonies from 7 young (321 colonies) and 7 
old (266 colonies) donors. Each dot indicates a single colony with median values 
indicated in horizontal lines (C) Frequency distribution of colony area of young donors 
(black curve) and old donors (grey curve). *p<0.05, Mann-Whitney U test. 
 
 
To investigate if there is a loss of bigger colonies in old donors, a frequency distribution 
curve was generated for the colony areas of both young and old donor MSCs (Figure 




Prism) of 5mm2 in order to analyse the differences in sizes as small as 5mm2. The 
frequency distribution of colony areas was next performed using GraphPad Prism 
software by generating a non-linear fit line based on modal values of pre-defined bin 
widths of 5 mm2. This analysis revealed unimodal colony area distributions in both 
young and old cohorts, however, a prominent shift towards smaller colonies was 
observed in the old group. The frequency distribution in the figure shows a tendency of 
young donors to have larger colony areas whereas, the data from old donors indicate a 
shift towards smaller colonies with colony areas less than 10 mm2. To segregate the 
colonies as ‘large’ or ‘small’, the median of all 587 colonies from both groups of donors 
(median=10.64 mm2) was used as the cut off limit.  
 
3.3.3 Age-related changes in  colony integrated density  
Colony density data was collected along with the colony area by ImageJ software and 
was measured in integrated density (ID) units. It was calculated as a product of the 
area and the mean grey value of a colony. The high mean grey value reflects the 
closeness of the cells that are stained within the colony, while zero grey value indicates 
un-stained empty space, that is, space with no cells. The greater the contact between 
the cells within a colony, the greater would be the mean grey value of the colony. 
 
It was hypothesised that the colonies with the highest IDs would be the biggest and the 
most dense (indicating the most highly proliferative MSCs) categorised by Oreffo and 
colleagues in 2013 as ‘large dense colonies’ (201). Conversely, the colonies with the 
lowest IDs would be equivalent to the ‘small sparse’ colonies (208), indicating the least 
proliferative MSCs. The first comparison was performed between the ID of all colonies 
from young donors (n=321) and all colonies from old donors (n=266) (Figure 3.8A). The 
comparison indicated a significantly 32% lower (p<0.0001) ID of colonies in old donors 
(median=1116 units) as compared to the ID of colonies in young donors (median=1643 
units). The next comparison was performed between all the small colonies (area less 
than median area of 10.64 mm2 described in the section above) from both young and 
old donors with all the large colonies from both young and old donors (Figure 3.8B). 
The data indicated a significant drop (p<0.0001) of over 3-folds in the ID of small 
colonies (median=777 units) when compared to the ID of large colonies (median=2661 
units). As the formula for ID was (area*mean grey value), both, the contact between the 
cells in a colony and the area of the colony are directly proportional to the actual ID 
calculated. The fact that the larger colonies generated higher values for ID than small 
colonies, it was therefore expected and indicated that such segregation may provide 





Figure 3.8 Age-related changes in colony ID 
(A) Comparison of colony ID of all colonies from young and old donors  (B) 
Comparison of all small and large colonies from both age groups based on median 
area (C) Comparison of ID of small colonies in young and old donors (D) Comparison 
of ID of large colonies in young and old donors. Black dots represent young donors 
(n=7) and grey dots indicate old donors (n=7). Median values in all the figures is 
represented by the black horizontal line.**p<0.01 and ****p<0.0001, Mann-Whitney U 
test 
 
To further understand if the ID of each colony type (large or small) had similar age-
related trends, the colony ID data for small colonies was first compared between young 
and old donors (Figure 3.8C). The ID of small colonies from old donors (median=563 
units) was significantly lower (p<0.0001) than the ID of colonies from young donors 
(median=981 units). Similar comparison was applied to large colonies for the two age 
groups (Figure 3.8D) and a similar trend of lower ID (p=0.0029) was observed in old 
donors (median=2325 units) as compared to the ID of large colonies in young donors 
(median=2850 units). The difference in ID was however greater in the small colonies 
(1.7-folds) as compared to large colonies (1.2-folds). This suggested that there were 
proportionally more small sparse colonies in old donors, rather than less large dense 
colonies. Irrespective of the colony size, if they were from young donors, they had 
higher colony area and ID indicating their higher potential to proliferate as compared to 




3.3.4 Proliferation of MSCs in human serum conditions 
3.3.4.1 Optimisation experiments 
The first step of testing the hypothesis that the proliferative capacity of MSCs is further 
reduced in ‘aged’ microenvironment was to ensure that the right controls were being 
used for comparison. Section 3.2.6 outlines the choices of medium used and the 
rationale behind these choices. To identify the best control(s),  young donors with more 
than 100 CFU-Fs/ml from fresh BMA and with over 107 frozen cells (Figure 3.3) were 
selected to generate approximately 25-30 colonies in 12 dishes each (3 dishes for each 
of the four different media). Young serum (YS - from 1 young male) was used to 
optimise the controls as it was more practicable and also because the volume of old 
serum (OS) was limited owing to rarity of the donors in this age group and so it was 
saved for the main experiment. Once the young donor cells were added to the dishes 
and the medium was changed as shown in Figure 3.4, after 14 days, dishes were 
stained and the number of colonies were counted.  
 
Figure 3.9 shows the results of the optimisation experiment where the dishes 
containing cells in DMEM+10%FCS on top panel and in DMEM+10%Mcult (bottom 
panel) did not have visible colonies. While there were groups or clusters of cells seen 
in both – DMEM+10%FCS and DMEM+10%Mcult, they had less than 50 cells to be 
considered as a colony for colony analysis. This was repeated with two other donors 
and the observation for both DMEM with FCS or Mcult was consistent throughout the 
three experiments. The cell count in dishes containing either DMEM with FCS or with 
Mcult also consistently revealed fewer or no cells at all (range 0-2 colonies per dish as 










































Figure 3.9 Selection of control media 
Top and bottom panel (outlined in red) medium conditions did not generate colonies 
resulting in their elimiation and finalising SM as the positive control. Numbers on the 
top right corner of every dish indicate the number of colonies in each dish. 
 
Colonies were expected in SM as it is commercially optimised for the adhesion, growth 
and proliferation of cultured and uncultured MSCs in vitro and was shown to generate 
colonies in previous experiments (section 3.2.1). Number of colonies counted in SM 
were greater than those in DMEM+10%YS. However, colonies in the latter appeared 
larger in size as compared to the colonies grown in SM. Mcult is also optimised for 
adhesion, growth and proliferation of MSCs but only for cultured cells. This could 
explain the absence of colonies in this experiment with uncultured cells. 




serum (206). However, the lot used for this experiment was not specifically selected for 
uncultured MSC growth. This can explain the lack of colonies from uncultured BMA. 
 
Based on these observations, only SM was chosen as the positive control for 
subsequent experiments. It can be argued that DMEM+10%FCS could have been still 
kept as negative control. However, keeping in mind that the number of MSCs declined 
in older donors (section 3.3.1) and the number of frozen cells required to set up these 
experiments (9 dishes x 25-60 colonies per dish), it was decided to finalise the 
experimental set up on 3 sets of conditions: human young serum, human old serum 
and SM and not perform negative controls. 
 
3.3.4.2 Proliferation of MSCs in media supplemented with human serum 
The aims of following experiments were to test if there was a decline in the most 
proliferative MSCs when grown in media containing old serum and also to evaluate the 
rejuvenation potential of growing old donor MSCs in young serum as compared to 
growing in old serum. 
 
As the number of old donors was limited and so were their number of MSCs in most 
cases, the old donors with 30 CFU-Fs/ml and above were considered for this 
experiment. Additionally, all of the frozen cells from the old donors were plated as 
described in section 3.2.5. Altogether, the colony formation from NCs from n=6 young 
donors and n=9 old donors was evaluated. As expected, seeding old samples that had 
less than 100 CFU-F/ml and less than 107 frozen NCs did not yield any colonies and 
thus could not be considered for further analysis. The results of the donors that 











Figure 3.10 Representative donors colonies in all 3 conditions 
Top panel shows the scanned image of the stained dishes following culture in SM 
medium followed by media supplemented with 10%YS in the centre panel and in media 
supplemented with 10%OS in the bottom panel. Left side indicate representative 
dishes from a young donor and the right side indicate dishes from an old donor. The 




Figure 3.10 (left side) shows colonies obtained from young donor following culture in 
SM, media supplemented with 10%YS and media supplemented with 10%OS. In SM 
(top panel), 36 and 34 colonies were observed. Comparing these colonies with those 
obtained in media containing human serum (10%YS or 10%OS), they were fewer in 
number as well as appeared smaller in size. Colonies from young donor MSCs grown 
in media supplemented with YS appeared merged due to larger colonies in close 





Figure 3.10 (right side) shows colonies obtained from old donor following culture in SM, 
media supplemented with 10%YS and media supplemented with 10%OS. In SM (top 
panel), 36 and 61 colonies were observed. Comparing these colonies with those 
obtained in media containing human serum (10%YS or 10%OS), they appeared 
smaller in size. However, colonies in SM were more than the number of colonies 
obtained from human serum, especially in media supplemented with OS (bottom 
panel). Colonies grown in media supplemented with YS appeared larger than colonies 
obtained from other 2 conditions. Colonies of varying sizes were observed in all 3 
conditions. 
 
Visually, Figure 3.10 suggests that the colonies are generally bigger in size in media 
containing human serum as compared to SM. While the difference between the 
number of colonies or their sizes was not strikingly evident between YS and OS, the 
general observation of larger colonies seen by the naked eye remained constant for all 
young donors (n=6) in YS as compared to SM (Figure 3.10).  
 
Using SM as the positive control, all the data for colony area from young and old donor 
MSCs grown in media supplemented with 10%YS or 10%OS were compared to SM. 
To confirm if the colonies grown in media supplemented with YS were actually denser 
than those grown in SM or in media supplemented with OS, the ID of all the colonies 
were also quantified. Due to the observation that SM generated good number of 
colonies but smaller in size and media in YS demonstrated otherwise, one of the 3 






















Figure 3.11 Colony and cell counts of young and old donor MSCs seeded in 
dishes with SM, media supplemented with YS and media supplemented with OS 
(A) Number of CFU-Fs as counted from stained dishes in young donors (left) and old 
donors (right) grown in SM, media supplemented with YS and media supplemented 
with OS (B) Cell counts from the third dish in young donors (left) and old donors (right) 
grown in SM, media supplemented with YS and media supplemented with OS. Bars 
indicate median and error bars indicate interquartile range. n=6 young donors and n=4 
old donors. 
 
Figure 3.11 represents the colony-forming capacity of young and old donor MSCs in 
SM, media supplemented with YS and media supplemented with OS. The data in 
Figure 3.11A shows no significant difference in the number of colonies between young 
and old donors grown in any of the 3 conditions. However, while the total number of 
colonies remained similar in SM, a non-significant decline in old donor MSCs was 
observed in both, media supplemented with YS and media supplemented with OS 



































































































The cells counted from the third dish (Figure 3.11 B) showed interesting additional 
trends. First, a trend for decline in the number of cells in media supplemented with OS 
was observed in both young and old donor MSCs compared to their growth in SM and 
YS conditions, in spite of plating equal number of cells in all conditions for each donor. 
This suggested that there were colonies with fewer cells in OS conditions when 
compared to SM and YS conditions. This was further tested by evaluating the colony 
areas and IDs using methods described in section 3.2.3 and 3.2.4.  
 
Figure 3.12 shows the comparison between colony areas of young and old donor 
MSCs in the 3 conditions, along with the frequency distribution of the colony areas. 
Figure 3.12 A, left panel represents the colony areas of all colonies from young donors 
grown in SM, media supplemented with YS and in media supplemented with OS. For 
young donors, YS conditions had produced the largest colonies with median area of 
11.89mm2. This was significantly higher than observed for the colonies grown in OS 
conditions (median area=11.08mm2, p=0.0062) or SM conditions (median 
area=8.42mm2, p<0.0001). Interestingly, the colonies grown in OS were also 
significantly larger than those grown in SM (p=0.0016).  
 
Frequency distribution of colonies from young donor MSCs (Figure 3.12 A, right panel) 
grown in SM (dashed line) peaked in between 5-10 and 10-15 mm2 area boundaries 
indicating that most frequent colonies in SM were more within this boundary. 
Frequency distributions of colonies from young donors MSCs grown in media 
supplemented with YS or OS did not show much difference, consistent with their 
median values being very close, as mentioned above. Both the curves appeared to 
have similar range of large and small colonies indicated by the nearly overlapping 
pattern of the black and grey line. As mentioned, the frequency distribution curve of the 
colonies from the same donors grown in SM appeared to have a strong shift towards 





















Figure 3.12 The analysis of colony area in SM, media supplemented with YS and 
media supplemented with OS 
(A) Comparison of colony areas in young donors (n=6, left) in SM (n=345 colonies), in 
media supplemented with YS (n=286 colonies) and in media supplemented with OS 
(n=301 colonies). Frequency distribution of colony area (right) based on bin centres of 
5 mm2 of colonies from young donors grown in SM (dashed line), media supplemented 
with YS (solid line) and media supplemented with OS (dotted line) (B) Comparison of 
colony areas in old donors (n=4, left) in SM (n=241 colonies), in media supplemented 
with YS (n=175 colonies) and in media supplemented with OS (n=165 colonies). 
Frequency distribution of colony area (right) based on bin centres of 5 mm2 of colonies 
from young donors grown in SM (dashed line), media supplemented with YS (solid line) 
and media supplemented with OS (dotted line). Median is indicated by black horizontal 
line. Data was considered significant when *p<0.05, **p<0.01, ****p<0.0001, Kruskal-
Wallis test with Dunn’s correction. 
 
Figure 3.12 B represents the colony areas of all colonies from old donors grown in SM, 
media supplemented with YS and in media supplemented with OS. For old donors too, 
YS conditions had produced the largest colonies with median area of 11.19 mm2. This 
was significantly higher than for the colonies grown in OS conditions (median 
area=8.38 mm2, p=0.0141). While there was no difference found between the colony 
area of colonies grown in SM (median area=10.14 mm2) and colonies grown in media 







































































































































colonies grown in media supplemented with OS (p=0.0215). Thus, in old donor MSCs, 
colonies grown in OS showed the lowest colony areas.  
 
Frequency distribution of colonies from old donors in SM (dashed line) once again 
peaked in near 10-15 mm2 area indicating that most of the colonies in SM were 
relatively small in size. However, very different from results in young donors, colonies 
from old donors in media supplemented with OS shifted further towards the left 
indicating the presence of colonies smaller in size than those grown in SM (Figure 
3.12B, right panel). As expected, colonies grown in media supplemented with YS 
demonstrated a prominent shift to the right (larger colonies), almost as seen in young 
donors (Figure 3.12A, right panel).  
 
Overall, this section showed that in young donor MSCs, colonies grown in SM are 
significantly smaller in size, while those grown in media supplemented with YS or OS 
do not show any differences in size indicating that OS does not have a detrimental 
effect on the growth of young donor MSCs. However, old donor MSCs grown in media 
supplemented with OS generated the colonies of the smallest size. Very interestingly, 
the same old donor MSCs, when grown in media supplemented with YS, formed bigger 
colonies. The frequency of colonies grown in media supplemented with YS generally 
showed a shift towards larger colonies in MSCs from both young and old donors. 
These data indicated that YS supplementation had a positive effect on the colony size 
from old donor MSCs. 
 
3.3.4.3 Age-related differences in colony ID in MSCs grown in SM, media 
supplemented with YS and media supplemented with OS 
Next, to understand the age-related differences in density of the colonies, the IDs of the 
colonies were then analysed for MSCs grown in all the 3 conditions. Colonies from 
young donors and old donors were segregated as small or large based on the median 
area of all colonies (colonies grown in media supplemented with YS and with OS) from 
young as well as old donors (9.4 mm2). Colony area evaluation in human serum 
suggested an age-related decline when MSCs were exposed to OS and this was 
observed for young donor MSCs as well as for old donor MSCs. Next, the data 
acquired for colony ID from ImageJ was analysed for small and large colonies, first in 
young donors and then in old donors. It was hypothesised that a similar trend for 
decline in colony ID would be seen in OS conditions, and particularly for old donor 




colonies were segregated into small and large based on the median area of all colonies 
(grown in all conditions and  from young as well as old donors, 9.4 mm2).  
 
Figure 3.13A represents colony IDs for small colonies from young donors grown in SM, 
media supplemented with YS and media supplemented with OS. Small colonies grown 
in media supplemented with YS had the highest IDs (median=1110 units) which was 
significantly higher than the IDs of colonies grown in SM (median=937 units, p=0.0208) 
or media supplemented with OS (median=887 units, p=0.0003). Even though the IDs of 
colonies grown in media supplemented with OS were the lowest, it was not statistically 





















Figure 3.13 ID of colonies from young donors MSCs grown in SM, media 
supplemented with YS and media supplemented with OS 
(A) ID of small colonies in SM (n= 156 colonies), in media supplemented with YS 
(n=108 colonies)  and in media supplemented with OS (n=129 colonies) (B) ID of large 
colonies in SM (n=153 colonies) in media supplemented with YS  (n=191 colonies) and 
in media supplemented with OS (n=172 colonies). Each dot represents a single colony 
and the median is indicated by black horizontal line across the data set. *p<0.05, 
















































Similar trend was observed for the large colonies from young donors (Figure 3.13 B) 
showing a significantly higher ID in colonies grown in YS (median=2598 units) as 
compared to the colonies grown in SM (median=2047 units, p=0.0080) or in media 
supplemented with OS (median=2200 units, p<0.0001). Altogether, the data presented 
in Figure 3.13 indicated that in young donors, OS conditions induced a significant 
decline in the ID of colonies as compared to those grown in SM and YS. This was true 
for both, small as well as large colonies. This implied that proliferation of MSCs was the 
lowest when grown in media supplemented with OS and the highest when grown in 
media supplemented with YS. Using colony ID as an indication of MSC proliferation, it 
can be concluded that growing MSCs in OS conditions reduced MSC proliferation 












Figure 3.14 ID of colonies from old donors MSCs grown in SM, media 
supplemented with YS and media supplemented with OS 
(A) ID of small colonies in SM (n=103 colonies), in media supplemented with YS (n=76 
colonies) and in media supplemented with OS (n=98 colonies). (B) ID of large colonies 
in SM (n=138 colonies) in media supplemented with YS (n=99 colonies) and in media 
supplemented with OS (n=67 colonies). Each dot represents a single colony and the 
median is indicated by black horizontal line across the data set. p<0.05*, , Kruskal-















































Small colonies from old donors did not show any significant difference between the ID 
of colonies grown in SM, YS or OS (Figure 3.14A). However, the IDs remained lower in 
OS conditions (median=1062 units) compared to YS conditions (median=1105 units) 
while being the lowest in SM (median=937 units). 
 
For the large colonies grown from old donor MSCs (Figure 3.14B), the IDs of colonies 
grown in media supplemented with YS (median=2729 units) were significantly higher 
than the IDs of colonies grown in SM (median=2441 units p=0.0170) and non-
significantly higher that the IDs of colonies grown in OS (median=2501 units).  This 
indicated that, while media supplemented with YS encouraged the proliferation of 
MSCs from old donors, the effects were small and statistical significance was not 
achieved. ID analysis of colonies from both young and old donors confirmed that 
growing MSCs in aged serum induced a decline in the overall proliferation capacity of 
MSCs (Figure 3.13 and 3.14). The data also indicated that proliferation capacity of 
MSCs in old donors could be slightly improved when grown in media supplemented 
with YS as compared OS (Figure 3.14B). The trends for a change were the same for 
large and small colonies suggesting that YS or OS factors were  equally affecting all 
colony types and were therefore not specific to small or large colonies.  
 
3.4 Discussion 
Literature regarding age-related differences in BM MSCs with respect to their numbers 
has been controversial (Table 3.1). Furthermore, while the number of CFU-Fs have 
been evaluated for counting MSCs, the size of the colonies has been discussed less 
often and their density, rarely. In this thesis, it was hypothesised that the number of 
MSCs in the BM shows an age-related decline. Additionally, the colony size and colony 
density measured were also hypothesized to show an age-related decline with the loss 
of the most proliferative MSCs that in this assay, formed the  largest and densest 
colonies. Furthermore, it was hypothesised that MSC ‘niche’, modelled here with the 
use of human serum, would additionally impact on MSC colony formation, leading to 
smaller and less dense colonies when grown in old donor serum. 
 
The data presented in this chapter showed a significant age-related decline in the 
number of MSCs quantified by CFU-F assay,  confirming our hypothesis and indicating 
an age-related decline in BM MSCs in vivo. Furthermore, the MSCs from older donors 
had significantly lower proliferative capacity than younger donor MSCs as indicated by 
colony area and colony ID analysis. The potential of human serum to support 




human serum and confirmed previous studies with culture expanded MSCs (206, 209). 
The colony area and colony ID results from human serum experiments indicated that 
‘aged’ serum (OS) provided conditions for lower proliferative capacity of MSCs, from 
both young and old donors. Finally, colony area and ID results indicated a  possibility 
for using young serum to potentially rejuvenate MSCs from old donors, by making 
CFU-F colonies significantly bigger and slightly more dense.  
 
CFU-F assay has been performed by many groups to investigate the change in the 
numbers of MSCs. However, the techniques of cell isolation, media used and other 
factors have varied in different laboratories (Table 3.1). Fewer groups (including our 
group) have performed the CFU-F assay on fresh BMA to detect the age-related 
changes in number of MSCs. The results of the current study indicated a significant 
age-related decline in the number of MSCs (Figure 3.6A), a 4-fold decline in MSC 
numbers between the young donors (163 colonies/ml BMA) and old donors (38 
colonies/ml BMA) using CFU-F assay (Figure 3.6B). These data in principle support 
previous data by Stolzing et al. (96) where they have shown a significant 4-fold decline 
in MSC numbers between paediatric (0-20 years old, median of 100 colonies/ml) and 
adult donors (21-40 years old, median of 25 colonies/ml) by CFU-F assay. However, 
the groups used in these two studies were different, spanning an age range of 5-55 
years old in the Stolzing et al., study and 19-89 years old in the present thesis. The 
numerical difference in the number of colonies in the common 40-60 years old age 
group in both the studies could be due to the fact that Stolzing et al., plated 5 x 104 
cells/well for CFU-F assay while fresh BMA was used for the current study. Even 
though the trend of age-related decline in the number of MSCs is common in both the 
studies, there is notable difference in the age range of donor age used, CFU-F plating 
method and in the number of donors recruited in the studies. Stolzing et. al showed a 
prominent drop in MSCs after the completion of skeletal growth which is also observed 
in the present study.  
 
D’Ippolito et al., performed similar studies and found a significant decline in the number 
of colonies (66.2 + 9.6 per 106 cells) in young (3-36 years old) donors as compared to 
old (41-70 years old) donors (14.7 + 2.6 per 106 cells) (132).  However, they used 
vertebral BM and counted CFU-ALP (alkaline-phosphatase positive), which could 
explain the variation in the number of colonies. Muschler et al., performed age 
correlations studies on iliac crest BMA and also counted CFU-ALP, and found a 
significant age-related decline in the number of CFU-ALP for both the genders. They 
also found a decline in the number of CFU-ALP per 106 NCs, sharper in females from 




Using a smaller cohort of patients, similar trend was recently observed by our group 
with a significant decline in the number of colonies in females as compared to a non-
significant decline in males, across the whole age range between 22 and 80 years old 
(111). Both these studies were in contrast to the gender related data obtained in this 
project. However, owing to the lower number of female donors in the young and 
intermediate groups and lower number of males in the old donor groups (Appendix 3, 
supplementary Figure 3.1), no firm conclusions can be made in terms of  age-related 
declines in the number of MSCs in separate genders. An equal number of donors from 
both the genders in each age group (minimum n=10) will be required for a firmer 
conclusion. 
 
The present results indicating a decline in the number of MSCs is in contrast to work 
done previously by Justessen et al., where they found no significant difference in the 
number of MSCs in normal conditions with respect to both, age and gender (196). They 
found a significant difference in the MSC colony number with age only in those treated 
with osteogenic medium (4+/-4 colonies of seeded 100,000cells/cm2 NCs for young 
donors aged 18-42 and 2+/-4 of seeded NCs for old donors aged 66-78). This study 
also used density centrifugation for erythrocyte removal, scored colonies with 16 or 
more cells in healthy donors and in osteoporosis patients, in contrast to this study 
where NH4Cl was used for erythrocyte lysis, colonies with only more than 50 cells were 
scored and only healthy donors were recruited.  
 
Jing Li and team used uncultured cells from BM of donors aged 1-52 years old and 
found no age-related decline in the number of colonies. In contrast, this study analysed 
uncultured BM MSCs from adults ranging from 19-89 years old and categorised donors 
in 3 age groups. It used direct BM plating technique which prevented the loss of cells 
that occurs in centrifugation. It also used a media that was standardised for growing 
uncultured BM MSCs along with ensuring that a colony always had >50 cells. Overall, 
in this study, a significant age-related decline was observed in the number of colonies 
obtained from uncultured BM MSCs with advancing age and a 4-fold decline in old 
donors (>60 years old) when compared to young donors (<40 years old). Importantly, 
the decline in the number of MSCs was notable from the age of 40 years old and not 
60 years old as expected. While the numerical value was the lowest in old donors, the 
decline was the steepest in the intermediate age group suggesting the skeletal ageing 
in vivo begins in the fifth decade of life. The other important observation was the 
presence of old donors with a relatively higher number of MSCs as compared to the 
others in the same age group, which was comparable to MSC numbers obtained from 




MSCs) potentially had a younger ‘biological age’ in comparison to others with the same 
chronological age (same age group). 
 
Colony area and colony ID were analysed next to evaluate the age-related differences 
in the proliferative capacity of MSCs. Age-related changes in proliferative capacities of 
MSCs have been studied by different methods using cell proliferation assays, 
cumulative population doublings calculations and population doubling time in cultured 
MSCs. Some have shown an age-related decline in MSC proliferation (211) and others, 
not shown a difference (197). As mentioned in this thesis Introduction (section 1.2.2), 
such studies are limited by the fact that cultured MSCs undergo passage-dependent in 
vitro ageing process that can over exaggerate or negate any age-related changes in 
MSCs in vivo. On the other hand, the  studies that have investigated MSC proliferation 
capacity prior to passaging are very limited. While they have measured colony area 
and the cellular contact between the cells in the colony (201), these factors have not 
been studied in relation to age-related changes. Therefore, the data from this study on 
any differences in colony sizes and IDs in relation to donor age are entirely novel. 
 
Gothard et al., proposed a segregation of BM MSC colonies into large (>2.5mm 
diameter) and small (< 2.5mm diameter) based on median diameter chosen form the 
entire diameter range observed. They also segregated colonies as dense or sparse 
based on cellular contact confluency within a colony. High cell contact (>80%) was 
defined as dense and low cell contact (<80%) was defined as sparse colony. In the 
present study, different sizes of colonies were observed, which did not indicate a clear 
visual segregation by size or density, and generated a unimodal distribution following 
frequency distribution analysis by the GraphPad software (Figure 3.7A). To make a fair 
comparison with the Gothard et al. study, in this study, the colonies were segregated 
based on the median area from all the colonies (10.64mm2) obtained from ImageJ 
software analysis which was equivalent to average diameter of 3.76mm. The diameter 
was larger than the average colony diameter described in Gothard et al. study and the 
area was similar to colony areas presented in D’Ippolito study (10.23mm2 for young 
donors, 8.64 mm2 for old donors (132)).  
 
Even though colony area measures the size of the colony indicating the spread of the 
cells, it does not measure the density of the cells within a colony. A colony can be large 
and dense or large and sparse as defined by Gothard et al., 2013. A large dense 
colony has more cells that are in close contact with each other indicating high 
proliferation and a small sparse colony will have fewer cells that are comparatively less 




MSC with high proliferative capacity and a small sparse colony will originate from the 
least proliferative or pre-senescent MSCs (208). Hence the area of a colony alone is 
not a true indicator of the proliferative capacity of the MSCs and the colony ID, which is 
a combined measure of area and density, is thus an improved measure of the 
proliferative capacity of the MSCs. As listed in Table 3.2, only 2 studies have 
mentioned colony density in their studies. While one of them found no age-related 
difference in their research using uncultured cells (200) (data was not shown), the more 
recent study using cultured cells by Travis et al., in 2017 observed an age-related 
decline in the colony density visually (no quantification) (139). 
 
ImageJ analysis of colony area and ID in this study helped to generate numerical ID 
values for all the colonies. The median values obtained from the analysis of colony 
area measured for all the colonies were used to categorize the colonies as large or 
small and then compare their ID in young and old donors. The results indicated a 
significantly higher ID of all colonies in young donors as compared to old donors 
(p<0.0001) (Figure 3.8A). Small and large colonies were observed in both, young and 
old donors but young donor colonies always had higher ID irrespective of the size of 
the colony (Figure 3.8C and D). The decline in IDs was more prominent in small 
colonies than in large colonies suggesting that old donor MSCs generate proportionally 
more small sparse colonies than proportionally less large dense colonies. This was 
opposite to the original hypothesis of fewer large dense colonies originating from most 
proliferative cells in old donor BM. These are important new data that highly-
proliferative MSC remain to be present in old donor BM. 
 
The presented data confirms the concept of decrease in the rate of MSC proliferation 
with increase in donor age in uncultured cells (212). The analysis of colony area and 
density has been previously done only by Gothard et al., (201), but they did not 
investigate these parameters on a large number of colonies with respect to donor age. 
Furthermore, no CFU-F study, as per my knowledge, has dissected the CFU-F assay 
at the single colony level to understand the age-related changes in colony area and ID 
making data from this chapter novel, in comparison to others to study age-related 
changes in proliferation of minimally cultured individual MSCs. Once the age-related 
decline in colony area and ID were established, next it was hypothesised that colony 
area and ID of MSCs when exposed to old donor serum (OS) will show an age-related 
decline as compared to media supplemented with YS. The other hypothesis with 
exciting potential applications was to test if the presence of young microenvironment 
(media supplemented with YS) could reduce the loss of proliferative capacity seen in 




their native conditions in vivo (100). To mirror the biological conditions of old donors, 
media supplemented with old and young donor serum was used instead of standard 
media supplemented with FCS. Preliminary experiments established optimal conditions 
and controls for these investigations, and established that human serum supported 
colony formation from MSCs better than negative control FCS (Figure 3.9). 
 
In this study, a decline in proliferative capacity of MSCs from both young and old 
donors was observed when they were grown in media supplemented with OS. Using 
both colony area and colony ID as parameters to measure MSC proliferation at single-
colony level, the data suggested that the use of OS negatively impacted the 
proliferative capacity of MSCs as seen by the presence of lower frequency of large 
colonies and higher frequency of small colonies in Figure 3.13 and 3.14. This was also 
shown by the low colony ID in young donors when grown in OS in Figure 3.13. This 
can be explained by the increase of ROS in cells as shown in a rat model (117) and by 
the presence pro-inflammatory factors (213) in OS that inhibit proliferation and 
eventually lead to MSC senescence. Increased levels of pro-inflammatory cytokines 
and SASP have been associated with increased age in human donors (214-216). 
Similar investigation in serum from human donors used for culturing young and old 
donor MSCs in this thesis, will help to explain the loss of proliferative capacity of MSCs 
from old donors. It will also provide evidence for the impact of aged microenvironment 
(SASP released from aged cells in medium containing human serum) in vivo.  
 
Abdullah and colleagues studied the effect of aged serum on hMSC-tert cell line and 
found that the gene expression of MSC multipotentiality markers in old serum was 
significantly lower (p<0.01) than the cells grown in young serum emphasising the 
impact of aged microenvironment on MSC-like cells (203). Josephson and colleagues 
performed experiments in mice and found a significant decline in the number of 
colonies from young (12 weeks) animal grown in serum from middle-aged (52 weeks) 
animals. They found an increase of SASP in MSCs grown in serum from middle aged 
animals (146). Quantification of pro-inflammatory cytokines and SASP molecules (like 
IL6, IL8, TNF, Tp53) from the media of old donor MSCs would further explain the loss 
of proliferative capacity of MSCs in OS. Additionally, proliferation of old donor MSCs 
grown in media supplemented with YS could be only slightly improved (limited 
rejuvenation). Human serum was used to reflect physiological conditions in vivo and 
indicated towards limited rejuvenation of old donor MSCs in YS. Serum is the fluid that 
remains after removal of all the clotting factors. The use of other human supplements 
like PL (platelet lysate) could potentially display stronger rejuvenation, owing to the 




platelets by freeze/thawing. Investigations using PL have shown that the osteogenic 
differentiation of MSCs  grown in young donor PL was more pronounced as compared 
to their differentiation when grown in PL from old donors (217, 218). 
 
The concept of MSC rejuvenation with culture in YS was not as pronounced in the 
present experiments, but positive trends were observed. The colony area 
measurements of old donor MSCs showed a trend for significantly bigger colonies 
when grown in media supplemented with YS as compared to OS (Figure 3.12B). Also a 
trend for higher ID of colonies from old donors grown in YS as compared to OS was 
found (Figure 3.14B). The fact that colony area was increased more than colony ID can 
be explained by the fact that YS increased cell migration out of the colony more than 
cell proliferation, this can be also useful for MSC function in vivo. This hypothesis can 
be further tested by using holographic microscopy by monitoring of cellular movement 
in real time (219). Growing old donor cells on extracellular matrix derived from younger 
donors as shown previously (139, 220), could also demonstrate noteworthy 
conclusions with possible clinical applications of rejuvenation. Overall, the present data 
indicate that exposing old donor MSCs to supplements (serum, PL, extracellular 
matrix– collagen fibres and proteins) from young donors can help aged MSC not lose 
their proliferative capacity any further, and possibly improve their migration capacity. 
Treatment of uncultured MSCs with anti-oxidants prior to clinical use (46), use of 
senolytic drugs that target senescent cells using MSC ageing surface markers (221) 
along with use of supplements to provide a ‘young’ microenvironment could also aid 
rejuvenation and delay the process of ageing.   
 
In conclusion, this chapter has shown a significant age-related decline in the number of 
BM MSCs in older donors compared to young resolving the existing controversy. 
Colonies from the CFU-F assays showed a significant age-related decline in their area 
and ID. For the first time, colony sizes and densities were quantified (measured in ID) 
along with colony area alone and correlated with donor age, and showed  an age-
related decline in the proliferative capacity of individual MSCs from old donors. The 
proliferative capacity of  young and old donor MSCs were also investigated in more 
physiological conditions with human serum to mirror in vivo conditions in which MSCs 
reside. OS negatively impacted the proliferative capacity of young and old donor MSCs 
and exposing old donor cells to YS stopped further loss in their proliferative capacity. 
These data, for the first time, suggest the importance of the microenvironment (MSC 
niche) in their functions and showing that both intrinsic and extrinsic factors should be 




Chapter 4 Investigating age-related changes in human BM MSC 
using the CD45lowCD271+ phenotype  
In the previous chapter, age-related changes in number and proliferative capacity of 
BM MSCs were investigated using the classical colony-forming assay. The results 
showed a significant decrease in MSC numbers across the whole age range (19-89 
years old) (section 3.3.1), as well as their reduced proliferative capacity measured by 
colonies’ integrated density (section 3.3.3). Reduced proliferative capacity was also 
observed in MSCs when they were grown in media supplemented with old donor serum 
as compared to media supplemented with young donor serum. This chapter will 
explore any potential changes in BM MSC gene expression with a focus on the 
molecules involved in MSC multipotentiality. For this, uncultured BM MSCs were sorted 
based on the CD45lowCD271+ phenotype, as previously described (109, 188, 222) and 
gene expression in young (19-40 years old) and old (60-89 years old) donor MSCs 
were investigated and compared.  
4.1 Introduction  
The identification and characterisation of uncultured BM MSCs has been previously 
performed using flow cytometry and a number of surface markers including Stro-1 
(133, 197), SSEA-4 (139, 223), MSCA-1 (224) and others, outlined in section 1.2.1. 
Over the years, new markers such as CD140a (225), CD140b (226), CD146 (227), and 
CD295 (228) have also been proposed, sometimes as single markers but usually in 
combination with ISCT panel markers (105, 229) for ensuring appropriate identification 
of BM MSCs. 
 
CD271 or Low affinity nerve growth factor (LNGFR) was proposed as a very specific 
BM MSC marker in 2002 (108, 230). The combination of CD45 (pan-hematopoietic 
lineage cell marker) and CD271 was later proven to be most useful for the identification 
of BM MSCs, as it provided the highest resolution and the least cross-reactivity with 
other BM cells. Since then, CD45lowCD271+ phenotype has been used by many 
independent laboratories where CD271 was consistently found to be present in BM 
MSCs making it a preferred choice for studying uncultured BM MSCs (109, 231, 232). 
In one study, Torales and colleagues carried out flow cytometry and compared the 
percentage of cells that expressed CD73, CD90, and CD105, and were negative for 
CD45 and CD34, with the percentage of cells that were CD271+ (233). They found that 
while the traditional ISCT panel showed an average 0.54% of mononuclear cells as 
putative MSCs, CD271+ alone was highly specific and 0.53% of BM cells expressed 




showed that the addition of CD45 as a ‘negative’ gating marker is necessary for a 
clearer MSC identification, and the removal of CD271low ‘passenger’ cells that appear 
to be of a hematopoietic origin (233). 
 
Considering that CD45lowCD271+ cell phenotype has been extensively used for 
identification of BM MSCs (section 1.2.1), this phenotype was chosen to be used in this 
chapter to further investigate age-related changes in the numbers and the gene 
expression in native BM MSCs without any culture manipulations. As shown in the 
previous chapter, the age-related decline in the number of BM MSCs quantified using 
the CFU-F assay was significant (Section 3.3.1), however, the CFU-F assay remains 
culture-dependent. It was thus logical to explore whether the same decline would be 
observed using flow cytometry, with no culturing steps involved, and to evaluate the 
results obtained by both methods. This is of particular importance as the studies that 
have investigated age-related changes in number of BM MSCs using flow cytometry 
methods remain limited (Table 4.1).   
 
Table 4.1 includes studies that have investigated the age-related changes in number or 
percentage of BM MSCs using flow cytometry. While most of the studies (4 out of 6) 
have indicated a decline in the number of BM MSCs with increasing age,  a number of 
variations can be observed. This includes disparities in grouping methods of ‘young’ 
and ‘old’, additionally, differences in cell isolation techniques and the markers used to 
identify BM MSCs were most notable. Interestingly, large donor variation is another 

























BM: bone marrow, BMA: bone marrow aspirate, Y: young, I: intermediate, O: old, F: females 




BM from iliac crest Y: 22-44;   O: 66-74 STRO-1 No change 
(197) 
 
Femoral head BM Y:<50;    I:50-65; O:>65 STRO-1 No change (237) 
BM  13-80; Y:<45 Multiple Decline (97) 
Femoral neck bone Y:28-31;     O:80-97 
CD271+    
SSEA-4+ 
Decline (223) 
BMA 22-80; no groups 
CD45low 
CD271high 
Decline         
(F only) 
(111) 
Iliac crest bone 
graft 







4.1.1 Candidate MSC multipotentiality genes 
As mentioned in section 1.2.2, the adipogenic bias of aged BM MSCs is among the 
most established age-related changes described to date. Table 4.2 lists previous 
studies that have investigated the shift from osteogenic to adipogenic differentiation in 
MSCs in aged donors. Of importance, all these investigations have been performed 
using cultured MSCs. The disruption in bone formation has been suggested to be due 
to the impaired ability of MSCs towards osteogenic differentiation in older donors. This 
loss in bone formation is compensated by excessive adipocyte formation. Different 
pathways and molecules have been suggested to be responsible for this shift, 
however, the exact mechanism is not yet completely understood. Of note, bone 
homeostasis is not only a result of bone formation, but also of bone resorption (section 
1.1.4).  In one study, an age-related increase in the expression of a bone resorption 
molecule RANKL in pre-adipocytes along with an increase in osteoclastogenesis, was 
observed within the BM (238). In part age-related bone loss is brought about by 
disruption of bone resorption, described in section 1.1.4. 
 
Apart from the shift towards adipogenic differentiation and bone remodelling, the other 
factor that is potentially affected by older age in MSCs, is their communication with 
other BM cells with the use of trophic factors including chemokines. CXCL12 (C-X-C 
motif chemokine 12) is one such chemokine known to be critical to maintain the HSC 
pool within the BM (239, 240) as well as being involved in MSC migration and 
apoptosis (241). CXCL12 is regulated by Cx43 and Cx45 (242), where Cx43 is the 
most common gap junction within the bone (148). However, age-related changes in 
CXCL12 production by native BM MSCs remain unexplored. In terms of direct cellular 
interactions, connexins are intercellular communication molecules and as an entire 
family of molecules, have been suggested to have an age-related decline in many 
tissues with a potential link to human ageing and cancer (243). Both of these molecules 
will be discussed further in 4.1.1.5. 
 
As BM MSCs are very rare cells (87), the numbers of purified cells are not sufficient to 
perform standard differentiation assays, which normally use a range of 2x105-2x106 
cells/ assay (108). Therefore, gene expression in CD45lowCD271+ cells was studied as 
the first step to explore their differentiation and cell communication potentials. 
4.1.1.1 Osteogenic-lineage transcripts 
RUNX2 (Runt related transcription factor 2) is the master regulator of bone formation 




share a common runt domain. RUNX2 is the earliest indicator of osteogenic 
differentiation and is also known to tightly regulate chondrocyte hypertrophy and 
vascular invasion of developing skeletons. In MSCs, levels of RUNX2 expression have 
been mainly investigated to detect their osteogenic differentiation capacity and MSC 
commitment towards osteo-progenitor lineage (244). With respect to age-related 
changes, overexpression of RUNX2 has been suggested to contribute to bone 
resorption in osteoblastic lineage cells by increasing RANKL expression (245). 
However, when narrowing to MSCs from human donors, investigations are sparse. In 
older donors, the expression of RUNX2 has either been observed to decrease or have 
no change in cultured MSCs providing no substantial evidence for age-related 
differences in uncultured MSCs (Table 4.2). Nevertheless, it could be hypothesised that 













































BM: Bone marrow, IC: Iliac crest, Y: young O: old, A:adult,  *: investigated at protein level
Function Source of cells/ 
MSCs 
Age groups Genes tested Age related changes Reference 
Osteogenic 
differentiation 
BM from humans 17-90; 
Y:<50; O:>50 
RUNX2 Decreased (133) 
BMA from IC in 
humans 
Y:<50; A:50-
65 ; O:>65 
RUNX2, OC, ALP, 
OPN 
No changes in RUNX2 (246) 
Bone graft from IC Y:18-49; 
O:>50 
RUNX2, OC, ALP, 
OPN 
No changes in RUNX2 (247) 
Adipogenic 
differentiation 




LPL, PPAR- No changes in PPAR- (97) 
Human ACL Y:17-27;       
O:69-79 
LPL, PPAR- No changes in PPAR- (248) 
BM from   iliac spine Y: 18-42;           
O: 66-78 
PPAR- No changes (196) 







BM from humans Y:<50; O:>55 RANKL, OPG RANKL increased, 
OPG decreased 
(249) 







SPARC (Secreted protein acidic and rich in cysteine) or more commonly known as 
‘Osteonectin’ is a non-structural matricellular glycoprotein in the bone that binds 
calcium. It is secreted by osteoblasts and pre-osteoblasts during bone formation and is 
needed for bone calcification (251). Both, over expression (252) and selective deletion 
of SPARC (253) have been associated with impaired motility, suggesting that its 
normal functioning is vital for bone growth and development. With respect to MSCs, the 
precursors of osteoblasts, it is not surprising that MSCs too express certain levels of 
SPARC, shown previously by our group (188). Its role in the functions outlined above 
suggests that it plays an important part in the MSC transition towards the osteogenic 
lineage. It is thus expected with increasing age, as the fat content increases with a 
compromise in bone formation, the levels of SPARC potentially decline. However, the 
number of studies investigating this also remain limited, with no study to date 
investigating any changes in its expression in uncultured MSCs. Interestingly, our 
previous study using cultured MSCs have shown that SPARC expression significantly 
increased in late-passage, pre-senescent MSCs (222) therefore the present evidence 
on the association of with MSC ageing or senescence remains controversial. 
 
SFRP1 (Secreted frizzled related protein 1) is a member of the SFRP family of 
molecules containing cysteine rich glycoproteins, homologous to the putative Wnt 
(wingless integrated)-binding site of the frizzled proteins (fzd receptors). It acts as a 
soluble modulator of the Wnt signalling pathway. Wnt signalling pathway is a major 
pathway involved in skeletal development, bone mass regulation and is often regarded 
integral for osteogenesis (254). SFRP1 is well known as a Wnt antagonist that acts by 
directly binding to Wnt proteins, making it a target for therapeutic approaches for bone 
remodelling and repair. SFRP1 has been extensively explored in bone and bone-
forming cells (254). The deletion of SFRP1 reduced osteoblast and osteocyte 
apoptosis in vivo and proliferation and differentiation capacity of  osteoblasts in vitro in 
mice (255). It has also been reported to block osteoblast induced osteoclastogenesis 
by inhibiting RANKL dependant osteoclast formation (256). SFRP1 was also found to 
suppress Wnt signalling in an immortalised osteoblast cell line (257). Overall, previous 
studies indicate that SFRP1 inhibits osteoblast formation and their coupling with 
osteoclasts. Based on these findings, SFRP1 inhibitors were developed as potential 
therapies with the aim of increasing bone formation (258). While their potency has 
been tested in vitro, in vivo efficacy in appropriate animal models or in human cells are 





The effect of age on SFRP1 expression has not been extensively studied to date. 
Rauner and co-workers investigated the level of expression of SFRP1 in the 
osteoblasts of young (6w), adult (6mo) and old (18mo) male C57BL/6J mice and found 
a significant age-related decline (259). Considering the above stated findings and the 
fact that the gene has been found on osteoblastic lineage, it can be hypothesised that 
MSCs, expression of SFRP1 could show an age-related decline. Indeed, this was 
observed in our previous study where SFRP1 displayed an age-related decline in BM 
CD45lowCD271+, cells but this was observed in paediatric donors compared to adult 
donors (188). 
 
Owing to their involvement in MSC osteogenic differentiation, these three transcripts 
were selected for investigating age-related differences in uncultured MSCs in relation 
to their osteogenic differentiation potential. 
4.1.1.2 Adipogenic-lineage transcripts 
An increase in the transcripts associated with adipogenesis have been observed in 
MSCs aged in vitro (section 1.2.2) or in aged animals in vivo (80, 143, 260). Among 
many transcripts, an increase in PPAR- (Peroxisome proliferator activated receptor-
gamma) and FABP4 (fatty acid binding protein 4) expression has been associated with 
the adipogenic differentiation of MSCs (261). LepR (Leptin receptor) plays an important 
role in bone-fat balance (262, 263) and its expression was shown to decline in 
uncultured cells by our group previously (188). However their donor range included 
paediatric samples and the oldest donor was 72 years old. Age-related changes in 
adults and in donors aged above 75, with respect to expression of these transcripts in 
uncultured MSCs is yet to be explored.  
 
PPAR- gene encodes a molecule termed the PPAR-receptor. There are two 
different isoforms of the protein, named PPAR-1 and PPAR-2 that exist due to 
alternative splicing of the gene. While PPAR-1 is expressed in various cell types 
including osteoblasts, PPAR-2 is restricted to adipocytes including those within the BM 
(264). The receptor is found in abundance not only in adipose cells but also in pre-
adipogenic cells, endothelial cells and vascular smooth cells (265). Owing to its 
requirement in adipose tissue formation, PPAR- is considered a key regulator of 
adipogenic differentiation. PPAR- in MSCs can be both, anti-osteogenic and pro-
adipogenic, therefore it can play the role of osteoblastic/adipogenic ‘switch’ (266). It 
has thus been described to show ‘tremendous potential in novel strategies for bone 
tissue engineering and clinical applications’ (267). As mentioned above, there is 




donors as well as in cells aged in vitro through culture expansion (143). Based on 
previous literature , it was hypothesised that there would be an age-related increase in 
the expression of PPAR-in native BM MSCs from older donors.  
 
Leptin receptor (LepR) is another transcript for which there is an increasing body of 
evidence on its role in the bone-fat balance (262, 263). LepR gene encodes for the 
surface receptor for leptin, a hormone secreted by adipocytes and known to regulate 
body weight and metabolism (268, 269). To understand the gene encoding for leptin 
receptor, it is worth taking a step back to understand the role of leptin. 
 
Leptin is an adipokine predominantly produced by adipose cells and is known to 
contribute to energy balance by acting on hunger/satiety centres located in the 
hypothalamus (270, 271). Its level increases with weight gain and decreases with 
reduced weight (272). The adipokine has also been shown to be secreted by skeletal 
muscles and bone cells and is an established growth factor for muscle and bone in 
early life (268). The receptor for the leptin adipokine (CD295) has been shown to be 
present in musculo-skeletal tissues (263). Initially, it was thought that leptin hormone 
contributed to age–related decline in bone mass via the hypothalamus and the beta-
adrenergic receptors (273). However, more recent studies suggest that the hormone 
may have a more direct role on bone lineage cells including MSCs (274).  However, the 
role of CD295, the leptin receptor in MSC differentiation to bone is not very well 
understood. With respect to ageing, Laschober and colleagues showed an age-related 
increase in the level of expression of LepR at the protein level (CD295) in BM MSCs 
(126). Their study also indicated that the CD295 positive BM MSCs in old donor MSCs 
were more apoptotic than young donor MSCs, quantified using Annexin-V staining. On 
the other hand, our group has previously shown an age-related decline of LepR gene 
expression in CD45lowCD271+ cells in a small number of donors (n=8) (188). We 
therefore hypothesised an age-related difference in the transcript of this gene in native 
BM MSCs from old donors. 
 
FABP4 belongs to the FABP (fatty acid binding protein) family of transport proteins that 
are responsible for the transfer of fat or lipophilic molecules across the cellular 
membranes and is a well-established marker for differentiated adipocytes (275). It was 
first detected in adipose tissues and mature adipocytes and has also been termed as 
adipocyte P2 (ap2) due to similarity with myelin P2 protein (276), which is also a part of 
the FABP family. It is highly expressed during adipogenic differentiation of MSCs and is 
transcriptionally controlled by PPAR- agonists, fatty acids and insulin. With respect to 




period of 21 days undergoing adipogenic differentiation in parallel to the expression of 
PPAR-(277). Based on these findings, an age-related increase in its expression in 
uncultured BM MSCs was hypothesised.  
4.1.1.3 Oxidative stress in MSCs and anti-oxidant enzyme SOD3 
Presence of reactive oxygen species (ROS) has been suggested as one of the 
potential drivers of the adipogenic bias of MSCs (278, 279). ROS are by-products of 
metabolism inside a cell, mitochondria being the major site of ROS production. 
Oxidative stress is the consequence of an excessive ROS production and limited 
activity of antioxidant enzymes to balance the negative impacts of ROS. A decline in 
the anti-oxidant enzymes with increasing age leads to reduced capacity of scavenging 
of ROS (280). Excessive ROS causes accumulation of DNA damage leading to cellular 
senescence in ageing and associated diseases (281). This ultimately drives the cell 
onto the apoptosis path and is believed to be one of the major causes of age-related 
differences in MSCs. 
 
During metabolism, ROS intermediate molecules like superoxide and peroxides are 
formed as a part of cell metabolism. These intermediate ROS products are scavenged 
by anti-oxidants enzymes like superoxide dismutase (SOD) and glutathione peroxidase 
catalase (Gx) to prevent the interaction of ROS with lipid membranes and proteins 
within the body (282). SOD converts superoxide ion to hydrogen peroxide, which is 
further converted into water and oxygen molecules under catalase and glutathione 
peroxidase activities (282). 
 
Anti-oxidants thus play an important role in critically maintaining the appropriate ROS 
levels. SOD or superoxidedismuatse form the first line of defence in scavenging the 
superoxide molecule (283). ‘Dismutation’ by definition is a redox reaction that involves 
the formation of two products of different oxidation states from a single molecule of 
intermediate oxidation state. Superoxide molecule (O2
-) has a negative charge which 
causes it to react with lipids and proteins nearby causing damage. SOD thus gets its 
name from the function of carrying out ‘dismutation’ of superoxide molecule to 
hydrogen peroxide (H2O2). H2O2 further is scavenged by Gx into water and oxygen 
molecule. SOD enzymes include SOD1, SOD2 or SOD3. SOD1, also known as 
Copper/Zinc SOD (Cu/Zn SOD) is mainly located in the cytosol of the cells. SOD2 is 
also known Manganese-SOD (Mn-SOD) is majorly located in the mitochondria of cells. 
As mitochondria is the major site of ATP production, SOD2 has been investigated in a 
large number of studies to understand the impact of this anti-oxidant enzyme in 





SOD3 is also known as extracellular SOD (EC-SOD) and gets its name from its 
location. SOD3 has been shown to be secreted by MSCs (284), while SOD2 and SOD1 
do not have any such cellular specificity. Due to its location, it is the only SOD that 
scavenges ROS in the extracellular compartment of cells and catalyses the dismutation 
of superoxide molecule. Within the BM, MSCs exist within a hypoxic BM niche with 
oxygen concentrations as low as 2-8% O2 (285). Culture expansion in artificial 
conditions automatically expose these cells to a ‘hyperoxic’ condition but it is usually 
referred to as ‘normoxic’ or normal oxygen concentration due to the widespread 
practice of in vitro expansion. An increase in the oxidative stress in MSCs has often 
been suggested as a potential cause for the senescence and their adipogenic bias in 
vitro (278, 286).   
 
Mohd Ali and colleagues compared the proliferative capacities of BM MSCs from young 
(<30) and old (>60) donors in hypoxic (5% O2) and normoxic (20% O2) conditions. They 
found that MSCs from older donors demonstrated reduced proliferative and 
differentiation abilities along with increase in cellular senescence. Interestingly, they 
found that MSCs cultured under hypoxic conditions in both age groups were able to 
demonstrate enhanced self-renewal and proliferative capacity (287). Another study 
investigated the changes in SOD3 at the mRNA and protein level during differentiation 
of cultured BM MSCs. The study found significantly higher levels of SOD3 during 
adipogenesis, lower levels during chondrogenesis but no difference during 
osteogenesis (288).  
 
Considering that increased adipogenic differentiation bias is also age-related (section 
1.1.4) and that increase in oxidative stress is among the oldest theories of ageing 
(section 1.1.1), it can be said that SOD3 may be affected in old donors. However, more 
clarity in how it alters in uncultured BM MSCs in old donors is required. It may be 
hypothesised that the level of ROS in old donor MSCs will be greater and the levels of 
anti-oxidant enzyme SOD3 in old donor MSCs will be lower than in young donor MSCs. 
4.1.1.4 Transcripts associated with bone remodelling 
Bone remodelling is a tightly regulated mechanism, which under normal conditions 
perfectly balances the rate of bone resorption by osteoclasts and the bone formation by 
osteoblasts. The bone remodelling cascade and the different cells involved was 





RANKL (Receptor activator of nuclear factor kappa beta ligand) is expressed by 
osteoblasts and binds to its target RANK that is expressed by osteoclast progenitors 
(64, 74). RANKL is a type II membrane protein from the tumour necrosis factor (TNF) 
super family. It is a homotrimeric protein and exists in both, soluble and membrane 
form. However, the soluble form is known to have lesser ability to form osteoclasts 
(289). MSCs have been known to contribute towards both, bone resorption by 
expression of RANKL and bone formation as precursors of bone forming cells (290). 
While culture expanded MSCs are able to express RANKL and have been shown to 
contribute to osteoclastogenesis (291), its expression in MSCs in relation to in vitro 
ageing remains controversial (Table 4.2) and in uncultured MSC, unexplored.  
 
RANK (Receptor activator of nuclear factor kappa beta) is the receptor for its ligand, 
the RANKL and is also designated TNFRSF11A. RANK is expressed on the surface of 
osteoclast precursors and RANKL binding to RANK initiates the process of osteoclast 
formation. It is expressed on osteoclast precursors (292) which upon maturation form 
bone resorbing osteoclasts. However, osteoclast formation takes place only after the 
activation of TNF associated receptor factor 6 (TRAF6) signalling (293). This then 
mediates the MAPK/NF-Kb pathway which eventually brings about osteoclastogenesis.   
 
OPG (Osteoprotegerin or Tumour necrosis factor super family member 11B/ 
TNFSFR11B) is expressed widely by a number of cells and is the natural 
decoy/inhibitor of RANKL. If OPG (instead of RANKL) binds to RANK, then osteoclast 
formation stops and bone resorption does not take place. It is highly expressed in 
tissues including osteoblasts, pre-osteoblasts and other cells of the bone lineage in the 
BM (71). It also belongs to the TNF receptor superfamily but is different from the other 
members as a secreted protein that does not contain a trans-membrane domain (294).  
 
An age-related increase in RANKL and decrease in OPG in MSCs was hypothesised, 
potentially contributing to increased bone resorption rates in vivo, accounting for the 
age-related bone loss in old age. 
4.1.1.5 Transcripts associated with cellular interactions 
CXCL12 (Chemokine motif 12 also known as SDF-1 or stromal derived factor-1) is a 
major chemokine facilitating the chemotaxis of HSCs, MSCs and other BM cells (295). 
It is a member of a large family of chemokines that are structurally related. It binds to 
its receptor CXCR4 on target cells and is known for its role in the maintenance of the 
hematopoietic compartment of the BM niche (239, 240) and in chemotaxis of MSCs 




stromal cells lining the endosteal surface (297). Most HSCs within the BM are usually 
in contact with cells expressing high amounts of CXCL12 which have been named 
CXCL12-abundant reticular cells (or CAR cells) in mice (239). CXCL12 is key to 
maintain the healthy pool of HSCs. The counterpart of CAR cells in human BM are 
likely to be adventitial reticular cells, topographically overlapping with CD45lowCD271+ 
MSCs (298). 
 
In addition to its support for hematopoietic cell activities, such as their retention and 
egression from the BM, CXCL12-CXCR4 signalling axis has also been implicated in the 
processes related to osteoclast recruitment, chemotaxis and bone resorption (299). 
There are also reports describing the impact of CXCL12-CXCR4 signalling in 
metastases of breast cancer, lung cancer and some hematopoietic malignancies to the 
bone (300). 
 
 Investigation in culture expanded MSCs to understand any differences with the 
advancement of in vitro ageing, to the best of my knowledge, does not yet exist. The 
information regarding the levels of its expression before culturing MSCs, also remain 
limited. Our group found very high levels of CXCL12 expression in uncultured CD45-
CD271+ BM MSCs as compared to CD45+CD271-  HLCs but there was no age-related 
differences observed with 8 donors. As red (hematopoietic) marrow is replaced by 
yellow (fatty) marrow as a function of age, it was hypothesised that there could 
potentially be an age-related decrease in the levels of CXCL12 in uncultured BM MSCs 
from aged individuals. 
 
Among the connexins, Connexin43 (Cx43) is the most abundant gap junction protein in 
bone cells, mainly associated with the intercellular interaction between osteocytes and 
osteoblasts (148). It is essential for intercellular interaction, normal bone formation and 
for the viability of osteocytes (301). As the main gap junction in mature bone-lineage 
cells, it is therefore an important molecule to investigate with respect to in vivo MSCs. 
In the BM, MSCs interact with each other forming an intricate net or scaffold upon 
which other BM cells including HSCs reside, these networks are facilitated by Cx43 
gap junctions. The gap junctions also regulate the transcription of CXCL12 in  a cell 
contact dependant manner (242). 
 
Previous studies investigating age-related differences in the expression of Cx43 have 
found a significant decline in native CD45lowCD271+ BM MSCs (188). Studies in human 
derived cultured expanded MSCs to investigate changes with in vitro ageing do not 




significance of Cx43 in bone formation and skeletal homeostasis in rats. They have 
found no age-related differences in Cx43 gene expression in cultured BM MSCs (302). 
Although the data remains controversial, these studies present Cx43 a potential 
molecule affected by age in native BM MSCs (303).  
 
At the protein level, Cx43 or gap junction protein alpha 1 (GJA1) is an intercellular 
membrane spanning channel that mediates direct exchange of small molecules, ions, 
nucleotides between neighbouring cells. The role of Cx43 in skeletal metabolism and 
homeostasis is now well established as gap junction intercellular communication 
(GJIC) (304).  In relation to the bone, a growing body of evidence exists on the 
importance of Cx43 in modulating bone cells to respond to mechanical signals and 
growth factors to enable bone healing post fracture (148, 305). Absence or reduced 
Cx43 function have been associated with reduced levels of osteogenic genes (306) 
and reduced level of osteoclast formation leading to decreased bone resorption (307). 
These findings have established that Cx43 is vital for growth, development and 
maintenance of healthy bone health. Owing to the various important roles played by 
this molecule in the BM, Cx43 was chosen to be tested at both, the gene and protein 
levels and was hypothesised to display an age-related decline in BM MSCs in this 
project.  
4.1.2 Candidate age-specific surface makers  
The knowledge of age-specific markers for uncultured BM MSCs remains limited, 
especially when investigating BM MSCs from young and aged human donors. It has 
been shown in various studies that BM MSCs from younger donors have good 
therapeutic potential. However, the use of BM MSCs from older donors for clinical 
applications usually requires further in depth investigation. Identifying a candidate 
surface marker that could differentiate young from old donor MSCs could be next 
considered as a marker to indicate the ageing status of native MSCs before further 
investigations.  
 
The previous chapter showed that there is a decline in the proliferative capacity of BM 
MSCs from old donors, irrespective of whether they formed large or small colonies. 
Identification of a marker that could indicate low-proliferative (aged) MSCs, would be 
very useful for cell sorting to remove these poorly proliferative cells before clinical and 







CD106 also known as vascular cell adhesion molecule (VCAM-1) is a cytokine-
inducible cell surface protein capable of mediating adhesion and immunomodulation 
(308, 309). It is a member of the immunoglobulin family and is expressed on BM MSCs 
(Table 4.3). However, the level of expression in human BM MSCs has shown 
considerable experimental variation, whereby decreasing expression (182), increasing 
expression (125) and random alternations (123) have been shown with in vitro culture 
expansion.  
Thus the information on what happens to the expression of CD106 with in vitro ageing 
remains controversial. Cellular adhesion, T cell activation and recruitment of 
lymphocytes at the site inflammation is known to be mediated by CD106. CD106 also 
plays an important role in MSC mediated immune-suppression (310). Considering that 
MSC display their immune-regulatory properties using cell-to-cell adhesion (311) and a 
general decline in the immune-suppression potential of BM MSCs with age (303), it 
was hypothesised that the expression of CD106 would display an age-related decline. 
4.1.1.6 CD146 
CD146 or Melanoma cell adhesion molecule (MCAM) is a 113kDa cell adhesion 
molecule which was originally described as an endothelial cell marker (312). It is also 
expressed in a variety of cells including lymphocytes (313). With respect to BM, CD146 
identifies the population of the perivascular MSCs (314).  A 2011 study by Tormin et 
al., showed that native BM MSCs with both phenotypes CD45lowCD271+CD146+ and 
CD45-CD271+CD146- formed comparable number of colonies in the CFU-F assay and 
generated similar cultures in vitro with similar cell morphology, FACS and gene 
expression profiles (227). In terms of their location, CD45lowCD271+146+ cells were 
found in the perivascular region whereas CD45lowCD271+146- cells were present as 
bone lining cells.  
 
With respect to age-related changes, a few studies listed in Table 4.3, have shown 
down regulation of the marker in culture. Previous work from our laboratory has shown 
a decline during in vitro MSC ageing in the expression of CD146, as well as CD106 
(182). Siegel and co-workers found an age-related decline in the geometric mean of 
CD146 expressing BM MSCs. However, no data  on the expression of CD146 in 
uncultured BM MSCs in relation to donor age is available. Based on previous evidence 
of decline in expression of CD146 in culture expanded BM MSCs (Table 4.3),  it was 







The aim of this chapter was to investigate any age-related changes in the number of 
uncultured BM MSCs using the CD45lowCD271+ phenotype in flow cytometry. The 
same phenotype would be used to segregate MSCs (CD45lowCD271+) and HLCs 
(CD45+CD271-) cells and investigate any age-related changes in multipotential gene 
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4.1.2 Hypotheses and Objectives 
Hypotheses: 
 
1. The number of CD45lowCD271+ uncultured BM MSCs demonstrates an age-related 
decline. 
2. The transcripts for osteogenic and adipogenic differentiation measured in 
CD45lowCD271+ BM MSCs demonstrate an age-related decline and increase, 
respectively. 
3. The level of ROS in CD45lowCD271+ BM MSC increases and the expression of anti-
oxidant enzyme SOD3 decreases with increasing age. 
4. The transcripts for bone remodelling measured in CD45lowCD271+ BM MSCs 
demonstrate an age-related bias for bone resorption over bone formation.  
5. The transcripts related to cellular interactions measured in CD45lowCD271+ BM 
MSCs demonstrate an age-related decline. 





1. To enumerate uncultured BM MSCs by flow cytometry using the CD45lowCD271+ 
phenotype across a broad donor age range. 
2. To measure transcripts associated with MSC osteogenic (RUNX2, SPARC, SFRP1) 
and adipogenic differentiation (PPAR-, FABP4, LepR) in CD45lowCD271+ BM MSCs in 
young and old donor groups.  
3. To quantify ROS and to examine the expression of anti-oxidant enzyme SOD3 in 
CD45lowCD271+ BM MSCs in young and old donors.  
4. To test the transcripts associated with bone remodelling (RANK, RANKL, OPG) in 
CD45lowCD271+ BM MSCs in young and old donors.  
5. To test transcripts associated with cellular interactions (CXCL12, Cx43) in 
CD45lowCD271+ BM MSCs in young and old donors.  
6. To investigate the expression of surface markers of CD106, CD295, Cx43 and 









4.2.1 Donor selection 
Fresh BMA from n=30 donors was used to perform enumeration of BM MSCs using the  
CD45lowCD271+ phenotype. Frozen BMA from a total of n=20 donors (10 young and 10 
old donors) were used for gene expression and surface marker expression 
experiments. Donors used in this chapter were n=10 young donors (19-40 years old, 
median age=27 years old) and n=10 old donors (59-89 years old, median age=68 
years old). Samples were defrosted as outlined in section 2.3 of the thesis and the 
exclusion criteria remained the same as described previously in section 3.2.1 
 
4.2.2 Native MSC enumeration by flow cytometry 
Flow cytometry was used as the method is automated, can be performed with minimal 
manipulation and without any culture expansion. For native BM MSC enumeration, 
100l of fresh BMA was placed in a FACS tube and incubated for 15 minutes at RT 
with the following antibodies: 20l CD271-allophycocyanine (APC) and 10l CD45-
phycoerythrin (PE)-cyanine dye 7 (Cy7); and 10l of 7-Aminoactinomycin D (7-AAD) 
was added to distinguish between live and dead cells. After staining, erythrocytes were 
lysed by using 500l of ammonium chloride (NH4Cl) solution (Appendix 2, Table 2 
Buffers) per the tube for 3-5 minutes at 37ºC. Finally, 50l of Count bright absolute 
counting beads were added at RT after vortexing. The cell and bead suspension (total 
volume 700l) was run using the Beckton Dickinson (BD) LSRII 4 laser flow cytometer. 
 
Unstained and single antibody stained samples were used to optimize the cytometer 
voltage settings and spectral compensation. Isotype controls for the antibodies IgG1 
APC and PE-Cy7 (Appendix 2, Table 2) were used to set the gating strategy on the 
population of interest (MSCs). A minimum of 100 MSCs (CD45lowCD271+ cells) were 
collected for each sample. The acquisition time was dependent on the cellularity of the 
sample. Data analysis and gating strategies were optimized based on the method 

































Figure 4.1 Uncultured BM MSC enumeration by flow cytometry using 
CD45lowCD271+ phenotype 
Gating strategy for enumeration of CD45lowCD271+ MSCs. Forward and side scatter 
plot was used to eliminate debris followed by separation of counting beads and cells 
based on granularity and fluorescence. Then live cells were identified based on 7-AAD 
negativity from where CD45lowCD271+ were identified as MSCs. Figure indicates 
representative donor. 
 
The analysis of the flow cytometry data was performed using the FACS Diva software. 
Cell debris were eliminated based on forward and side scatter and the counting beads 
were distinguished based on their granularity and fluorescence. The dead cells were 
excluded by the uptake of 7-AAD dye. The cell population of interest (MSCs) were 
identified as CD45lowCD271+ and the number of MSCs perl of BMA was calculated 
using the bead manufacturer’s formula [number of live MSC events/number of beads 
events x number of beads per 50l/ total sample volume]. The number of MSCs per l 
was multiplied by 700 to get the total number of MSCs in 100l of BMA which was then 





4.2.3 Sample preparation and quantification of ROS in uncultured MSCs 
BMA samples from young and old donors were collected as mentioned in section 2.2. 
RBCs were lysed using NH4Cl and 2x10
6 NCs were added to each of the flow tubes. 
While one tube was not exposed to any chemical, the other tube was exposed to 8mM 
tert-butylhydrogenperoxide (TBHP) for the generation of ROS under extreme oxidative 
stress as per optimised protocol (315). Both tubes were then incubated for an hour at 
37C and 5% CO2. Cells that were not exposed to TBHP served to measure ‘basal’ 
levels of ROS in the MSCs.  
After incubation, the cells were washed with 2ml 1X PBS and centrifuged at 400g for 5 
minutes. The supernatant was discarded and the cells were re-suspended with 100μl of 
medium containing DMEM+10%FBS. The cells were stained with 20μl CD45 V450 and 
20μl of CD271 PE-Vio770 and 2μl of CellROX (FITC) for staining MSCs at the same 
time for 15 minutes. To identify ROS, cells were stained with CellROX which is a non-
fluorescent dye under reduced state but exhibits strong fluorescence upon oxidation 
localized within the cell. Exposure to TBHP causes additional formation of ROS 
resulting in further oxidation which was detected by the dye and measured by flow 
cytometry. The entire process has been summarized in Figure 4.2 below. After 15 
minutes of incubation, the cells were washed with PBS for 5 minutes at 400g. The 
supernatant was discarded and the cells were re-suspended with 100μL of medium 
containing  DMEM+10%FBS. Finally, 2μl of Sytox (APC), dead cell dye was added to 
distinguish live cells from the dead cells and after 15 minutes of incubation, the sample 
was quantified for measurement of ROS using flow cytometry. 
MFI for CellROX that was indicative of the amount of ROS in the sample was recorded 
and compared between pre and post stimulation with TBHP. The values were then 























Figure 4.2 Steps involved in the quantification of ROS in CD45lowCD271+ BM 
MSCs 
 
(A) BMA was treated with ammonium chloride to eliminate RBCs. This was followed by 
treatment of cell suspension with tert-butylhydrogenperoxide (TBHP) or no treatment 
(basal) for an hour in incubator. The cells were then washed, stained with antibodies 
and quantified using flow cytometry. (B) Gating strategy for measuring ROS in 
CD45lowCD271+ MSCs, recently published by Jawhari et al., (315). Forward and side 
scatter plot was used to eliminate debris (left panel) followed by identification of live 
cells using Sytox negativity (middle panel). Live cells were identified as CD45lowCD271+ 
MSCs (C)  Histogram representation of MFI indicating ROS in CD45lowCD271+ MSCs. 






4.2.4 Cell sorting 
The technique for cell sorting has been described in section 2.4. In brief, frozen 
nucleated BM cells from both donor groups with at least 40x106 frozen cells were 
defrosted using TM (section 2.3). The cell suspension was then centrifuged at 400g for 
5 minutes for the removal of DMSO. The supernatant was discarded and the cells were 
re-suspended in 5 ml of the TM. The MSCs were then enriched using Anti-fibroblast 
microbeads that positively select for cells with D7-fib receptor to enrich the percentage 
of CD45lowCD271+ MSC by positive selection, as previously developed in our laboratory 
(108) and described in section 2.4. 
 
After enrichment, the cells were distributed in 10 tubes for staining. For isotype controls 
tubes, a minimum of 2x105 cells were used for each antibody and for cell sorting, up to 
3x106 cells were used to collect sufficient number of MSCs. The duration of cell sorting 
from setting up the spectral compensation and up to the completion of cell sorting for 3 
samples varied from a minimum of 180 minutes up to a maximum of 270 minutes 
depending upon the cellularity of the samples. As a rare population in the BM, the 
number of CD45lowCD271+ cells collected after sorting ranged from a minimum of 999 
cells to a maximum of 15,000 cells depending on donor age, technical challenges 
during defrosting and cell loss due to enrichment. Simultaneously, a maximum of 
70,000 cells of the control population of CD45+CD271- HLCs were also collected. Their 
collection was usually accomplished within 45-60 minutes owing to the relatively larger 
proportion of these cells within the BMA. The number of HLCs collected was thus 
considerably higher than the number of MSCs collected. 
 
Analysis of flow cytometry data was performed using FlowJo software. Unstained and 
single antibody stained tubes were used as controls. Gating strategy as described by 
Cuthbert et al., (207) was followed to record the number of cells and MFI in a selected 
gate as shown in Figure 4.11. The recorded values of MFI for each surface markers 
were plotted as a dot plot for young donors (black) and old donors (grey) using 
GraphPad Prism with median values to illustrate and compare any difference in the 
MFI. 
4.2.5 Gene expression between young and old donors 
The general method of qPCR has been described in section 2.5. The experiments were 
performed in integrated fluid circuit Flex SixTM  chip (Fluidigm) which has 2 partitions 
with 6 compartments each (Figure 4.2). One side of the chip is for placing the TaqMan 
assays (assays inlet) and the other side is for samples’ cDNA (samples inlet). Each 




barrier plugs to prevent any external contamination before being used (Figure 4.3, top 
panel). The accumulator is the region where the control fluid is added that eventually 
enables the mobilisation of the assay and the corresponding sample to their reaction 




















Figure 4.3 Flex SixTM chip showing its different segments as described in the text 
and shown in manufacturer’s protocol 
 
 
The volumes of reagents, assays and samples used have been described in section 




below. This technique was chosen over traditional RT-PCR owing to the lower volume 
of sample and low concentrations of RNA needed for the experiment. As mentioned 
earlier, CD45lowCD271+ is a rare population in the BM and numbers of cells obtained 
after cell sorting were as low as 999 cells. The collection and elution of RNA was 
performed to ensure minimal dilution of the RNA content and at the same time to get 
sufficient RNA quantity for performing experiments. The guidelines provided by the 
manufacturers were followed in order to carry out the experiment. 
 
For analysis, Fluidigm software was used to set the Ct values and the expression of 
genes were exported as a Microsoft excel file. In the excel file, first the data was 
normalised with HPRT1 as the housekeeping gene to generate the Ct values for each 
gene using the formula [Ct target gene - Ct housekeeping gene]. Finally, the Ct values were 
converted to ‘relative expression’ for each gene using the formula [2-Ct] and the values 
were compared between young and old donor cohorts. To observe trends across the 
whole donor cohort, cluster analysis was performed using Cluster and Tree view 
softwares. The software generated a cluster in red (+3 units) indicating genes and 
samples with highest expression and green (-3 units) indicating genes and samples 
with comparatively lower expression. Relative expression values closer to the centre of 
the defined range (-3 to +3) were depicted in black and the values that were below 
detection level were depicted in grey (shown further below in Figure 4.6). 
Table 4.4  List of TaqMan probes used for gene expression study in this chapter 
 
Gene symbol   Genes (full name) Assay 
RUNX2 Runt related transcription factor 2 Hs00231692_m1 
SPARC 
Secreted protein acidic and rich in cysteine/ 
Osteonectin 
Hs00277762_m1 
SFRP1 Secreted frizzled related protein 1 Hs00610060_m1 
PPAR-ɣ    
Peroxisome proliferator activated receptor - 
gamma 
Hs01115513_m1 
FABP4   Fatty acid binding protein 4 Hs00609791_m1 
LepR Leptin Receptor, encoding CD295 protein Hs00174492_m1 
SOD3 Superoxide dismutase 3 Hs04973910_s1 
TFNSF11A/RANK Receptor activator of nuclear factor kappa-B Hs00921372_m1 
TNFSF11/RANKL 
Receptor activator of nuclear factor kappa-B 
Ligand 
Hs01092186_m1 
TNFRSF11B/OPG Osteoprotegerin Hs00900360_m1 
Cx43 Connexin43  Hs00748445_s1 
CXCL12 C-X-C motif chemokine 12 Hs00171022_m1 
HPRT1 







4.2.6 Statistical analysis 
The normal distribution of the data was assessed using the Shapiro-Wilk and 
Kolmogorov-Smirnov tests for normality. Cluster analysis was used to observe any 
differences in gene expression across the entire donor cohort. Statistical analysis and 
graphics were performed using GraphPad Prism software (version 7.0a). As no data 
were found to be normally distributed, Kruskal-Wallis test with Dunn’s correction was 
used for multiple comparisons, Wilcoxon rank test was performed for paired data and 
Mann-Whitney test was performed for unpaired data. Spearman test was used to 
analyse correlations. The results were considered significant at p value of <0.05. 
 
4.3 Results 
4.3.1 Age-related changes in the number of CD45lowCD271+ cells  
Using the CD45lowCD271+ phenotype for native BM MSCs, their numbers were 
quantified for n=30 (10 young, 11 intermediate age, 9 old) donors. Once data collection 
was completed, the numbers of MSCs were correlated with the age of the donors. The 
correlation showed an age-related decline in the number of MSCs. However, the 









Figure 4.4 Enumeration of MSCs by flow cytometry 
(A) Age-related correlation of number of MSCs (CD45lowCD271+ cells) measured by 
flow cytometry. (B) Age-related change in number of MSCs between the age groups. 
Data were compared using Kruskal-Wallis with Dunn’s correction. Each dot represents 
an individual donor. Black line in A indicates slope and in B indicate median values for 
number of cells per milliliter of BM 
 
When the same data was divided into age groups (Figure 4.4B, right panel), a steeper 
decline was observed in the number of cells per ml of aspirate in intermediate age 




the donors of the old age group (median=3006) compared to the young donor group. 
This was in agreement with the CFU-F findings where the number of MSCs showed a 
considerable decline commencing form the 5th decade of life. The trend was similar as 
seen in the number of MSCs detected by the CFU-F assay (as shown previously on 
Figure 3.4) but the changes in the number of MSCs measured by flow cytometry were 
found to be non-significant. This could be due to the fact that not all CD45lowCD271+ 
cells identified by flow cytometry may attach to plastic and proliferate into a colony of 
more than 50 cells.  
 
To find how many cells identified by CD45lowCD271+ phenotype could potentially form a 
colony, the number of MSCs counted by CFU-F assay and by CD45lowCD271+ 
phenotype in donor matched samples were compared (Table 4.5). Across the whole 
age range, the ratio CD45lowCD271+/CFU-F suggested that 1 in every 38 
CD45lowCD271+ cell (median value) detected by flow cytometry would form a colony in 
our laboratory conditions. However, the ratio of CD45lowCD271+/CFU-F was found to be 
1 in 26 in young donors, 1 in 27 in the donors of intermediate age and 1 in 73 in old 
donors (Table 4.5).  
 









years old Median 
CFU-F (colonies/ml, 
medians) 206 (n=19) 48 (n=18) 41 (n=15) 81 
CD45lowCD271+ (cells/ml, 
medians) 5339 (n=10) 1326 (n=11) 3006 (n=9) 3094 
Ratio (CD45lowCD271+/ CFU-
F, medians) 25.92 27.63 73.32 38.20 
 
 
This suggested that the number of colony forming MSCs within CD45lowCD271+  cell 
phenotype declines with age. This supported data on colony IDs presented in section 
3.3.3 indicating that MSC proliferative capacity declines with age. The next step was to 
investigate any age-related changes in the transcripts chosen to reflect their 
multipotential functions.  
 
4.3.2 MSC specificity of the selected genes 
Prior to the investigation of any age-related changes in uncultured BM MSCs, the MSC 




CD45+CD271-  HLCs. The list of genes included transcripts for osteogenic 
differentiation (RUNX2, SPARC, SFRP-1), adipogenic differentiation and bone-fat 
balance (FABP4, PPAR- and LepR), bone remodelling (RANK, RANKL and OPG), 
and cell communication (CXCL12 and Cx43). All of the transcripts were tested for their 
level of expression in both MSCs and HLCs and a high level of specificity for MSCs 
was observed for all the molecules in both young and old donors combined, as shown 
in the cluster analysis in Figure 4.5.  
 
The cluster analysis clearly grouped all the MSCs on the left hand side and the donor 
matched HLCs on the right hand side (Figure 4.5). Interestingly, within each of the 
populations of MSCs and HLCs, there was no segregation associated with the donor 
age. Both, young and old donors were placed randomly by the algorithm of the cluster 
analysis within the cell subset specific clusters. The grey boxes indicate samples that 
were below detection. In the figure below, it can be seen that RANK was expressed in 
very few MSCs in MSCs while OPG, SFRP1 and SOD3 and were almost absent in 
MSCs. The fold changes and p values indicating the specificity of the individual 











Figure 4.5 Cluster analysis of multipotentiality transcripts in MSCs and HLCs  
MSCs form the left side of the cluster and HLCs form the right side of the cluster. Grey 
squares indicate values that were below detection and black areas indicate values that 
were closest to the middle of the range (-3 to +3). Dendogram on the top indicate 







Table 4.6 Median fold increase in the expression  of multipotentiality genes in 
MSCs compared to HLCs  
 
Transcript Young donors Old donors 
 
Fold difference p value Fold difference p value 
RUNX2 2.5 0.0541 3.2 0.0002 
SPARC 139.5 0.0002 557 <0.0001 
SFRP-1 ND in HLCs NA ND in HLCs NA 
PPAR- 55.2 0.0019 154.6 <0.0001 
FABP4 269.2 0.0012 122.1 <0.0001 
LepR 245.3 0.0002 2050 0.0002 
SOD3 ND in HLCs NA ND in HLCs NA 
RANKL 103.8 0.0003 24.2 0.0047 
RANK 1.6 NS 10.8 NS 
OPG ND in HLCs NA ND in HLCs NA 
Cx43 21.3 0.0047 11.3 0.0005 
CXCL12 63428 0.0002 56182.2 <0.0001 
Gene expression levels were measured relative to HPRT1. MSCs: Mesenchymal 
stromal cells, HLCs: Hematopoietic lineage cells, ND: not detected, NA: Not Applicable, 
NS: Non significant, Mann-Whitney U test 
 
 
4.3.3 Age-related differences in osteogenic and adipogenic genes in MSCs  
After establishing MSC specificity of the selected transcripts, the next investigation 
involved comparing the transcripts levels reflecting multipotentiality of MSCs between 
young (19-40 years old) and old (59-89 years old) age groups. The median fold 
differences for each of the transcripts between young and old groups are shown in 














Table 4.7 Median expression levels and fold differences in selected genes in 











(O/Y) p value 
MSCs 
RUNX2 1.40 1.10 0.79 NS 
SPARC 17.41 20.51 1.18 NS 
SFRP1 1.41 2.76 1.96 NS 
PPAR- 2.60 6.20 2.38 NS 
FABP4 1.71 1.76 1.03 NS 
LepR 1.93 4.12 2.13 NS 
SOD3 0.58 0.29 0.50 NS 
RANKL 0.16 0.35 2.19 NS 
OPG 0.99 2.43 2.45 NS 
RANK 1.36 0.76 0.56 NS 
CXCL12 1051.00 1554.00 1.48 NS 
Cx43 36.64 31.54 0.86 NS 
HLCs 
RUNX2 0.56 0.34 0.61 NS 
SPARC 0.12 0.03 0.25 0.0281 
SFRP1 ND ND NA NA 
FABP4 0.006 0.014 2.33 NS 
PPAR- 0.05 0.04 0.85 NS 
LepR 0.0080 0.002 0.25 NS 
SOD3 ND ND NA NA 
RANKL 0.0016 0.0146 9.13 0.0047 
OPG ND ND NA NA 
RANK 0.10 0.07 0.71 NS 
CXCL12 0.02 0.03 1.69 NS 




Gene expression levels were measured relative to HPRT1. MSCs: Mesenchymal 
stromal cells, HLCs: Hematopoietic lineage cells, YD: Young donors, OD: Old donors, 
ND: not detected, NA: Not Applicable, NS: Non significant; Mann-Whitney U test 
 
 
Relative expression of RUNX2, SPARC and SFRP-1 in MSCs showed no statistical 
difference between young and old donor groups (Figure 4.6).  However, while the 
expression of RUNX2 and SPARC remained largely the same based on the median 
values, SFRP-1 was expressed nearly 2-fold higher in old donors MSCs compared to 




differentiation in BM MSCs from old donors did not show significant differences in their 


















Figure 4.6 Expression of osteogenic and adipogenic transcripts in MSCs from 
young and old donors  
(A) Expression of RUNX2, SPARC and SFRP-1 in MSCs. (B) Expression of PPAR-, 
FABP4 and LepR in MSCs. Young and old donors are indicated in black and grey dots, 
respectively. Horizontal lines indicate median values. 
 
 
For the selected adipogenic transcripts, PPAR- showed 2-fold higher expression in 
old donors but FABP4 did not show any age-related differences (Figure 4.6 and Table 
4.7). The level of LepR also was 2-fold higher in old donors however the differences 
failed to reach statistical significance (Figure 4.6 and Table 4.7). Overall, data for 
selected adipogenic molecules in uncultured BM MSCs indicated a potential trend for 
increase in some transcripts which merits further investigations in a larger cohort of 
donors. Interestingly, small increases in PPAR and LepR were not mirrored by similar 







4.3.4 Resistance to oxidative stress 
Resistance to MSC to oxidative stress was measured by quantification of basal 
intracellular ROS in CD45lowCD271+ cells by flow cytometry as well as ROS generated 
by exposing MSCs to TBHP using methods previously established in our group (315). It 
was hypothesised that the levels of basal ROS and ROS generated using TBHP would 
display an age-related increase in MSCs. To potentially explain any differences in 
ROS, the expression of the anti-oxidant enzyme SOD3 was also quantified by qPCR. 
SOD3 expression levels were expected to display an age-related decline that could 
























Figure 4.7 Measurement of ROS and anti-oxidant enzyme SOD3 gene in MSCs 
from young and old donors 
(A) Increase in ROS before and after stimulation with TBHP measured by CellROX 
median fluorescent intensities (MFI) in young donors (left) and old donors (right), 
Wilcoxon rank sum test. (B) Comparison of ROS levels between young and old donors 
before stimulation with TBHP (left) and after stimulation (right). (C) Comparison of 
expression of anti-oxidant enzyme SOD3 in young and old donors by gene expression. 
Young and old donors are indicated in black and grey dots, respectively. Wilcoxon rank 







Comparing stimulated and unstimulated levels of ROS in young and old donor MSCs 
(Figure 4.7A) showed a significant increase in stimulated state indicating that the 
exposure to TBHP led to the production of more free oxygen radicals that were 
detected as higher levels of CellROX. After showing that ROS can be measured by this 
method in MSCs before and after stimulation, basal levels of ROS were first compared 
between young and old donors. The basal levels of ROS is indicative of the inherent 
mitochondrial activity in cells and showed no difference in old donor MSCs compared 
to young donor MSCs (Figure 4.7B, left panel). When the level of ROS was quantified 
in the stimulated state, indicating a cells ability to combat extreme oxidative stress, 
there was similarly no statistically significant difference (Figure 4.7B, right). However, 
there was a 2-fold decline in the level of stimulated ROS when old donor MSCs were 
compared to young donor MSCs, based on median values (Figure 4.7B, right panel) 
and the expected increase in ROs was not observed. 
 
SOD3 the anti-oxidant enzyme is the first line of defence in presence of harmful ROS 
and is known to be  specifically secreted by MSCs. To investigate if this gene declined 
with advancing age,  its expression was compared between young and old donor 
MSCs using qPCR. Here again, the difference was not statistically significant but the 
level of SOD3 transcript was 2-fold lower in old donor MSCs (Figure 4.7C).  
 
4.3.5 Age-related differences in bone remodelling and cellular interaction genes 
in MSCs 
The transcripts associated with bone remodelling also showed no statistically 
significant differences between young and old donor MSCs. As seen from the cluster 
analysis (Figure 4.5) RANK expression was specific for HLCs and barely detected in 
MSCs. This was expected, as RANK is expressed primarily on T cells (section 1.1.4) 
(63, 316). In contrast to RANK, MSCs from old donors showed an over 2-fold increase 
in the expression of both, RANKL and OPG, as compared to young donors (Table 4.6). 
Of note, RANKL was detected in only 6 out of the 8 donors MSCs and OPG was 
detected in 7 out of 8 donors MSCs.  
 
Overall, even though statistical significance was not achieved, there was a trend 
indicating an age-related increase in RANKL and OPG, in uncultured BM MSCs from 






















Figure 4.8 Expression of transcripts associated with bone remodelling and 
cellular interactions in MSCs from young and old donors 
(A) Expression of RANK, RANKL and OPG  (B) Expression of CXCL12 and Cx43. 
Young and old donors are shown in black are grey dots, respectively. Horizontal lines 
across the data indicate median values. 
  
The transcripts associated with cellular interactions were next investigated. CXCL12 is 
involved in chemotaxis of cells within the BM (section 4.1.1.5), and its expression level 
was among the highest in CD45lowCD271+ MSCs in comparison to other transcripts as 
seen in the cluster (Figure 4.5) suggesting its presence in high quantities in uncultured 
BM MSCs. No difference in the level of its expression was found between young and 
old donors (Figure 4.8B, left panel). Cx43 is involved in intercellular interactions in cells 
within BM (section 4.1.1.5) and also showed no age-related differences in its gene 
expression levels in CD45lowCD271+ MSCs.  
 
4.3.6 Age-related differences in selected gene transcripts in HLCs  
The HLCs were sorted as CD45+CD271-cells and included the lymphoid and myeloid 
cell lineages (188, 222). In this project, donor matched CD45+CD271- cells served as a 







chosen transcripts was very high for MSCs, with the exception of RANK. However, with 
prior knowledge, that most of these transcripts are also expressed by other cells (even 
if at the low levels, section 4.1.1) their gene expression was next investigated in HLCs 
and compared between young and old donor groups. 
 
For osteogenic transcripts, while RUNX2 and SPARC were detected in low levels in 
HLCs, the expression of SFRP1 was below detection in HLCs further illustrating 
selectivity of these genes for MSCs. There was 1.6-fold age-related decline in the 
expression of RUNX2, however not statistically significant, and SPARC (4-fold, 














Figure 4.9 Expression of genes associated with osteogenic and adipogenic 
differentiation in HLCs from young and old donors 
(A) Expression of RUNX2, SPARC and SFRP1  (B) expression of PPAR-, FABP4 and 
LepR. Horizontal lines across the data indicate medians. Young and old donors are 
shown in black are grey dots, respectively. p< 0.05*, Mann-Whitney U test. 
 
The transcripts related to adipogenic differentiation and bone-fat balance were next 
analysed. All three transcripts were detected in higher levels in MSCs compared to 
donor matched HLCs, as seen in cluster (Figure 4.5). PPAR- did not show any age-




increase, whereas LepR displayed considerable 4-fold age-related decline in HLCs, 
which narrowly missed statistical significance (Table 4.6, p=0.0541).  
 
Bone remodelling transcripts were next scrutinised (Figure 4.10A). RANKL showed a 
significant 9-fold increase (p=0.0047) in old donor HLCs. As mentioned, OPG was not 
detected in HLCs (confirming it’s high-level specificity for MSCs). The last group of 
genes to be investigated in HLCs were those involved in cellular interactions. Both the 
genes, CXCL12 and Cx43 were detected in young and old donor HLCs but showed no 

















Figure 4.10 Expression of transcripts associated with bone remodelling and 
cellular interactions in HLCs from young and old donors 
(A) Expression of RANK, RANKL and OPG. (B) Expression of CXCL12 and Cx43. 
Horizontal lines across the data indicate medians. Young and old donors are shown in 










Similar to the observations in MSCs, the expression of all transcripts in HLCs exhibited 
large donor variation within the same age group. Altogether, there were no statistically 
significant differences observed in transcript expression levels in young and old donor 
HLCs for most transcripts, with the exception of SPARC which decreased and RANKL 
which increased in old donors. This was in contrast to MSCs, in which only a trend for 
increase in PPAR-, LepR, RANKL and OPG was found in older donors.  
 
Two of these transcripts were also investigated at the protein level (LepR/CD295 and 
Cx43) along with other potential MSC age-related surface molecules CD106 and 
CD146 (section 4.1.2). The next section includes the results obtained from the 
investigation of these surface markers in uncultured BM MSCs and control HLCs. 
 
4.3.7 Expression of the selected surface markers on MSCs 
Frozen-thawed nucleated cells from young and old donors (Appendix 1, Table 2) were 
processed for native MSC isolation and characterisation using the CD45lowCD271+ 
phenotype. As a control population, CD45+CD271- cell fraction (HLCs) that contained 
the lymphoid and myeloid lineage cells was also analysed (188). First, the specificity of 
the selected surface markers for MSCs (CD45lowCD271+ cells) was tested. For the 
measurement of the surface marker expression the median fluorescent intensity (MFI) 

































Figure 4.11 Quantification of surface marker expression in BM MSCs and in 
HLCs 
 
(A) Gating strategy for identification of live cells based on 7-AAD negativity followed by 
CD271 and CD45 gating for the selection of populations of interest (MSC and HLCs) 
(B) Histograms for individual surface markers in MSCs and HLCs from representative 
donor. Numbers in the top-right corner indicate MFI. 
 
The MFI of each surface marker was first compared between MSCs and HLCs. Figure 
4.11 below shows the expression of each surface molecule in donor matched MSCs 








































Figure 4.12 Expression of candidate age-specific surface markers on MSCs and 
HLCs from all donors combined 
(A) Expression of CD106 (B) Expression of CD295 (C) Expression of CD146 (D) 
Expression of Cx43. Each panel shows the expression of the respective marker in 
MSCs and HLCs in donor-matched cells. Each dot represents an individual donor. 
*p<0.05 and ****p<0.0001, Wilcoxon rank sum test 
 
 
All surface markers were expressed in significantly higher levels in MSCs compared to 
HLCs from all donors. The differences in CD106 (p<0.0001), CD295 (p<0.0001) and 
CD146 (p<0.0001) were highly significant indicating very high specificity for MSCs. 
CD106 and CD295 showed the highest specificity in terms of fold differences (10-fold 
each, Figure 4.12A and B), followed by CD146 (nearly 4-fold, Figure 4.12C). While 
Cx43 showed the lowest fold differences between expression in MSCs and HLCs (less 
than 2-fold) and the p value (p=0.0266), but remained significantly specific for MSCs, 
nevertheless (Figure 4.12D).  
 
The expression of CD295 in MSCs was the  highest (ranging between 101 and 103 
MFI) while the expression of CD146 and Cx43 were the lowest, both of which were 
below 102 MFI. All antibodies were used at the manufacturer’s recommended 




















































the gene level (Figure 4.5 and Figure 4.11, Table 4.6) suggesting consistency in 
techniques used and results obtained. 
4.3.8 Age-related differences in selected surface markers in MSCs 
Expression of all four surface markers was then compared between young and old 
donors, in MSCs and then HLCs separately. No difference in the expression levels in 
any of the markers in MSCs was found between young and old donors (Figure 4.13). 



















Figure 4.13 Expression of candidate age-related surface markers in MSCs from 
young and old donors 
(A) Expression of CD106 (B) Expression of CD295 (C) Expression of CD146 (D) 
Expression of Cx43. Young  and old donors are represented by black and grey dots, 
respectively. Each dot represents an individual donor. Horizontal lines across the data 
represent median values. 
 
 
Neither of the markers demonstrated any trends when compared between young and 
old donor MSCs suggesting no age-related difference in the expression of these 
markers in uncultured BM MSC. The expression of these markers were then 

















































4.3.9 Age-related differences in selected surface markers in HLCs 
Expression of the four surface markers in HLCs also displayed no age-related 




















Figure 4.14 Expression of candidate age-related surface markers in MSCs from 
young and old donors 
(A) Expression of CD106 (B) Expression of CD295 (C) Expression of CD146 (D) 
Expression of Cx43. Young  and old donors are represented by black and grey dots, 
respectively. Each dot represents an individual donor. Horizontal lines across the data 
represent median values. 
 
 
Even in HLCs, the surface markers showed no differences in the level of expression in 
young and old donors. Overall, section 4.3.7 to 4.3.9 displayed significantly higher 
expression of surface markers in MSCs than in HLCs. With respect to age-related 
differences, the expression of these age-specific markers displayed no age-related 






















































In this chapter, an age-related decline in the number of CD45lowCD271+ native BM 
MSCs using flow cytometry was established confirming the results from previous 
chapter based on the CFU-F assay. Gene expression of all the selected molecules 
(apart from RANK) showed very high specificity for MSCs as compared to HLCs. The 
osteogenic transcripts’ expression showed no age-related trends in MSCs. Adipogenic 
transcripts also did not reach significance between young and old groups but displayed 
a non-significant 2-fold increase in the expression LepR and PPAR- in the old donor 
group. Interestingly, unlike in the MSCs, LepR displayed a significant 2-fold decrease in 
the HLCs. Quantification of ROS and anti-oxidant enzyme SOD3 gene expression also 
did not show any statistically significant difference in old donors, however, the level of 
SOD3 detected in old donors as well as the stimulated level of ROS detected in old 
donors, declined by 2-folds. Transcripts for cellular interactions also did not show any 
age-related changes in the MSCs or the HLCs. Similarly, surface marker expression 
exhibited no difference between young and old donor groups and each surface marker 
was significantly higher-expressed on MSCs compared to HLCs. 
 
Flow cytometry data revealed a trend for native BM MSC to decline with age. However, 
the decline was not as significant as indicated by the CFU-F assay.  Flow cytometry 
analysis depends upon the gating strategy which can be subjective. However, the 
analysis and gating strategy used in this study were the same as previously published 
by our group (111, 234). As shown in previous studies (111, 207), not every 
CD45lowCD271+ cell forms a colony in standard CFU-F conditions, and consistent with 
these publications, flow cytometry data revealed higher number of MSCs per ml of 
BMA compared to CFU-F assay. The age-related decline was lower as measured by 
flow cytometry possibly because it identifies all the CD45lowCD271+ cells as MSCs, 
irrespective of their ability to proliferate into a colony from a single cell; while a colony 
having less than 50 cells was not scored as a colony in the CFU-F assay. Overall, the 
data on BM MSC enumeration by flow cytometry in this study confirmed their age-
related decline as measured by CFU-F assay. This has not been shown before when 
other surface markers for uncultured MSCs were used (237).  
 
Use of CD45lowCD271+ cells for enumerating MSCs has been established on fresh BM 
cells before and used by our group (111, 207) and the data was compared to the total 
colony area showing a positive correlation. The studies however did not look into age-
related differences in MSC number by both CFU-F and flow cytometry. Recently, our 
group also measured CD45lowCD271+ cells by flow cytometry and CFU-F assay and 




However, the study was aimed at comparison of two flow cytometry techniques for 
evaluation of CD45lowCD271+ MSCs and was not specifically focussed on age- or 
gender-related differences. Furthermore, it used a smaller cohort of donors ranging 
from 22-80 years old. In agreement with data presented in this chapter, recently, 
Josephson and co-workers also showed a decline in CD45lowCD271+ cells by flow 
cytometry when compared across the entire age range (24-89 years old) as well as 
between young (<50 years) and old (>50) donors (146). However, their group 
definitions were different and they were not able to show the bigger drop in MSCs 
occurring from early 40s rather than later in life (from 60s). 
 
A group of transcripts was next chosen to explore if various functions in MSCs may be 
affected by donor age. Many of the molecules have been previously shown to be 
specific for MSC by our group (188). In fact, an age-related decline in LepR and 
SFRP1 was observed in our previous study using a cohort of patients with ages 
ranging from 2 to 74 years old. This was not seen in this study with uncultured BM 
MSCs, most likely due to different age-range of this study that did not include paediatric 
donors, as in the former.  
 
In this project, there were no or non-significant age-related trends in the transcripts 
related to osteogenic and adipogenic differentiation. Based on previous studies, the 
general consensus has been that there is an age-related decline in the osteogenic 
potential of MSCs paralleled to an increase in their adipogenic potential (Table 4.2). 
Studies that supported this concept have been based on in vivo assays by examining 
trabecular bone volume, bone mineral density (BMD), total bone volume and marrow 
adipocyte content. These parameters have been discussed in the introduction in 
section 1.1.4. These studies provide robust in vivo data supporting the process of ‘age-
related bone loss’ and increased bias towards marrow adipogenicity, and formed the 
foundation of our initial hypothesis for reduced osteogenic and increased adipogenic 
commitment of uncultured BM MSCs. As these cells were not expanded in culture, they 
better represent the in vivo MSCs in BM, making the data novel and reliable. 
 
However, in vitro data relating to both donor-related and passage-related MSC ageing 
in terms of their osteogenesis remained controversial. Yang and co-workers in 2018 
compared the differentiation potential of BM MSCs between passage 4 and passage 8 
(123). They tested the differentiation potential using both, in vitro differentiation assay 
and by using gene expression of classic osteogenic and adipogenic markers (RUNX2 
and PPAR- respectively). They found that cells from passage 8 were able to maintain 




was concluded that the process of adipogenic differentiation is ‘better preserved’ in BM 
MSCs than osteogenic differentiation and the growth medium had a strong impact on 
their differentiation potential, further highlighting the limitation of using cultured MSCs in 
MSC ageing studies. The present data using a limited number of transcripts have not 
provided strong evidence for any bias in MSCs, however interesting trends in PPAR- 
in particular were observed that supported our original hypothesis. Similar investigation 
of osteogenic and adipogenic molecules at the protein level using with more donors 
would help to understand the age-related shift towards adipogenic differentiation in 
bone in vivo. 
 
Another molecule that plays a role in osteogenic-adipogenic balance in the BM is LepR 
or CD295. In this project, LepR was tested at both the transcript and protein levels. By 
both techniques, LepR showed a trend for a two-fold increase in MSCs from old 
donors. Before discussing the biological relevance of this data, it is important to note 
that  CD295 was proven to be the most specific of the all tested molecules for human 
CD45lowCD271+ MSCs (10-fold higher in MFI compared to control HLCs). Yue and 
colleagues published a paper on LepR+ BM MSCs in mice showing that LepR is not 
needed for the maintenance of MSCs but acts on MSCs to inhibit osteogenesis and 
promote adipogenesis (262). They also found that the mice fed with a high fat diet not 
only had increased levels of plasma Leptin, but their bone-lineage progenitors formed 
significantly lower CFU-Fs in comparison to the mice that were not fed the high fat diet. 
This indicated that high serum Leptin may directly inhibit MSC colony formation ability. 
This was the first study that had connected intake of high fat diet with the impact of 
LepR+ cells on the regeneration ability of these cells. However, as only adult mice 
(6mo) were used, no correlations with donor age could be made in this study.  
 
In 2009, Laschober and co-workers studied the expression of CD295 by flow cytometry 
in cultured BM MSC obtained from donors aged between 7-78 years old without any 
age grouping. Their findings suggested that CD295 was up-regulated in the ‘dying 
cells’ marked by Annexin V (marker for cell death by apoptosis) and that it was found to 
be higher in old donor BM MSC cultures. They suggested that CD295 is an 
indicator/marker for apoptotic cells (which are higher in old donor cultures) in BM MSCs 
(126).  
 
The data from the present study showed a tendency of both, the receptor expression 
and the gene encoding for the receptor to increase in BM MSCs in older donors, but 
the differences failed to reach statistical significance. A similar trend was observed for 




cohort study, CD295 expression should be further tested for predicting the adipogenic 
fate of BM MSCs in vivo. Even though the change was not significant, it must be noted 
that these experiments were performed with nearly no laboratory manipulation of donor 
MSCs precluding any artefacts due to in vitro culture conditions and thus better 
reflecting MSC age-related changes in vivo. The present findings are interesting and 
complement previous studies showing that its ligand, the hormone Leptin itself, shows 
an age-related increase in its blood levels (317). This may lead to an overall 
enhancement of Leptin signalling in MSCs and negatively affect their colony-formation 
potential. 
 
Knowledge in the increased adipogenic bias of BM MSCs in vivo and its potential link 
to age-related changes of BM MSCs is vital for developing new treatment for diabetes, 
obesity, osteoarthritis and osteoporosis, the risks of which are much higher in the aged 
population. The risk of obesity is higher for new-borns that are born to obese mothers 
and the MSCs from these babies show a greater potential to become adipogenic (318). 
While the exact mechanism for MSC fate decisions remains to be discovered, literature 
from past and present projects shed new light on the topic. Future investigations should 
include obese and non-obese donor cohorts, which quantify both circulating Leptin 
levels along with LepR from BM MSCs at the gene and protein level. These future 
studies will help to dissect the age-related and diet/obesity-related changes in bone 
homeostasis due to Leptin and its impact of age-related skeletal disease like 
osteoarthritis. 
 
As previously stated (section 4.1.1.3), several studies have reported increased ROS 
during adipogenic differentiation of MSCs as compared to osteogenic differentiation. 
Accumulation of ROS is also one of the main features of aged cells (281). Based on 
these considerations, this project investigated the levels of ROS and the expression of 
anti-oxidant enzyme SOD3 in BM MSCs in young and old donors. SOD3 transcript was 
highly specific to MSCs and was not detected in HLCs (Table 4.6). Therefore we 
expected an age-related increase in the level of ROS in old donors, parallel to a 
decrease in SOD3.  
 
Even though the results were not statistically significant, the decline in the induced 
levels of ROS in old donor MSCs as compared to young donor MSCs, was 
unexpected. A 2-fold decline was observed in the expression of SOD3 in old donor 
MSCs but it did not reach statistical significance. Recently, Agrahari et al., found that 
MSCs engineered to overexpress SOD3 were better adapted for survival under serum 




MSCs from old donors (96) as well as long-term cultured BM MSCs have shown to 
possess lower levels of anti-oxidants such as SODs, as well as increased vulnerability 
to oxidative stress (320, 321). However, measurement of active ROS and anti-oxidant 
enzyme expression in uncultured BM MSCs has not been carried out before, making 
the data from this chapter very novel.  
 
Overall, with respect to the idea that MSCs display an age-related bias towards 
adipogenic differentiation and there is increased ROS in older donors, this chapter 
suggests no or only subtle differences in uncultured BM MSCs. While larger donor 
group numbers could potentially display statistically significant results, the data 
suggests that at the transcript level, BM MSCs are not necessarily or strongly biased 
towards adipogenic differentiation. An additional sample set previously treated in 
hypoxic conditions or with anti-oxidant before inducing oxidative stress in BM MSCs 
would help explain the decline in both ROS levels and SOD3 as seen this project. 
Additionally, exploring other anti-oxidant molecules like Gx, SOD1 and SOD2 at gene 
and protein levels would also help in understanding age-related differences in dealing 
with oxidative stress.  
 
In regards to bone remodelling transcripts, subtle non-significant increases in both 
RANKL and OPG in old donors were found. Principally, increased levels of RANKL 
suggest increased bone resorption, therefore the obtained data are contradictory but 
remain interesting in relation to BM MSC adipogenesis. The idea that increased BM 
adipogenesis and bone remodelling are inter-related and impact each other is not 
completely new. The evidence for this has been furnished in Takeshita et. al who 
suggested that the increased BM adipogenesis is linked to the age-related increased 
expression of RANKL (238). They used uncultured whole BM cells from mice and 
isolated stromal cells and macrophages. They found increased osteoclastogenesis in 
adipogenic marrow cultures from aged mice, indicating increased bone resorption and 
adipogenic bias in vivo. They also found an increase in the expression of PPAR- and 
other adipogenesis related markers with a 3-fold age-related increase in the level of 
RANKL in whole BM cells. Investigating macrophages from human donors will provide 
with more comprehensive knowledge about age-related differences in bone 
remodelling within the BM. 
 
Apart from testing this on uncultured cells, they also used murine BM stromal cell line 
ST2. The baseline expression of RANKL in this cell line was low and the level of OPG 
expression was very high. When the cell line was subjected to adipogenic 




reversing their expression levels. While this study confirmed the age-related adipogenic 
bias and increased bone resorption in C57BL/6 mice aged 2 months (young) and 2 
years (old), animal studies are often criticised for the lack of IVIVC (in vitro in vivo 
correlation) with humans. This is because organ systems and genetic makeup of 
animals are not identical to humans. In the presented study, the RANKL increase in old 
donor MSCs was expected, but OPG increase was unexpected highlighting such 
differences between animals and humans. 
 
The transcripts associated with cellular interaction have also shown no age-related 
changes in the present study. Recent examination by Gomariz and co-workers, 
suggested that CAR and sinusoidal endothelial cells within the BM compartment of 
mice remain mostly unaltered and show no age-related difference when inspected for 
quantitative and structural analysis (322). While they did note an insignificant age-
related decline in the number of CARs in old mice (20-24 months old) compared to 
young (8-12 weeks old) mice, the difference was minor suggesting that CXCL12 
abundant (CAR) cells remain largely preserved in old age. Interestingly, they defined 
CAR cells by the CD295+ phenotype, which confirms similar cell identity to MSCs as 
identified in the present study. While there were a good number of studies outlining the 
CXCL12-CXCR4 signalling and its potential role in BM homeostasis in mice (239, 240), 
it is difficult to find many studies aimed at investigating age-related changes in this 
chemokine in cultured or uncultured human BM MSCs. Against our original hypothesis, 
the data presented in this chapter displayed no age-related decline in the expression of 
CXCL12. Considering the high levels at which CXCL12 is expressed, detection and 
quantification of the transcript in large number of donors should not be a hurdle and will 
be interesting as the present data indicate a very subtle age-related increase of 
CXCL12 expression in BM MSCs.  
 
With respect to Cx43, the most abundant connexin within bone, no age-related 
differences were found in this study both at transcript and protein levels. Kar et al., 
showed age-related decline in mouse osteocytes (323) and more recently,  Davis and 
colleagues have suggested that microRNA21 (miR21) is potentially responsible for this 
osteocyte Cx43-mediated age-related bone loss (305). Cx43 in osteoblasts has been 
shown to play an important role in bone remodelling by controlling both bone resorption 
and bone formation (324) and another study suggested that Cx43 in bone development 
acts in coordination with RUNX2 (325). All of the aforementioned studies were 
performed on differentiated cells, suggesting that techniques for detecting age-related 






Cx43 has been also implicated in controlling the damaging effects of ROS within the 
stem cell niche. Grayson et al., observed a significant increase in the Cx43 
immunocytochemistry staining in human BM MSCs cultured in hypoxic conditions. 
They suggested that Cx43 potentially contributes to maintaining MSC proliferation and 
‘stemness’ (326). On a similar line of thought, Ishikawa et al have shown the protective 
role of Cx43 for HSCs within the BM of mice. They suggested that Cx43 mediates the 
transfer of ROS from HSCs to the stromal cells within the BM thus protecting HSCs 
from damage. Similarly, Kar and colleagues had shown that Cx43 contributes to the 
protection of osteocytes against oxidative stress (323).  
 
Based on these studies, our proposed hypothesis was for an age-related decline in 
Cx43 in uncultured BM MSCs. However, the investigation at both, transcript and 
protein level did not reveal any age-related differences. Examination of the molecule 
using a different technique may be needed to further strengthen our conclusion of no 
age-related differences. Owing to the presence of Cx43 at cellular junctions, 
immunostaining techniques or the use of confocal microscopy that has labelled Cx43 at 
cellular junctions would be a useful tool to investigate and quantify the intensities of 
stains between young and old donor MSCs. 
 
Investigations of multipotentiality genes in HLCs displayed a significant decline in 
SPARC and a significant increase in RANKL in old donors. SPARC is also known to be 
an immunomodulatory molecule and thus it is not unexpected to observe an age-
related decline in SPARC in HLCs (316). RANKL, as mentioned earlier is expressed on 
T cells (316). An increase in RANKL suggests increased bone resorption. Higher bone 
resorption with advancing age is expected owing to overall age-related bone loss that 
has been established in literature (62, 81). The data presented in this chapter with 
respect to gene expression in HLCs was thus expected and supported the decline in 
immunomodulatory properties and increasing bone resorption observed with advancing 
age. 
 
With regards to surface markers, CD106 and CD146 were chosen based on previous 
evidence of their altered expression in in vitro aged MSCs (Table 4.3). For CD106, the 
results were far from conclusive, with all the studies reported very high donor variation, 
even within the same age groups (123). Liu et. al used human BM MSC cell lines and 
found significant downregulation of CD106, at both transcript and protein levels, when 
cells were expanded in vitro (327). In contrast, Laschober and co-workers found an 




years old (138). They also found that CD106 was highly expressed in MSCs when 
exposed to inflammatory cytokines TNF- or IFN- (138). Other studies have linked 
CD106 in MSCs with various immune and inflammation related changes (311, 328), 
suggesting a potential link between CD106 and inflamm-ageing within BM niches. 
Finally, Siegel and co-workers found a significant age-related decline in CD106 across 
a broad age range (20-80 years old) (97). 
 
Since the literature pertaining to cultured MSCs remained contradictory, it was 
interesting to investigate CD106 expression in uncultured MSCs. The current study 
showed no age-related difference in the level of CD106 expression in uncultured 
CD45lowCD271+ BM MSCs. In agreement with previous studies, this study too found 
the highest donor variation in the expression of CD106 compared to other markers. In 
future, investigations in larger number of donors and at the protein level will further 
increase our understanding. 
 
Similar to CD106, CD146 expression on CD45lowCD271+ MSCs in the present study 
also showed no age-related differences. This is in contrast to cultured MSC data, which 
commonly showed passage- or donor-age related decline. For example, Siegel et. al  
found a donor age-related decline in CD146  expression in BM MSCs at passage 1 
(97). More recently, Yang and co-workers examined CD146 expression in culture 
expanded BM MSCs between passages 4 and 8 and found a passage-related decline 
in its level expression (123). In contrast, Hagmann and co-workers did not observe any 
age-related change in the expression of CD146 in culture expanded MSCs (329). Only 
one study looked at the CD146 MSC expression in vivo and found that the 
CD271+CD146+ cells were reduced in frequency in old donors (>55 years old) 
compared to young donors (19-55 years old)  (229).  
 
In conclusion, the present data on CD106 and CD146 suggests that using culture-
expanded MSC data for the search of MSC ‘ageing’ marker in vivo is unlikely to be very 
fruitful. Other methods, for example using cell surface proteomic approach (330) and 
combining histological staining with flow cytometry for quantifying cell surface target 










Chapter 5 Expression of type 1 interferon (IFN1) and 
senescence genes in human BM MSCs  
The previous chapter described a non-significant age-related decline in number of BM 
MSCs measured using the CD45lowCD271+ phenotype and also examined differences 
between young and old donor MSCs in level of ROS, anti-oxidant enzyme SOD3 
transcript, and selected multipotentiality genes and surface markers. Investigation of 
SOD3 in MSCs from old donors interestingly revealed a two-fold decline but differences 
were not statistically significant. Similarly, some trends were observed in the 
expression of PPAR-, LepR, RANKL and OPG (over 2-fold increase in older donors), 
however they too did not reach statistical significance. Unlike MSCs, HLCs displayed a 
4-fold decline in osteogenic gene SPARC and 10-fold increase in bone remodelling 
gene RANKL in old donors, both of which were statistically significant. This indicated 
towards the fact that age-related gene expression differences for multipotentiality and 
possibly other genes could be more pronounced in HLCs as compared to MSCs. 
 
Age-related changes in HSCs and their lineages are better understood owing to the 
larger number of investigations performed as compared to MSCs. Among these age-
related changes, the decrease in lymphoid cells and increase in myeloid cells (myeloid 
skewing), loss in proliferation and increased DNA-damage in old donors have been 
well documented (332-334). The theories explaining these differences in aged HSCs 
are the same that describe MSC ageing (DNA damage, ROS accumulation, increased 
senescence and others, as explained in section 1.1.1). More recently, the IFN1 
pathway has attracted an increasing interest as a potential link between DNA-damage 
response (DDR), oxidative stress, senescence and ageing in HSCs (335, 336).  
 
As mentioned, HSCs are the progenitors for HLCs which eventually give rise to 
lymphoid and myeloid lineages. Considering that HSCs give rise to HLCs and that 
these cells share the same BM niche with MSCs, this chapter aims at investigating new 
exploratory genes emerging from the HSC ‘ageing’ field and including those associated 
with senescence and the IFN1 pathway, in MSCs as well as in HLCs. As in the 
previous chapter, this chapter also explores any age-related changes in the expression 
of these genes in uncultured cells and compares young donor and old donor cohorts. 
Finally, the chapter also aimed at inspecting if  age-related changes were more 






5.1 Introduction  
Due to the relatively higher number of studies in HSCs, age-related differences in this 
cell type have been explored to a greater extent than for MSCs. Previous investigations 
in HSCs, have revealed an age-related increase in the myeloid lineage cells along with 
a decline in HSC proliferative capacity (337). The tendency to produce less lymphoid 
lineage cells and more myeloid lineage cells is known as ‘myeloid skewing’  and 
potentially contributes to age-related increase in vulnerability to infections (332). 
Interestingly, the hypothesised mechanisms of these changes that include DNA 
damage, stem cell exhaustion and the effects of ROS (28, 338) are no different from 
the hypothesised mechanisms of age-related differences in MSCs that were described 
in Chapter 1 Section 1.1.1 in theories of ageing. Considering that both MSCs and 
HSCs reside within the same BM niche (section 1.1.3), it is possible that these 
damaging factors act on both cell populations (339).     
5.1.1 Senescence, SASP and age-related bone loss  
Residing within the same niche, MSCs are known to support activities of HSCs 
including their myeloid and erythroid differentiation and early lymphopoiesis (340). 
MSCs reside together with other cells in a regulated BM niche that helps maintain the 
functioning of the microenvironment (Chapter 1, section 1.1.4). MSCs are also known 
to directly and indirectly modulate and control T cell responses (341) and to inhibit the 
proliferation and differentiation of B cells (342, 343).  
 
With advancing age and accumulation of ROS and DNA damage in ageing cells, an 
increasing number of BM cells become senescent (344). Senescence is the state of 
irreversible growth arrest and is a regulated response to cellular insults like ROS and 
DNA damage (345). Senescent cells have been identified by various methods including 
an increase in SA--gal, Prelamin A, cell surface lipids like Lipofuscin, Tp53, critically 
short telomeres as well as differences in gene methylation patterns (131). Tp53 is a 
transcription factor well known for its function in cell-cycle, DNA-repair, and inducing 
cell growth as well as apoptosis (346, 347). While the presence of Tp53 is vital for 
maintenance of cells including BM MSCs (348), excessive levels of the transcription 
factor are known to be detrimental to healthy ageing (346). Aligned with this, our group 
found an age-dependant increase in the levels of Tp53 quantified by flow cytometry in 
culture expanded BM MSCs (96). Considering the aforementioned knowledge, Tp53 
was hypothesised to be expressed in higher quantities in old donor cells as compared 





Along with increase in ROS and DNA damage, senescence is also characterised by 
the senescence associated secretory phenotype (SASP) (130), which includes the 
release of pro-inflammatory cytokines (like IL6, IL8) and metalloproteinases (MMPs) 
from senescent cells (345), and can then induce senescence and inflammatory 
responses in neighbouring cells (131). Senescent MSCs release higher amount of 
SASP, which reduces the multifunctionality of MSCs (80, 349) as well as accelerates 
the rate of ageing in younger cells (350). Interestingly, the level of serum IL6 has more 
than often been found to be higher in older donors as well as in donors with age-related 
diseases (214, 351, 352) and is an accepted marker of SASP and inflamm-ageing. 
Inflamm-ageing is defined as inflammation associated with increasing age and age-
associated diseases and is explained further below (215, 353). With respect to MSCs, 
over-expression of IL6 has been shown to disrupt their role in maintaining HSC 
functionality and homeostasis (354). Thus in this project, the expression of IL6 was 
hypothesised to display an age-related increase in both cell populations. 
 
IL7 is essential for B cell development, survival and proliferation (355) and has long 
been known to be secreted in high quantities by BM MSCs (356). While it is not 
classified as a pro-inflammatory marker, its role in supporting B cell development in the 
BM and thus contributing to BM niche homeostasis makes it an important cytokine to 
investigate. In culture expanded BM cells, IL7 activity was found to drop dramatically in 
old mice (357) while in synovial fluid of old human donors, the level of IL7 was found to 
increase (358). Thus, in spite of knowing that IL7 is majorly produced by BM MSCs and 
its role in B cell formation and development, what happens to its levels in relation to 
advancing age remains unclear. Knowing that B cells functionalities decline with 
increasing age even though the change in number remains debateable (359), it was 
hypothesised that IL7 expression will show an age-related decline in both cell types. 
 
Along with IL6, IL8 too has been identified as an indicator of SASP (360, 361). While 
the number of investigations in relation to ageing are relatively fewer for IL8 compared 
to IL6, it is a known pro-inflammatory marker associated with high stress levels, is 
increased proportionately with age in urine samples (362) and in cancer patients (363). 
In BM MSCs co-cultured with colorectal cancer cells, IL8 production was found to 
enhance the proliferation tumour angiogenesis (364). Thus in this project, the 
expression of IL8 was hypothesised to be higher in old donor cells as compared to 
young donor cells. 
 
Within the bone, increase in SASP has been shown to correlate with advancing age in 




young mice (6 months) (365). Increased senescence, adipogenic shift of MSC 
differentiation, increased oxidative stress are all associated with age-related factors 
giving rise to increased levels of inflammation, which is now referred to as ‘inflamm-
ageing’ (353). Inflamm-ageing conceptually postulates that increasing age is 
associated with an intrinsic decline of the proliferation potential of immune cells, their 
increased senescence and DNA damage. This is accompanied with the reduction of 
protective extrinsic mechanisms within the cellular microenvironment that aim at 
removal of senescent cells and accumulated damage, that is, autophagy (366). As 
mentioned in section 1.1.1, autophagy is the body’s internal mechanism for the removal 
of senescent cells and damaged cell organelles by lysosome degradation. This is 
known to prevent the accumulation of DNA damage in the young and healthy (21). 
However, with the passage of time and increasing age, efficiency of autophagy 
declines. This means that the body’s inherent capacity to identify and eliminate 
senescent cells/damaged organelles, also declines (21).  
 
As autophagy declines, the number of senescent cells increase and so does the 
accumulation of damaged cells and organelles. These senescent cells release pro-
inflammatory cytokines and growth factors (SASP), that ultimately contribute to 
inflamm-ageing (366). Expectedly, the understanding of senescence, autophagy, 
inflamm-ageing and their contribution in age-related diseases, makes senescence a 
promising target for anti-ageing strategies (366). These strategies may use seno-
therapeutics aimed at removal of senescent cells by killing senescent cells (senolytics), 
or by modulating SASP (senomorphics) or by the clearance of senescent cells 
mediated by the body’s immune system (seno-inflammation) (367). While senescence 
and SASP can indicate ‘ageing’ when they increase in body, anti-ageing genes also 
play an equally important role in maintaining ‘youthful’ characteristics of cells (368).  
 
Sirt6 is an anti-ageing gene (369) recognised for regulating DNA breaks and damage 
repair (370) and its over-expression was found to expand the lifespan of male mice 
(371). In human dermal fibroblasts, an age-related decline in the expression of Sirt6 
was observed along with higher resistance towards reprogramming. However, the 
addition of Sirt6 in old donors dermal fibroblasts (>50 years old) was found to enhance 
the reprogramming efficiency (372). In relation to MSCs, Sirt6 has been shown to 
regulate osteogenic differentiation of BM MSCs in rats (373) and to protect embryonic 
MSCs from oxidative stress characterised by dysregulated redox metabolism in Sirt6-/- 
human MSC cell lines (374). Another study in 2016 found that knocking out Sirt6  gene 




aforementioned observations, the expression of Sirt6 was hypothesised to show an 
age-related decline in both cell populations. 
 
Investigations with another anti-ageing gene Klotho (Kl) have shown that its 
overexpression leads to extended life-span (376), while its mutations lead to decreased 
lifespan in mice (377) and promoted the process of ageing by damaging telomerase 
activity (378). The Klotho protein (379) was found to be inversely correlated with 
increasing age in the serum of human donors (380). Considering these findings, it is 
not surprising that genetically modified BM MSCs expressing Kl has been patented 
aimed at cell based therapies for many age-related diseases in humans (381). 
Interestingly, the potential mechanism of Kl to reduce senescence and extend life-span 
has been thought to be via the Tp53/p21 pathway (382). With this collective 
knowledge, it was hypothesised that there would be a decline in the expression of Kl in 
cells form older donors as compared to young donors. 
5.1.2 Type 1 Interferons (IFN1) 
IFNs are a group of cytokines that are known to elicit pleotropic biological effects  such 
as immuno-modulation and cell differentiation (383). They were initially recognised for 
their interference with viral replication, however other broad range of properties beyond 
their antiviral actions have been recognised recently in various cell types including 
fibroblasts, dendritic cells and HSCs (384). In stem cells in particular, they have been 
known to play a role in differentiation, immune-modulation, and their anti-proliferative 
potentials (385). IFNs may be activated due the presence of extrinsic factors like 
virus/infection or due the presence of intrinsic stress factors leading to DNA damage. 
 
In health, the levels of type 1 IFNs and IFN responses are fine-tuned to maintain the 
immune homeostasis between protection against viruses (386) and its toxic effects, 
which are widely associated with pathological conditions such as autoimmune diseases 
(i.e. Systemic lupus erythematosus or SLE) (387), chronic infection (388) and cancers 
(389). IFN1 binds to its receptor that is heterodimeric cell surface receptor, consisting 
of two transmembrane spanning subunits IFNAR1 and IFNAR2. Most cells types are 
known to express the receptor (390) including fibroblasts, dendritic cells, and peripheral 
blood cells including monocytes (391).  
 
The canonical signalling pathway involves IFN1 production and binding to the IFNAR. 
The receptor is phosphorylated and triggers downstream signal transduction cascade 
via activation of Janus kinases 1 (JAK) and non-receptor tyrosine kinase 2 




STAT2. Phosphorylated STAT1 and STAT2 dimerise, dissociate from IFNAR2 and 
form a trimolecular complex with IFN regulatory factor 9 (IRF9) known as Interferon 
stimulated gene factor 3 (ISGF3) (392, 393). This complex then translocates to the 
nucleus where it binds to DNA sequence motif known as IFN stimulated response 
elements (ISRE) to eventually activate the transcription of a wide range of IFN 
regulated genes, also known as the IRGs, in an autocrine and paracrine way (Figure 
5.1, top panel).  
 
Recently, a study from our group examined the immune-modulating property of MSCs 
from cancellous bone fragments on CD3/CD28- stimulated CD4+ T cells. It found a 
‘dose dependant suppression of CD4 T-cell proliferation’ along with an increase in the 
levels of TGF in co-cultures (316). It also identified a list of candidate genes that 
potentially were responsible for eliciting MSC immunomodulation. Interestingly, many 
transcripts belonged to the IFN1 responsive family of genes, raising interest in 
understanding age-related differences in the expression of these genes in uncultured 
BM MSCs and HLCs, and their potential link to inflamm-ageing.  
 
In an early study in 1984, the levels of IFN1 secreted from mononuclear cells were 
shown to decline in donors aged over 50 (394). In contrast, study in 2011 described 
DDR-induced expression of IFN genes after double stranded DNA breaks were 
introduced in HeLa cell lines (395). An intracellular molecule STING was increasingly 
becoming the core molecule mediating IFN expression induced by DDR (396). In 
health, DNA remains localised to the nucleus or the mitochondria. Thus, the presence 
of the DNA in the cytoplasm of the cell is expected to trigger DDR. In 2013, cGAS was 
found to detect the presence of the DNA in the cytoplasm and undergo conformational 
change. This conformational change in cGAS could now convert ATPs to the second 
messenger cyclic GMP-AMP (cGAMP) (397) which is a high affinity ligand to the 
adaptor protein stimulator of IFN genes (STING) (398). STING translocates from the 
endoplasmic reticulum to the golgi bodies which activates IFN regulatory factor 3 
(IRF3) which leads to the production of IFN1 (399). 
 
Based on this evidence, the cGAS-cGAMP-STING pathway has been reported to be 
the link between inflammation-based DDR, senescence as well as cancer (399). 
Considering that the presence of extrinsic/intrinsic stress factors illicit IFN1 response 
via STING, cGAS-STING-IFN1 pathway has been proposed as one of the pathways for 
autophagy (400-402). As mentioned, there has been an increased interest in 
unravelling the links between DDR, ROS, cell senescence and IFN1 signalling in HSC 




these molecules in MSCs (Figure 5.1, bottom panel). Furthermore, the connection 
between DNA damage and the ATM-BID-MTCH2 pathway has been recently proposed 
to mediate the negative impact of  ROS in HSCs (31). In HSCs from a mouse model 
deficient for Mixed Lineage Leukemia 5 or MLL5), BID (BH3 interacting domain) 
regulated mitochondrial ROS in DNA damage pathway downstream IFN1 signalling. 
Another protein - MTCH2 (mitochondrial carrier homolog 2) - protected cells from 
oxidative stress-induced death, and BID which is the precursor of MTCH2 in the ATM 
(ataxia telangiectasia mutated kinase)-BID pathway, worked as a MTCH2 antagonist 
(404).  
 
Figure 5.1 IFN1 signal 
activation and signalling pathway associated with ROS and intrinsic factors 
(adapted from (393) and (31)) 
 
(A) Left: General IFN1 signalling pathway activation by extrinsic factors. IFN1 binds to 
its receptor and conformational changes begin the cascade of phosphorylation of 
STAT1 and STAT2 to form ISGF3 that ultimately leads to IFN response elements in the 
nucleus. Right: IFN1 may also be activated by intrinsic factors like cytoplasmic DNA 
written in red.  (B) Intrinsic factors leading to IFN1 response in MSCs: Intrinsic ROS 
causes DNA damage which leaks out of nucleus and becomes cytosolic DNA. This 





Under low level of DNA damage, ATM through BID phosphorylation, reduces the level 
of BID and consequently, the level of ROS in HSCs. However, during DNA damage; 
loss of BID phosphorylation directs it toward the mitochondria and results in massive 
ROS production by interacting with MTCH2 (403). To date these investigations have 
not been performed on human cells. Moreover, the presence of ATM-BID-MTCH2 
pathway molecules in MSCs has not been explored before. Because HSCs and MSCs 
coexist in BM niche, this pathway may be potentially affected in MSCs exposed to 
oxidative stress and DNA damage (both previously associated with age-related 
changes).  
 
The role of IFNs and related signalling pathways in the complex and dynamic interplay 
between MSCs and HLCs in the BM niche remains unexplored. Taking the work from 
our group that recently found the expression of many IRGs in MSCs, forward along 
with some more exploratory transcripts related to senescence and anti-ageing, this 
chapter examined age-related changes in these transcripts in MSCs and HLCs. It was 
expected that DNA damage and senescence associated genes could potentially be 
higher in old donor cells, and possibly more in HLCs than in MSCs. List of analysed 
transcripts is shown in Table 5.1. Furthermore, considering that IFN1 signalling has 
been more commonly linked to innate immune cells, which are derived from HSCs, it 
was hypothesised that genes associated with IFN1 pathway would be expressed in 
higher levels in HLCs as compared to MSCs. Moreover, senescence and SASP genes 
were hypothesised to increase in older donors in MSCs and in HLCs. Age-related 
changes in anti-ageing genes, IFN receptors as well as IFN-associated genes would 
also be expected to be more pronounced in HLCs as compared to MSCs. 
 
This chapter aimed at exploring if uncultured BM MSCs expressed any IFN1 
responsive genes in comparison to HLCs along with the expression of senescence 
associated genes. The chapter also aimed at investigating any age-related changes in 












5.1.3 Hypothesis and objectives 
The following hypotheses and aims were postulated for this chapter 
 
Hypotheses: 
   
1. Senescence and SASP associated genes display an increased expression in 
old donor cells, with greater increase in BM HLCs than in BM MSCs. Anti-
ageing genes display the opposite trend. 
2. Both BM MSCs and HLCs express the exploratory genes from the IFN1 
responsive family of genes, but their expression is higher in HLCs, including 
selected molecules linking IFN pathway with DNA damage, ROS and 
senescence. 
3. These exploratory transcripts would show age-related decline in cells from older 




1. To quantify the expression of senescence, SASP and anti-ageing genes in 
uncultured BM CD45lowCD271+ MSCs and CD45+CD271- HLCs from young and 
old donors. 
2. To compare the expression of exploratory genes linking IFN pathway with DNA 
damage, ROS and senescence in uncultured BM MSCs and HLCs. 
3. To investigate the age-related changes in these exploratory genes in uncultured 
BM MSCs and HLCs. 
5.2 Methods 
5.2.1 Donor selection 
A total of n=12 donor BM cells, 6 young (19-40 years old, median age=27 years old) 
and 6 old (59-89 years old, median age=68 years old) were used for investigation in 
this chapter. The description of donor samples used in this chapter have been outlined 
in Appendix 1, Table 3. 
 
5.2.2 Gene expression for exploratory transcripts analysis 
The general method has been described in section 2.5. Briefly, frozen nucleated cells 
from BM of donors were defrosted (Section 2.3), enriched using anti-fibroblast beads 
(Section 2.4) and then sorted to collect CD45low CD271+ MSCs and CD45+CD271- 
HLCs and frozen in lysis buffer at -80ºC for further use. Next, these cell lysates were 
defrosted and the RNA was extracted (Section 2.6.4). The RNA was then reverse 




then qPCR was performed on BioMark™ (Section 2.6.7) using 48.48 dynamic array 
(Figure 5.2). The principle of these reactions are the same as those described in 
















Figure 5.2 48.48 gene chip outlay 
 
The quantification was performed during analysis wherein the Ct values for each gene 
of interest were normalised to Ct value of HPRT1 as the housekeeping gene to 
generate the Ct values for each gene using the formula [Ct target gene- Ct housekeeping gene]. 
Finally, the Ct values were converted to ‘relative expression’ for each gene using the 
formula [2-Ct] and the values were compared between young and old donors for both 
BM cell populations (MSCs and HLCs). 
5.2.3 Statistical analysis 
Cluster analysis was used to observe any differences in gene expression across the 
entire donor cohort. Statistical analysis and graphics were performed using GraphPad 
Prism software (version 7.0a). The normal distribution of the data was assessed using 
the Shapiro-Wilk and Kolmogorov-Smirnov tests for normality. As data were found to 
be not normally distributed, Mann-Whitney U test was performed for unmatched data. 







5.3.1 The expression of all exploratory transcripts in BM MSCs and HLCs 
The expression of transcripts for type 1 IFNs, IFN Receptors and IRGs, as well as 
genes associated with IFN1>BID>ROS pathway and senescence, was investigated in 
sorted uncultured BM MSCs and HLCs, based on the CD45low CD271+ and 
CD45+CD271-  phenotypes, as described in the previous chapter for the whole donor 
cohort. Cluster analysis of gene expression data revealed the presence of two distinct 
clusters  for MSCs and HLCs, with the exception of one sample (Figure 5.3). High 
variation in gene expression between the donors was noted, but surprisingly, an overall 
pattern of higher expression (more red colour) in s compared to HLCs was found. The 
higher expressed IRGs in MSCs relative to MSCs included IFITM1, IFITM3, IFI27, 
SERPING and IRGs with higher expression in HLCs included RGS1, IL8  and BID 
(Figure 5.3).  
 
The statistical analysis including the fold differences in the expression of gene shown in 
figures are shown in Table 5.1. The median values and differences between 



















































Figure 5.3 Expression of exploratory genes in MSCs and HLCs  
 
Expression of IFNA1, IFNB1, IFN receptors, IRGs, genes associated with 
IFN1>BID>ROS pathway, senescence and other exploratory genes grouped by cluster 
as MSCs (left) and HLCs (right). Colour key in shown at the bottom right of the figure. 





5.3.1.1 Analysis of expression of senescence and anti-ageing associated genes 
in MSCs and HLCs 
 
For the whole donor cohort, analysis of transcripts associated with senescence and 
anti-ageing showed that Tp53 and Sirt6 displayed no statistically significant differences 
(p<0.05 for both genes) between MSCs and HLCs, although Sirt6 had slightly higher 
expression in MSCs as compared to HLCs (2.86-fold). However, the expression of Kl 
was significantly (25-fold) higher in MSCs (p=0.0083) as compared to HLCs (Figure 
5.4). In combination, the pattern of expression for all three genes indicated a possibility 







Figure 5.4 Expression of senescence and anti-ageing genes in MSCs and HLCs  
Expression of Tp53, Sirt6 and Kl in donors in MSCs and HLCs. Horizontal line across 
data set indicates median values. p<0.01**, Mann-Whitney U test. 
5.3.1.2 Analysis of expression of SASP-associated genes in MSCs and HLCs 
Two out of three SASP cytokine genes were also differentially expressed between 
MSCs and HLCs. Cytokine IL6 showed no difference in expression between the two 
cell populations (Figure 5.5). As expected, IL7 displayed significantly higher expression 
in MSCs (p=0.0005) in comparison to HLCs, and IL8 displayed higher expression in 







Figure 5.5 Expression of SASP-associated cytokines in MSCs and HLCs 
Expression of IL6, IL7 and IL8 in MSCs and HLCs. Horizontal line across data set 







































































5.3.1.3 Expression of IFN1, IFN Receptors and IRGs in MSCs and HLCs 
 
Expression of IFNA1 and IFNB1 did not show differences in their expression levels 
between MSCs and HLCs (Figure 5.6A). Very interestingly, the levels of expression of 
IFNAR1 and IFNAR2 showed a significantly higher expression in MSCs (p=0.0018 and 
p=0.0332, respectively) compared to HLCs (Figure 5.6B), which was unexpected, 














Figure 5.6 Expression of IFNA, IFNB and IFNA receptor genes in MSCs and in 
HLCs 
(A) Expression of IFNA1and IFNB1 in MSCs and HLCs. (B) Expression of IFNAR1 
and IFNAR2 in MSCs and HLCs. Horizontal line across data set indicates median 
values. p<0.05* and p<0.01**, Mann-Whitney U test. 
 
Among the IRGs, many of them including USP12, IFITM1 and IFITM3, displayed higher 
expression levels in MSCs (Figure 5.7). Similarly, there were genes including PRDM1, 
LAIR and CASP1 that were significantly higher expressed in HLCs (Figure 5.8). 
Overall, and as indicated by the cluster analysis shown in Figure 5.3, a higher 
proportion of the genes displayed significantly higher expression in MSCs than in 






























Figure 5.7 Genes displaying significantly higher expression in MSCs than in 
HLCs  
Expression of most significantly differentially expressed genes in MSCs over HLCs. 
Horizontal line across data set indicates median values. p<0.01**, p<0.001*** and 




























































































































































































































Figure 5.8 Genes displaying significantly higher expression in HLCs than in 
MSCs  
Expression of most significantly differentially expressed genes in HLCs over MSCs. 
Horizontal line across data set indicates median values. p<0.05*, Mann-Whitney U test. 
 
5.3.1.4 Analysis of expression of genes involved in IFN1>BID>ROS pathway 
As discussed in the introduction to this chapter, damage to the DNA due to external or 
internal factors is known to activate IFN1 signalling via STING, IRF3 and STAT1 
through IFNA receptors. This has eventually been shown to mobilize BID, which exerts 
its expression via MTCH2, which is the mitochondrial receptor for BID. Mobilisation of 
BID has been shown to lead to accumulation of mitochondrial ROS leading to 
functional defects and senescence in the HSCs. Because HSCs give rise to HLCs and 
MSCs coexist with HSCs in the BM niche, it was thus in the interest of this project to 


























































































































































































Figure 5.9 Expression of genes associated with IFN1>BID>ROS pathway in MSCs 
and HLCs 
Expression of STING, IRF3 and STAT1 (top panel), BID and MTCH2 (bottom panel) in 
each group. Horizontal line indicates median values. p<0.05*, Mann-Whitney U test. 
 
 
Both IFNAR1 and IFNAR2, displayed higher expression levels in MSCs as shown in 
figure 5.6B. STING showed no significant difference in expression between MSCs and 
HLCs although a trend for higher levels in MSCs was noted (Table 5.1). IRF3 and 
STAT1 displayed higher expression levels in MSCs as compared to HLCs (p=0.0205 
and p=0.0242 respectively, Figure 5.9, top panel). BID displayed significantly higher 
(p=0.0188) expression in HLCs as compared to MSCs while MTCH2 showed no 



























































































































 Table 5.1 Medians of expression of genes shown in Figures 5.4 to 5.6 and 5.9 in 
MSCs, HLCs, fold differences and their p values 
 
 
NS: Non-significant, Gene expression is normalised to HPRT1, Mann-Whitney U test. 
 
Overall, this gene expression pattern potentially indicated a higher level of constitutive 
IFN1 signalling in MSCs, as well as their possession of the necessary molecular 
machinery to combat oxidative damage via IFN1>BID>ROS pathway. 
5.3.2 Age-related differences in IFN1 signalling pathway related genes 
The median values for each gene shown in the figures below in young and old donors, 
the fold difference with advancing age and their p values are indicated in Table 5.2 and 
Table 5.3. Similar tables for the all the exploratory genes are shown in Appendix 4, 
Table 5.2 and 5.3 for age-related differences in MSCs and in HLCs, respectively 
5.3.2.1 Age-related differences in the expression of senescence and anti-ageing 
associated genes in MSCs and HLCs 
Senescence-associated gene Tp53 and anti-ageing genes of Kl and Sirt6 did not show 
any differences between young and old donor MSCs (Figure 5.10A). In HLCs, the 
expression of all of these genes declined in old donors (Figure 5.10B) with Tp53 
showing a statistically significant decline (p=0.0043). At least in relation to anti-ageing 
genes, these data indicated a possibility for stronger ‘ageing-resistance’ molecular 








(MSCs/HLCs) p value 
IFN1 and 
receptors 
IFNA1 6.97 3.01 2.32 NS 
IFNB1 1.50 1.59 0.95 NS 
IFNAR1 4.28 0.88 4.86 0.0018 




STING 2.64 1.54 1.72 0.0684 
IRF3 2.051 1.90 1.08 0.0242 
STAT1 4.33 2.26 1.92 0.0205 
BID 0.21 1 0.21 0.0188 




Kl 0.51 0.02 25.50 0.0083 
Sirt6 0.50 0.17 2.86 NS 
Tp53 2.5 1.59 1.57 NS 
SASP 
IL6 0.15 0.27 0.56 NS 
IL7 1.48 0.016 93.73 0.0005 



















Figure 5.10 Expression of senescence and anti-ageing genes 
(A) Expression of Tp53, Sirt6 and Kl in young and old donors MSCs (B) Expression of 
Tp53, Sirt6 and Kl in young and old donor HLCs. Young and old donors are indicated in 
black and grey dots, respectively. Horizontal line across data set indicates median 
values. p<0.01**, Mann-Whitney U test. 
 
5.3.2.2 Age-related differences in SASP-associated cytokine transcripts in 
MSCs and HLCs 
 
IL6 transcript levels were found to be 4-fold higher in old donor MSCs as compared to 
MSCs from young donors however the differences failed to reach statistical 
significance. IL7 and IL8 did not show any difference between young and old donor 
MSCs either (Figure 5.11A). In HLCs, IL6 transcript was similarly nearly 4-fold higher in 
from old donors as compared to young donors however the differences did not reach 
statistical significance. IL7 showed a slight decline and IL8 did not show any difference 





















Figure 5.11 Expression of cytokines 
(A) Expression of IL6, IL7 and IL8 in young and old donor MSCs. (B) Expression of IL6, 
IL7 and IL8 in young and old donor HLCs. Young and old donors are indicated in black 
and grey dots, respectively. Horizontal line across data set indicates median values.  
 
5.3.2.3 Age-related differences in IFN1, IFN Receptors and IRGs in MSCs and 
HLCs  
 
Cluster analysis between young and old donor MSCs revealed no patterns for 
differences in type 1 IFN, IFN receptors, IRGs and cytokines. Similarly, investigation of 
differences between young and old donor HLCs using cluster analysis also revealed no 
particular trends.  
 
IFNA, IFNB and IFNAR transcript levels showed no significant differences or particular 
trends between young and old donors MSCs (Figure 5.12A). However, in HLCs, some 
differences were significant. IFNA1 transcript levels displayed a trend for over 2-fold 
increase in old donors HLCs compared to young donors. IFNB1 showed no differences 
between young and old donor HLCs (Figure 5.12B). IFNAR1 and IFNAR2 transcript 
levels showed declines in their expression in old donor HLCs, which was statistically 




































Figure 5.12 Expression of IFNA, IFNB and IFNA receptor genes 
(A) Expression of IFNA1 and IFNB1 (top panel) and IFNAR1 and IFNR2 (bottom panel) 
in young and old donor MSCs (B) Expression of IFNA1and IFNB1 (top panel) and 
IFNAR1 and IFNAR2 (bottom panel) in young and old donor HLCs. Young and old 
donors are indicated in black and grey dots, respectively. Horizontal line across data 
set indicates median values. p<0.05*, Mann-Whitney U test. 
 
Out of all the exploratory IRGs, RNF213 was the only gene that showed statistically 
significant lower expression in MSCs from old donors as compared to young donors 
(p=0.041, Figure 5.13A).  In the HLCs, more IRGs displayed significant decline in old 
donors (Figure 5.13B) and Appendix 4, Table 2. This potentially indicted reduced IFN1 



































Figure 5.13 Expression of genes displaying statistical age-related differences 
(A) Expression of differentially expressed genes in MSCs in young and old donors and 
(B) Expression of differentially expressed genes in in HLCs in young and old donors. 
Young and old donors are indicated in black and grey dots, respectively. Horizontal line 










5.3.2.4 Age-related differences in genes associated with IFN1>BID>ROS 
pathway  
 
The analysis of genes associated with the IFN1>BID>ROS pathway also revealed 
interesting findings. Again, investigation in MSCs did not show any significant age-
related differences, although STAT1, IRF3 and STING showed a trend for an increase 
in MSCs from old donors. BID expression demonstrated a non-significant, nearly 3-fold 
decline in old donor MSCs (Figure 5.14A).   
 
Interestingly, investigation of expression of the same genes in young and old donor 
HLCs revealed different results. While STAT1 expression showed no difference, IRF3 
displayed a significant decline in old donors HLCs (p=0.033) (Figure 5.14B). Significant 
declines in old donor HLCs were also seen for MTCH2 and STING expression 
(p=0.0152 and p=0.041, respectively) while BID did not show any age-related 
differences.  
 
Altogether, investigation of IFN1 family of genes, SASP cytokine genes and other 
genes linking IFN pathway and cell senescence did not reveal any significant 
differences between young and old donor MSCs, except for RNF213 gene, which is an 
IRG with yet unknown function. While expression of these genes in MSCs did not show 
any age-related differences, the same genes in HLCs revealed interesting expression 
patterns. In particular, IFNAR2, many IRGs and genes linking IFN1 pathway with ROS 
and cell senescence displayed a decrease in their expression in old donor HLCs. 
Altogether, these data indicated a potential reduction in constitutive IFN1 signalling in 




































Figure 5.14 Expression of genes associated with IFN1>BID>ROS pathway 
(A) Expression of STING, IRF3, STAT1,BID and MTCH2 in young and old donor MSCs 
(B) Expression of STING, IRF3, STAT1,BID and MTCH2 in young and old donor 
MSCs. Young and old donors are indicated in black and grey dots, respectively. 
















difference*  p value 
IFNA1 5.136 9.15 1.78 NS 
IFNB1 1.247 1.725 1.38 NS 
IFNAR1 4.278 4.757 1.11 NS 
IFNAR2 5.82 5.76 0.99 NS 
STING 2.63 4.88 1.86 NS 
IRF3 1.946 3.13 1.61 NS 
STAT1 3.42 5.16 1.51 NS 
BID 0.3 0.11 0.37 NS 
MTCH2 1.43 1.27 0.89 NS 
Kl 0.51 0.48 0.94 NS 
Sirt6 0.506 0.406 0.80 NS 
Tp53 2.25 2.88 1.28 NS 
IL6 0.05 0.2 4.00 NS 
IL7 1.481 1.169 0.79 NS 
IL8 2.24 5.14 2.29 NS 
 
*Age-related difference calculated by median expression in old donor/median in young 
donor. NS: Non-significant, Gene expression is normalised to HPRT1. Mann-Whitney U 
test 








difference* p value 
IFNA1 0.295 7.443 25.23 NS 
IFNB1 1.53 1.591 1.04 NS 
IFNAR1 1.1 0.48 0.44 NS 
IFNAR2 2.75 1.38 0.50 0.041 
STING 2.293 1.033 0.45 0.026 
IRF3 1.561 0.66 0.42 0.0411 
STAT1 2.17 2.4 1.11 NS 
BID 1 1.03 1.03 NS 
MTCH2 1.61 0.79 0.49 0.0152 
Kl 0.04 0.011 0.28 NS 
Sirt6 0.28 0.15 0.54 NS 
Tp53 2.93 1.21 0.41 0.0043 
IL6 0.16 0.6 3.75 NS 
IL7 0.038 0.013 0.34 NS 
IL8 46.47 67.21 1.45 NS 
 
*Age-related difference calculated by median expression in old donor/median in young 






This chapter presents novel data with respect to the presence and expression of genes 
associated with senescence, SASP and anti-ageing genes in uncultured BM MSCs. 
There were no differences observed in their expression between young and old donor 
MSCs but all their expression declined in HLCs with Tp53 displaying a significant 
decline in expression. In SASP, while IL6 showed a non-significant increase in old 
donors in both MSCs as well as in HLCs, IL7 and IL8 showed no particular differences 
in old donors in both, MSCs as well as in HLCs 
 
With respect to a the exploratory IFN1 family of genes, a number of novel findings were 
observed. Firstly, a large number of genes were found to be differentially expressed. 
Second, there were more highly expressed genes in MSCs over HLCs rather than the 
other way around, which was unexpected. This indicated towards the potential 
immune-related functions of BM MSC via IFN1 pathway as indicated by cancellous 
bone MSCs previously (316), that will require further explorations. Interestingly, IFNA1, 
IFNB1 and the IFNA receptors, were expressed significantly higher in MSCs as 
compared to HLCs. Genes involved in the IFN1>BID>ROS pathway (403) also 
revealed interesting trends with STAT1 and IRF3 indicating greater expression in 
MSCs, while BID displayed higher expression in HLCs as compared to MSCs and this 
supported the hypothesis of this chapter (31). Among the senescence associated and 
anti-ageing genes, Kl displayed higher expression in MSCs in comparison to HLCs. 
Finally, in cytokines, IL7 displayed higher expression in MSCs as compared to HLCs 
and IL8 displayed otherwise. 
 
When compared for age-related differences; IFNA1, IFNB1 and IFNA receptors 
showed no differences in MSCs, but IFNAR2 displayed a significant decline in HLCs 
from old donors. The only IRG that showed an age-related difference in MSCs was 
RNF213, while a number of IRGs were found to display a decline in their expression in 
HLCs. Analysis of genes involved in the IFN1>BID>ROS pathway also showed no 
changes in expression between young and old donors in MSCs, while in HLCs, STAT1, 
IRF3 and MTCH2 displayed a significant decline in expression between young and old 
donors. 
 
A recent study investigating the effect of retrotransposon (RT) in human fibroblasts 
found that the RT in human (long-interspersed element-1 or L1) becomes 
transcriptionally depressed in senescent cells which activates IFN1 response (336). 
The senescent cells were prepared by culturing them in vitro until their proliferation 




highly upregulated in senescent cells which were IRG or associated with the IFN1 
signalling.  
 
Over 30 of these genes were also tested in this thesis but in relation to age in 
uncultured BM MSCs and did no observe any age-related grouping in cluster analysis. 
Also, while other studies found a number of IFN1 associated genes to be upregulated 
in replicative senescent cells (336), this thesis found a significant decline in only one of 
the IFN1 associated genes in MSCs. This could be due to the fact that firstly, the cells 
described in this thesis were MSCs and not skin fibroblasts and secondly, the MSCs 
and HLCs used in this thesis were uncultured and did not undergo replicative 
senescence by in vitro culture expansion.  
 
The same study also examined the presence of L1 in aged mice and found a significant 
increase in IFN1 associated genes. They treated old mice with nucleoside reverse 
transcriptase inhibitors known to antagonise the effect of L1 reverse transcriptase. In 
doing so, they observed that not only did the IFN1 associated genes showed a 
downregulation but the SASP pro-inflammatory state was also alleviated. Their in vivo 
mice study thus linked senescence to ageing in mice. The only SASP gene that was 
found to increase in this project was IL6 while Tp53 and IFN1 associated genes were 
mainly found to decline in older donors, unlike in the above mentioned study. Similar 
treatments using nucleoside reverse transcriptase inhibitors in uncultured BM cells in a 
larger number of donors could shed light on the senescence profile of BM cells in 
association with IFN1. 
 
In this project MSCs did not display any difference in the level of expression of any of 
the above genes between young and old donors except RNF213 that showed a 
significant decline. RNF213 or ring finger protein has also been known as ‘mysterin’ 
owing to the lack of knowledge curated about this gene. It is known as the causative 
gene for Moyamoya disease which is a disease of blocked arteries within the brain. 
The disease is more prevalent in East Asian countries of Japan, Korea and China and 
is more common in women (405). Not much is known about the gene and more 
exploratory studies are needed to reveal its function in MSCs, as well as in HLCs.  
 
There were a good number of transcripts with over 2-fold age-related differences in 
MSCs. For example, pro-inflammatory cytokines IL6 and IL8 were found to be 4-fold 
and 2-fold higher in the old donors MSCs as compared to young donors, respectively. 
Of note, while literature suggests that IL6 is higher by 2-4 fold in older donors (MSCs), 




in old donors with chronic inflammation (406). Age-related differences were more 
prevalent in the HLCs, wherein genes like IFN regulatory factor 2 and 9 (IRF2 and 
IRF9) and cyclin D2 (CCND2) displayed a significant decline in old donor HLCs. Similar 
decline in IRGs has been observed in the peripheral blood mononuclear cells in older 
donors (394).  
 
BID and MTCH2 regulate the oxidative metabolic state of HSC and thus manage their 
oxidative stress, which was discovered not too long ago. The hypothesised mechanism 
behind it was described by Gross et al., in 2017 where DNA damage in the nucleus 
lead to accumulation of ROS in mitochondria via the IFN>BID>MTCH2 pathway. HSCs 
as a population have extensively been studied for understanding their biology and 
ultimately for use in several cell therapies. Not only did this project confirm the 
expression of these transcripts but also compared it between young and old donor 
MSCs. While no age-related differences were observed in MSCs, there was a 
significant age-related decline in MTCH2 observed in the HLCs.   
 
An age-related decline in IFN1 signature genes was also observed in activated CD4+ T 
cells from donors of older age (65-85 years old) as compared to younger donors (20-35 
years old) when investigated in cells isolated from peripheral blood mononuclear cells 
(407). Considering that IFN1 are an integral part of the innate immune system that is 
responsible for triggering responses in bacterial and viral infections, it may suggest that 
the decline in IFN1 in old age compromises their ability to respond to these infections. 
With the knowledge that DDR can activate IFN1 signalling and that DNA damage 
increases in the older age, it may also explain the reduced ability of recognising this 
damage in older donors owing to the decline in IFN signature genes. Even though the 
number of investigation of IFN1 on MSCs remain limited, the existing studies have 
shown the presence of IRGs in culture expanded BM MSCs. The study also showed an 
increase in the number and size of colonies when BM MSCs were treated with 
monoclonal antibody against the IFNAR1 chain of human type 1 (385).  
 
The transcripts associated with anti-ageing and senescence namely Kl, Sirt6 and Tp53 
showed no age-related differences in uncultured BM MSCs. Kl has been a well-known 
anti-ageing gene, the absence or deletion of which observed ageing-like syndrome in 
mice. In general, overexpression of Kl has been observed to increase lifespan, 
whereas repressing the transcript has been associated with premature ageing. Tp53 is 
crucial for DNA repair and induction of apoptosis and senescence and has previously 
been shown to be increased in MSCs from old donors (96). Age-related decline in Tp53 





A study in 2016 aimed at identifying senescent cells within mice bone 
microenvironment and performed varying investigations in T cells, B cells, myeloid 
cells, MSCs, osteoblasts as well as in osteocytes of young (6mo) and old (24mo) mice 
(365). They observed an increase in senescence and SASP profile in old mice. While 
P16 increased in all the cell types, Tp53 was highly expressed in osteocytes and 
myeloid cells and not in MSCs. However, in this thesis, Tp53 was found to expressed 
higher in MSCs as compared to HLCs and declined in older donors in both MSCs and 
in HLCs which was unexpected as Tp53 increases in old senescent cells (408).  
 
With respect to studies in humans, De Oliveira found that Kl down-regulation induced 
premature senescence in human fibroblasts and downregulation of p53 in Kl 
attenuated cells restored normal growth in the cells (382). Overall their study 
demonstrated that Kl regulated cellular senescence via the p53/p21 pathway 
highlighting on the anti-ageing role of Kl. More recently, Zhang et al., found that 
addition of Kl protein to MSC cell lines, attenuated their osteogenic differentiation ability 
(409). Another human study examined the serum of healthy volunteers and found that 
Kl declined with increasing age. Their study had a broad range of donor age (0.1-88 
years old) including toddlers as well as old donors. While they did observe a decline in 
Kl across the entire age range, they segregated their young and old groups age <17 as 
young donors and over 20 years old as old donors (380). The specificity of the Kl in 
MSCs has never been showed before making the data from this project very novel. As 
an anti-ageing gene, this transcript could potentially be used to understand ageing in 
vivo in MSCs. 
 
Along with Kl, Sirt6 is another transcript that is recognised for its anti-ageing potential, 
the deficiency of which has been associated with age-associated degenerative 
processes (410). It is known to be expressed in BM MSCs and Sun and colleagues 
found that while its knockout has resulted in decreased osteogenic differentiation and 
proliferation, its overexpression increased osteogenesis in mice (373). They also found 
that Sirt6 was doing so via partial suppression of the NF-kb pathway in old mice. Zhang 
et al., also found the Sirt6 promoted osteogenic differentiation in mice (411), however, 
their results contradicted the results of Sun and colleagues, and demonstrated the 
involvement of the BMP pathway instead. Around the same time, another study that 
generated MSCs from human embryonic stem cells found that Sirt6 played a protective 
role against ROS in MSCs (374). They found that cells that were depleted of Sirt6 not 
only were more susceptible to accelerated degeneration but were also more vulnerable 




related decline in the expression of Sirt6 in uncultured MSCs but did not observe any 
differences in this project.  
 
Taken together, the anti-ageing transcripts and transcripts associated with senescence 
showed significant differences in HLCs, but no difference in MSCs. This was as 
expected in the hypothesis suggesting the MSCs in vivo are relatively more resilient to 
ROS and DNA damage in comparison to HLCs. Previous investigations of these 
transcripts in uncultured MSCs is sparse, making data from this thesis novel.  
 
Among the cytokines, IL6 showed no significant difference in its expression level 
between MSCs and HLCs. This was unexpected as IL6 has closely been associated 
with inflammation (351). In contrast, IL7 exhibited very high expression levels in MSCs 
and IL8 displayed higher expression in HLCs. IL6 has been a well-known indicator of 
inflamm-ageing and has been reported to be higher in old donors and significantly 
higher in old donor with inflammation (406). Thus it was no surprise that the expression 
of IL6 was found to be higher in old donors in both cell types, MSCs and HLCs. IL6 and 
IL8 are also associated with SASP and have been shown to increase in MSCs that 
were DNA damaged (354). However, that study was based on MSCs and HSCs in co-
culture conditions. In this thesis, the expression of IL7 showed no age-related 
differences in either cell populations while IL8 displayed a non-significant increase in 
HLCs.  
 
Considering that both HSCs and MSCs originate within the BM (section 1.3.1), they are 
bound to impact each other. The protective role of MSCs in preventing HSCs from 
ROS with the help of Cx43 has already been discussed in section 4.4. It is a well-
known fact that age-related changes of increased adipogenesis in MSCs and shift 
towards myeloid lineage (myeloid skewing, section 1.3.1) in HSCs occur within the 
same BM niche. However, as the two belong to different stem cells types, they have 
often been examined separately. Among the few scientists to have linked the two and 
acknowledge the relationship, were Kovtonyuk and colleagues in their 2016 study 
(412). Referring to previous studies, they outlined that adipocytes negatively impacted 
HSC functions supporting B-cell lymphopoiesis. As adipogenesis increased in old age, 
there is a high possibility that it enhanced the process of age-related myeloid skewing 
in old individuals.  
 
In summary, this chapter was the first to quantify the expression level of IFN1 
associated and other genes in uncultured BM cells. Interestingly, a large number of 




finding is novel. Furthermore, a number of genes also displayed age-related 
differences, more in HLCs than in MSCs, and displayed the potential link to DNA 
damage, IFN1, aging, senescence  and oxidative stress. HLCs appear more vulnerable 
to age-related damage at cellular level as compared to MSCs in vivo. Future work 
would involve exploring the protein levels and functions of the genes that displayed 
significantly higher expression in MSCs than in HLCs. Ideally, this would require 
recruitment of a larger donor cohort and controls including investigation of cells that 
were exposed to extreme oxidative stress prior to analysis of gene and protein 
expression. Correlation of this data with DNA damage performed by comet assay and 
senescence assay from the same donors would provide extremely useful links between 











































Chapter 6 Gene and surface marker expression of human BM 
MSCs in hip osteoarthritis 
6.1 Introduction 
Osteoarthritis (OA) is a classic age-related degenerative disease which, some 
researchers think, is inevitable in old age. It is by far the most common joint disease in 
the world. It leads to a poor QOL by causing debilitating pain in the joint which in turn 
impacts  gait, all of which reduces the daily functions (100). In spite of considerable 
variation in the definition of the condition, age has been an underlying factor for most of 
the cases observed (413). While the frequency of OA incidences have been found to 
increase with age, it is known that not all old people suffer from the disease (414). 
Increasing age does however, escalates the chances of someone suffering from OA 
due to decrease in body immunity and accumulation of damage at the cellular level 
including MSCs (100). 
 
Section 1.3 of this thesis outlined that the impact of OA is not only confined to the 
patients but also affects the family members and the economy in general, considering 
the high rate of occurrence of the disease, globally. While OA may have different 
aetiology and be caused by various factors like lifestyle, mechanical load on the joints, 
genetics, environmental factors, physical damage and injury; the management of the 
disease usually involves the same approach. This indicates our lack of understanding 
in the disease, especially in terms of its pathophysiology at the in vivo cellular level. 
The other example supporting our lack of understanding of the disease are many 
different theories of OA development and disease progression, which vary between 
research scholars and OA clinical experts alike.  
 
Early detection of the disease can significantly prevent and/or alleviate the pain and the 
poor QOL in patients, before it gets to the point where surgery is the only option 
available. This outlines the need for an increase in the intensity of basic research and 
applied science research for early OA diagnostics. The last decade has seen a rise in 
the idea that OA is not a single disease, but a culmination of a number of progressive 
conditions. One of these conditions may indeed be the premature ageing of bone 
resident MSCs, leading to altered bone homeostasis and the inability of the 
subchondral bone to support cartilage nutrition and shock absorbance properties (415, 
416). To better understand these individual contributing factors and their pathologies, a 
number of OA animal models that mimic different aspects of the disease in humans 




ageing of MSCs (or even ageing in general), animal models of OA too are varied in 
several parameters. A number of models exist, each of which have their own 
advantages, limitations and their applicability for OA ageing studies is discussed below. 
6.1.1 Hip OA  
In the last 15 years, the aetiology of hip OA has been proposed as different to knee 
OA. While a number of factors like sex, obesity, genetics, occupation and local injuries 
are known to contribute to the progression of OA (418), age has strongly been 
associated with hip OA displaying a sharp increase of incidence from 0.7% in people 
aged 40-45 to 14% in people aged over 85 (419). Many of the strategies provided for 
hip OA management have been derived from those developed for knee OA. This has 
been due to the higher prevalence of knee OA worldwide and due the fact that knee 
OA is relatively easier to image, scan and analyse as compared to OA of the hip (420).  
 
Pain and stiffness in the hips are the first symptoms of OA. Diagnosis of hip OA is 
either by radiographic evidence or by clinical examination or a combination of both. 
Radiographically, K/L scale (section 1.1.5) is used to determine the extent of the 
damage in the hip joint. Higher K/L score indicates greater extent of bone and cartilage 
damage including osteophyte formation, narrowing of joint space and subchondral 
bone sclerosis (421). In spite of radiographic evidence providing significant information 
about OA of the hip, it has often been criticised when used by itself for the diagnosis of 
OA. There is strong evidence in the literature that suggests that not every patient with 
hip pain has radiographic  signs of OA. Also, most elderly patients with higher risk of 
hip OA did not show its evidence by radiography (422). Another study in 2013 
‘compared the sensitivity of physical examination with radiographs’ in the diagnosis of 
clinically significant hip OA. Interestingly, they found that physical examination was 
significantly more accurate in diagnosis of hip OA as compared to radiography (423). 
 
Treatment of OA of the hip does not follow an approach any different from that of OA of 
another part of the body. Despite of the different theories/hypotheses existing around 
the progression of the disease, the treatment is fundamentally symptomatic. Use of 
NSAIDS, pain management and changes in lifestyle is often suggested to the patients 
(424). These include pharmacological intervention similar to those described earlier in 
section 1.1.5 along with other medications such as anti-resorptives (425). NSAIDs work 
by inhibiting cyclooxygenase 2 (COX2) which blocks the production of prostaglandins 
(PGs) at sites of inflammation and tissue damage (426) while anti-resorptives, as the 





Unfortunately, most of the cases of a detected hip OA often result in a much invasive 
hip replacement surgery. The extent of hip damage is what determines whether or not 
an adult needs to undergo the hip replacement surgery. The surgically added hip 
implant usually stays intact for up to 15 years, after which there might be a revision 
surgery. The revision surgery often has poorer impact on supporting the patient after 5 
years of revision as compared to the primary total hip replacement (THR) surgery. THR 
with metal-on-polyethylene bearing surfaces remain the gold standard for the treatment 
of end-stage hip OA. It provides good relief from pain along with steady longevity as 
observed across patients (427). 
 
From the literature presented in the above two sections, it is evident that a better 
understanding of hip OA pathophysiology, including the ‘age component’ of the 
disease, could have a significant socioeconomic impact, and that there is no suitable 
animal models faithfully replicating its progression in humans. The study of MSCs in hip 
OA joints, and comparing their characteristics to MSCs from healthy aged individuals 
may shed new light on the progression of this condition potentially leading to new 
therapies. 
6.1.2 Senescence, SASP, ROS and OA 
Senescence is a process of irreversible growth arrest that has been observed in ageing 
cells, and has been outlined in this thesis in sections 1.2.2 and 5.1.1. Considering OA 
has been associated with older age, a number of studies have investigated cell 
senescence in OA (428) largely focussing on OA cartilage (429). The presence of 
senescent cells and the associated secretory phenotype has been found to be 
significantly higher in OA cartilage compared to healthy cartilage. The SASP detected 
in OA has largely been attributed to pro-inflammatory cytokines like IL1, IL6 and IL8, 
and matrix metalloproteinases (MMPs) (430). The initiating factors are believed to be 
increased DNA damage (431) due to increased ROS (432, 433) leading to increased 
inflammatory mediators. The presence of senescence in OA is further confirmed by the 
development of OA-like condition in mice that were injected with senescent fibroblasts 
in their knees (434). 
 
Basic research has steadily contributed to our knowledge of the multi-factorial aspects 
of OA including the role of age-related senescence (428) and inflammation in the 
disease pathogenesis (435). Even though the pieces of the puzzle of OA and 
senescence are far from complete, there has been significant increase in our 
understanding of the two. The fact that both, senescence and OA are multifactorial and 




evidence in spite of the hypothesised potential link between the two. Nevertheless, 
there is a growing body of evidence connecting the impact of cell senescence to 
primarily degenerative diseases, like OA.  
 
IL6 has been shown to be expressed in high quantities in the serum of patients with OA 
(436, 437). The Chingford study (Livshits et al., 2009) on middle aged British women 
with radiographic knee OA (RKOA, K/L grade>2) confirmed that higher circulating 
levels of IL6 in obese patients were indicators for potential OA in future. They found 
that first, the circulating levels of IL6 in patients with RKOA were consistently higher 
than in non-OA donors, which increased proportionally with increase in OA severity, 
and second, that the levels of IL6 increased with increasing BMI (437). Thus, they 
suggested that higher BMI and increasing serum levels of IL6 are both predictive 
biomarkers of RKOA and outlined the need for future research on IL6 in OA. This study 
importantly highlighted the impact of lifestyle (obesity) as a contributor to the disease.  
 
Obesity results in an increased load on joints along with the secretion of adipogenic 
factors (like adipokines, adipogenic hormones) that mediate inflammatory responses. 
Also, the fact that there is a well-known shift from muscle mass and bone formation 
towards increased adipogenic tissue formation also suggests that obesity contributes to 
both, inflamm-ageing and OA. Another factor that crops up when discussing adipogenic 
factors and OA, is the presence of harmful reactive oxygen species (ROS) as data from 
previous research indicates that ROS may be key contributor to the adipogenic bias of 
MSCs at the expense of their osteogenic potential (438). 
 
The role of ROS in most diseases has been found to be fundamental, owing to the fact 
that ROS is a by-product of cellular metabolism. It has been closely linked to a number 
of diseases occurring in almost every organ in the human body (281). This is expected 
as every organ is made of functionalised tissues which are basically, groups of highly 
specialised cells. As it may be expected, ROS has been found to be a key contributor 
of age-related articular cartilage degradation, which has been a major evidence 
correlating ageing to OA (439-441). In particular, ROS was suggested to contribute to 
the loss of proliferative capacities of chondrocytes, senescence of chondrocytes, and 
increase in the production of inflammatory markers along with an increase in oxidative 
stress in OA cartilage (441, 442).  
 
Alterations in cartilage proteoglycans and other proteins within the cartilage matrix 
have been discussed at length in several publications over the last two decades (443, 




within cells has been thought to be due to the imbalance of natural anti-oxidants in the 
body (section 4.1.1.3.) Considering this imbalance, several research groups have 
assessed ROS damage by quantifying ROS in OA samples or by measuring the anti-
oxidant enzymes within the cells (445-447). Theoretically, an increase in the ROS 
levels in OA  (433) is expected to be accompanied by a decrease in the levels of anti-
oxidant enzymes (446, 447) that ultimately lead to genomic instability and cell 
senescence of chondrocytes (448).  
 
Regan and colleagues examined the levels of extracellular SOD (SOD3) in the 
cartilage of hip OA patients by ELISA and found a 4-fold decline in the levels of the 
SOD3 in OA donors (445). Similarly, other studies have confirmed the decline in the 
levels of the different naturally occurring anti-oxidant enzymes in OA, but for all of 
these studies, the focus has been on cartilage/ chondrocytes (449, 450). Altogether, 
evidences discussed above suggest that age and lifestyle choices taken together may 
play an important role in OA pathogenesis. These changes manifest themselves as 
inflamm-ageing and oxidative stress that lead to cellular senescence, which in itself 
may be a strong contributor to OA. While current research focuses mostly on 
chondrocytes, similar processes may also occur in MSCs residing in the underlying 
subchondral bone.  
 
Results from previous chapter indicated the potential involvement of certain IFN1 
transcripts in age-related changes within the BM niche. It was thus worth examining if 
these IFN1 pathway transcripts have any role in OA pathogenesis, even though there 
has been no such investigation so far. Interestingly, in Lupus, an auto-inflammatory 
disease extensively studied for the role of IFN1 in its progression, BM MSCs have been 
shown to be senescent and express altered IFN1 signature. Based on the outlined 
literature evidence, it could be hypothesised that not only chondrocytes, but also MSCs 
from OA patients could possess an increased expression of senescence and SASP 
associated genes,  compared to non-OA old age donors. On the other hand, the 
expression of anti-ageing genes Kl and Sirt6 could be lower. With respect to IFN1 and 
associated genes, there are no studies that have investigated them with respect to OA. 
A number of studies, however, have indicated an association between increased IFN 
signalling in Lupus with increased MSC senescence in the disease, which may also 
take place in OA MSCs (387, 391, 451).   





Previous investigations of age-related changes in OA have focussed on the articular 
cartilage where the first noticeable physiological alterations of OA have been 
historically found. Only relatively recently, OA has begun to be acknowledged as a 
disease of the entire joint including considerable changes in the subchondral bone 
(452), as well as cartilage (outlined in section 6.1). The limited research performed on 
primary OA guinea pig model indicated that alterations in microstructures of 
subchondral trabecular bone pointed towards changes in the bone  preceding the 
visible changes in the cartilage (171). However, investigations performed on human 
bone/bone cells and consequently, the data available for human bone cells including 
MSCs remains very limited.  
 
A recent study from our laboratory has established that the numbers of MSCs 
measured by both CFU-F assay and flow cytometry was significantly higher in OA-
affected bone (in bone marrow lesions, BML) as compared to a less affected bone in 
hip OA patients. Compared to non-BML MSCs, the proliferative capacity of BML-MSCs 
was lower, and they had altered  expression levels of bone remodelling molecules 
RANKL and OPG (183). While this was the first study to demonstrate numerical, 
topographical, gene expression and functional alterations in MSCs from OA hips, these 
examinations were performed on culture expanded MSCs. Furthermore, no study has 
been yet performed to compare gene expression profiles of MSCs from OA patients 
with age-matched healthy individuals. 
 
A subsequent study from our group has shown increased expression of bone lineage-
related transcripts RUNX2, OPG and SPARC in hip OA MSCs compared to healthy 
bone (69), however while their OA MSC donors were in the age-range of 55-89 years 
old, their healthy controls ranged from a much younger 38 years old up to 93 years old 
and not age-matched (section 1.3.1).  
 
This chapter aimed at exploring MSC multipotentiality genes, senescence and anti-
ageing genes, IFN1 genes and other exploratory genes previously explored in Chapter 
4 and Chapter 5, in uncultured MSCs from OA donors compared to MSCs from a 
cohort of age-matched healthy old donors. The investigation was also performed to find 
whether genes that displayed age-related trends in the previous two chapters were 
further aggravated in OA. 
 
The list of transcripts chosen for investigation in this chapter is presented in Table 6.1 





Table 6.1 List of genes investigated for study in MSCs from OA donors 
 
Gene Gene (full name) 
Evidence 
in OA 
RUNX2 Runt-related transcription factor 2  (69, 453) 
SPARC Secreted Protein Acidic And Rich in Cysteine       (69) 
SFRP1 Secreted frizzled-related protein 1   
PPAR- Peroxisome proliferator activated receptor gamma (69)  
FABP4 Fatty acid binding protein 4 (69)  
LepR Leptin receptor/CD295      (454) 
SOD3 Superoxidedismuatse 3 (445)  
RANKL Ligand for Receptor Activator of Nuclear factor-Kappa B  (69)  
OPG Osteoprotegerin (69)  
RANK Receptor Activator of Nuclear factor-Kappa B    
CXCL12 C-X-C motif chemokine ligand 12 (455, 456)  
Cx43 Connexin43  (457) 
IFNA1 Interferon alpha 1   
IFNB1 Interferon beta 1   
IFNAR1 Interferon alpha receptor 1   
IFNAR2 Interferon alpha receptor 2   
STING Stimulator of interferon genes   
IRF3 Interferon regulatory factor 3   
STAT1 Signal transducer and activator or transcription 1   
BID BH3 interacting domain   
MTCH2 Mitochondrial carrier homolog 2   
Kl Klotho (409)  
Sirt6 Sirtuin 6 (458, 459)  
Tp53 Tumour protein 53 (460)  
IL6 Interleukin 6 (437, 461)  
IL7 Interleukin 7   
IL8 Interleukin 8   
                      
List of transcripts investigated and discussed in this chapter. The top panel includes 
MSC multipotentiality genes and the bottom panel includes exploratory genes that were 
investigated in chapter 5 and will be explored in this chapter.  
 
6.1.4 Changes in age-related surface markers in MSCs from OA donors 
Among the age-specific surface markers discussed previously in this project (Chapter 
4), CD106 expression levels on OA synovial fibroblasts has been reported to be highly 
elevated as compared to non OA synovial fibroblasts (462).  Schett and colleagues in 
2009, examined the level of CD106 in the serum from control and hip OA donors and 
found significantly higher levels of CD106 in the OA donors (463). Not too long after 




significantly higher in donors with erosive hand OA compared to non OA hands (464). 
Another study showed that the levels of serum CD106 was an indication of the number 
of joints affected by OA (465). More recently, a study investigated CD106 in hip OA 
and found no significant increase in men or women or in the total population  with 
respect to the CD106 levels (466). Serum CD106 could be shed from many different 
cell types inside the body, and no study has yet explored CD106 expression on 
uncultured hip OA MSCs or HLCs. Based on this evidence, it was hypothesised that 
expression of CD106 levels on hip OA MSCs or HLCs would be higher in OA. 
 
The growing evidence connecting obesity to OA in the last two decades has witnessed 
an increased interest in the hormone Leptin and its potential contribution to OA (467). 
However, the hormone Leptin has been studied considerably more than its receptor. 
An increase in both, the levels of the hormone leptin and its receptor CD295 in the 
synovial fluid (468), subchondral osteoblasts (469) and cartilage of OA patients has 
been observed, correlating positively with the severity of the disease (454). More 
recently, Voultaneeho et al., in 2014 and Moqi Yan and colleagues in 2018 have found 
leptin with its receptor contribute to obesity in OA development (470). Voultaneeho et 
al., suggested that in an obese person, there is an unbalanced leptin signalling which 
results in an increased production of pro-inflammatory factors (270). Their work, in 
some way connects Leptin to OA along with the pro-inflammatory factors which have 
often been associated with inflamm-ageing. Co-incidentally on similar lines, Stannus 
and co-workers investigated the ‘association between Leptin, IL6 and radiographic hip 
OA in older people’ (471). While they did not mention the term ‘inflamm-ageing’ in their 
article, their data set forms the baseline for future studies to investigate the association 
between OA, obesity and inflamm-ageing. Based on all the evidence, it was 
hypothesised that Leptin receptor/CD295 levels in OA MSCs would be increased. 
 
Cx43 was another surface marker that was investigated in this project due to its high 
prevalence on bone cells and related functionalities (section 4.1.3.3). Apart from being 
closely associated with intercellular interactions within bone cells, Cx43 has also been 
identified as a crucial player for cell communication in OA. Andrew and colleagues in 
2004, found that the number of gap junctions in synovial biopsies of OA donors were 
increased (4-fold) as compared to the non OA donors (472). In 2014, Gupta et al., 
showed that the overexpression of Cx43 in human synovial fibroblast cell lines 
enhanced the expression of genes associated with inflammation in OA and a decrease 
in the expression of Cx43 in these cells, reduced the expression of many of the 
catabolic and inflammatory genes (473). In agreement, Casagrande and colleagues 




compared to healthy controls. Higher levels of Cx43 at the protein level were also 
observed in human chondrocytes (457). In another investigation, Shichomura et al., 
compared the levels of Cx43 in patients with RA, OA and in healthy controls (474). In 
contrast to the above mentioned studies, they found that Cx43 was ‘hardly detected’ in 
patients with OA. Based on this evidence Cx43 was expected to be most likely 
elevated in OA MSCs. 
 
CD146 or MCAM, as discussed previously (Chapter 4) has been used to define MSCs 
in a number of human tissues (227, 229). The sparse data available for this marker and 
how its expression alters with the progression of OA, suggests that CD146 positivity 
was an indication of late stage OA (475). However, another study did not find any other 
major differences between OA patients and controls with respect to CD146 expression 
(476). More recently, another group examined the MSCs from synovial fluid of OA 
patients and found a significant increase in the number of colonies and colonies of 
larger diameter from OA donors (477). They also inspected the levels of CD146 in both 
control and OA MSCs by flow cytometry, but found no difference in its expression. 
Based on this contradicting evidence, CD146 expression on OA BM MSCs was 
expected to be similar to age-matched healthy MSCs and display no OA-related 
differences. 
 
The investigations on cellular senescence in OA remain largely limited to cartilage and 
chondrocytes and information on bone cells in OA related senescence has a long way 
to go before catching up with the amount of information available on cartilage. Obesity, 
DNA damage, senescence, ROS - all of these factors appear to play a key role in OA, 
therefore any alterations in the signalling molecules connecting these pathways  in OA 
MSCs would be a highly novel finding. 
 
This chapter aimed at investigating the expression of all the genes in Chapter 4 and 5 
and the surface markers in MSCs and HLCs from hips of OA donors, in comparison to 











6.1.5 Hypotheses and objectives 




1. The transcripts for BM MSC osteogenic and adipogenic differentiation potential, 
stromal functions and bone remodelling, in CD45lowCD271+ MSCs are altered in OA 
patients compared to age-matched healthy individuals. 
2. The transcripts related to senescence and IFN1 pathways in CD45lowCD271+ MSCs 
are altered in OA patients, with possible increases in senescence and IFN1 related 
genes as compared to age-matched healthy individuals. 
3. Surface markers CD106, CD295, CD146 and Cx43 are altered in OA patients, with 
possible increases in CD106 and Cx43 as compared to age-matched healthy 
individuals. 
4. Based on findings from the previous chapter, that HLCs were more susceptible to 
age-related differences than MSCs, OA-related trends in CD45+CD271- HLCs were 




1. To quantify the level of transcripts indicating BM MSC osteogenic and adipogenic 
differentiation potentials, stromal functions and bone remodelling, in MSCs from OA 
patients by qPCR and compare with old donor MSCs. 
2. To quantify the level of transcripts related to senescence and IFN1 pathway in BM 
MSCs and HLCs from OA patients by qPCR and compare with old donor MSCs. 
3.  To quantify surface markers CD106, CD295, CD146 and Cx43 in MSCs from OA 
patients by flow cytometry and compare with old donor MSCs. 
6.2 Methods 
6.2.1 Donor selection 
Appendix 2, Table 4 outlines OA samples used. The donor cohort included 5 males 
and 8 females ranging from 56-83 years old with a median age of 74. Exclusion criteria 
included any history of cancers, previous surgery of the hip or any other disorder 
directly affecting the bone. As these donors were mostly above the age of 60, they 
were more likely to have primary (non-traumatic) hip OA. The FHs once obtained after 








6.2.2 Cell sorting 
Frozen vials with up to 106 nucleated cells from digested OA FHs were defrosted using 
TM (section 2.2) and washed with PBS for the elimination of any residual DMSO 
(section 2.4). Once washed, cells were counted and distributed into FACS tubes and 
stained (refer section 2.5, Table 2.1). Owing to the large number of MSCs in the FH 
digest (183), the cells from FHs were used not only for the purpose of OA MSC and 
HLC sorting, but also for instrument setting for MSCs from BMA. 
 
 For this purpose, these cells were used as both unstained cells and cells stained with 
isotype controls to establish the sorting gates for positively-stained cell populations. In 
contrast to rare BM MSCs, these cells did not undergo any enrichment (section 2.4) 
prior to cell sorting. This experimental design helped to preserve rare healthy MSCs for 
sorting (as none were wasted for instrument settings) and ensured consistency as 
healthy and OA MSCs were always sorted on the same day. The cells were treated 
with a blocking buffer for 10 minutes followed by staining with respective antibody or 
isotype control (section 2.5, Table 2.1). 
 
 In the end, 7-AAD was added to the cells and they were then passed through a filter-
capped FACS tube to prevent any cellular aggregates to avoid blocking of the flow 
channel. The instrument settings and the isotype controls were set as explained in 
section 2.4 and the sorted cells were collected directly into a tube containing lysis 
buffer. The populations collected included the same two populations of CD45lowCD271+ 
(MSCs) and CD45+CD271- (HLCs) as previously described for healthy BM MSCs 
(section 2.4).The gating strategy and the histograms for single markers are shown in 




































Figure 6.1 Quantification of surface marker expression in OA FH MSCs and HLCs 
(A) Gating strategy for identification of live cells based on 7-AAD negativity followed by 
CD271 and CD45 gating for the selection of populations of interest (MSC and HLCs) 
(B) Histograms for individual surface markers from representative donors in MSCs and 
HLCs from representative donor. Numbers in the top-right corner indicate MFI. 
 
6.2.3 Gene expression 
Transcripts were investigated (Table 6.1) out of which the first 12 were MSC 
multipotentiality transcripts and the next 9 were associated with senescence and anti-
ageing, IFN1 pathway, and ROS. The procedures followed for the quantification of 
MSC multipotentiality transcripts has previously been described in Section 2.5. In brief, 
RNA was extracted from cell lysates (obtained from cell sorts) and stored in -80C until 
further use. 2μl of RNA was reversely transcribed to cDNA which was stored in -20C 
until further use. All samples were then preamplified in the thermocycler using 18 
cycles and were stored at −20°C before processing on the BioMark HD. Quantitative 
PCR was performed using Fluidigm Flex Six™ (MSC multipotentiality genes) and 
48.48 IFC (genes associated with senescence and anti-ageing, IFN1 pathway, and 
ROS) on BioMark HD. Samples and assays were loaded into the reaction chambers 
of the Flex SixTM using the IFC Controller HX, and then transferred to the BioMark 




60 sec). The Ct values for genes of interest were normalised to the endogenous control 
HPRT1 using the formula [Ct = Ct target gene- Ct housekeeping gene] and relative expression 
was calculated as 2-Ct and used for statistical analysis.  
6.2.4 Statistical analysis 
Cluster analysis was used to observe any differences in gene expression across the 
entire donor cohort. Statistical analysis and graphics were performed using GraphPad 
Prism software (version 7.0a). The normal distribution of the data was assessed using 
the Shapiro-Wilk and Kolmogorov-Smirnov tests for normality. As no data were found 
to be normally distributed, Wilcoxon rank sum test were performed for paired data and 
Mann-Whitney test was performed for unpaired data. The results were considered 
significant at p value <0.05. 
6.3 Results 
The results presented below include evaluation of the MSC multipotentiality gene 
expression, as first described in chapter 4 (section 4.3) followed by a panel of the 
exploratory genes, that were covered in chapter 5 (section 5.3). OA patients (median 
age 74 years old, range 56-83), were compared to the healthy old donor group (median 
age 68, range 61-89), as described in section 3.3.1. Number of MSCs sorted from 
control healthy donors ranged from 999 to10,000 cells (median 4,700 cells) and an 
average 70,000 MSCs were sorted from OA FHs. HLCs from healthy old donors and 
OA patients were collected from a minimum of 50,000 cells up to a maximum of 70,000 
cells. 
6.3.1 Differences in the expression of multipotentiality genes between OA 
MSCs and healthy old donor MSCs 
First, the expression of genes indicating MSC multipotentiality was compared in MSCs 
from clinically diagnosed hip OA patients and healthy old donor MSCs (Figure 6.3, 
























Figure 6.2 Expression of genes associated with MSC multipotential functions in 
MSCs from healthy old donors and OA patients  
(A) Expression of RUNX2, SPARC and SFRP-1,  (B) Expression of PPAR-, FABP4 
and LepR, (C) Expression of RANK, RANKL and OPG (D) Expression of CXCL12, 
Cx43 and SOD3. Healthy old donors and OA patients are indicated in grey dots and 
black empty circles, respectively. Horizontal line across data indicate median values. 
p<0.001*** and p<0.0001****, Mann-Whitney U test. 
 
With respect to osteogenic transcripts, there was no significant differences in the level 
of their expression between OA and old donor MSCs. Expression of RUNX2 was 2.43-
fold higher in OA patients and expression of SFRP1 was 4-fold lower in OA patients but 
the differences failed to reach statistical significance (p=0.062). Expression of SPARC 





Next, the transcripts associated with adipogenic differentiation and bone-fat balance 
were examined. Both LepR and PPAR- showed significant decline (55-fold, p<0.0001 
and 16-fold, p<0.0001, respectively) in OA MSCs compared to healthy old donor 
MSCs. FABP4 showed a tendency of lower expression in OA MSCs (2.5-fold), 
however, the differences failed to reach statistical significance. Overall, all the three 
transcripts displayed a decline in OA patients indicating a decline in the formation of 
adipose tissue in OA patients as compared to healthy old donors (Figure 6.3B). 
 
There was a non-significant decline in the expression of RANKL and a significant 
decline (10-fold) in OPG  expression in OA patients as compared to healthy old donors 
(Figure 6.3C) potentially indicating changes in the rate of bone remodelling in OA 
patients. Among the transcripts associated with MSC stromal function, Cx43 showed 
no difference in expression between OA patients and healthy old donors but CXCL12 
was found to be significantly 58-fold lower (p<0.0001) in OA patients (Figure 6.3D). 
This indicated that the stromal functions in MSCs from OA donors were potentially 
impaired as compared to MSCs from healthy old donors. The expression of SOD3 was 
found to increase by 2-fold in OA MSCs as compared to MSCs from healthy old 
donors. While this was unexpected, future evaluation of this gene along with ROS 
quantification in FH MSCs would help in gaining better understanding of oxidative 
stress in uncultured BM MSCs. 
 
Overall, these data potentially indicated a lesser impairment in the osteogenic capacity 
of OA MSCs, compared to their other functions (such as adipogenesis and stromal 
support).    
6.3.2 Differences in the expression of multipotentiality genes between OA HLCs 
and healthy old donor HLCs  
 
The investigation of transcripts associated with MSC osteogenic differentiation in HLCs 
is indicated in Figure 6.4 and the median values for the same is outlined in Table 6.1, 
bottom panel. No differences were observed in the expression of RUNX2 and a 
significant 13-fold increase in the expression of SPARC (p=0.0003) in OA HLCs 
compared to healthy old donors HLCs (Figure 6.4A). Adipogenic transcripts LepR and 
PPAR- did not display any difference in OA HLCs compared to old donors HLCs, but 
FABP4 showed significantly 8-fold higher levels in OA HLCs (p=0.0409), which is 





With respect to bone remodelling transcripts, RANK and RANKL showed no difference 
in HLC expression levels between healthy old donors and OA patients. OPG was not 
detected in healthy old donors, therefore it could be reasonably assumed that its 
expression in OA donors HLCs was elevated (Figure 6.4C).  
 
When the transcripts associated with MSC stromal support were investigated, there 
was no significant differences in the HLC levels of either Cx43 or CXCL12 transcripts 
between OA patients and healthy old donors. Nevertheless, the expression of CXCL12 
was found to be 2-fold higher in OA HLCs whereas, expression of Cx43 was 2-fold 
lower in OA HLCs as compared to HLCs from healthy old donors (Figure 6.4D). 
 
 Differences in multifunctionality genes in OA were not aggravated from ageing and 
thus were only associated with OA. Increase in the expression of SOD3 in both MSCs 
and in HLCs in OA was unexpected as OA is often associated with declined SOD3 and 
increased ROS (446). This suggests need for future work including the detection of 











































Figure 6.3 Expression of genes associated with MSC multipotential functions in 
HLCs from healthy old donors and OA patients  
(A) Expression of RUNX2, SPARC and SFRP-1,  (B) Expression of PPAR-, FABP4 
and LepR, (C) Expression of RANK, RANKL and OPG (D) Expression of CXCL12, 
Cx43 and SOD3. Healthy old donors and OA patients are indicated in grey dots and 
black empty circles, respectively. Horizontal line across data indicate median values. 










Overall, HLCs displayed a different pattern of differences to MSCs between OA 
patients and healthy old donors. Fold differences and p values of all of the above 
mentioned transcripts in healthy old donors and OA patients are shown in Table 6.1 
and 6.2 
Table 6.1 Differences in the expression of MSC multipotentiality genes in OA 











RUNX2 1.09 2.65 2.43 NS 
SPARC 20.51 24.54 1.20 NS 
SFRP1 2.83 0.71 0.25 NS 
PPAR- 6.20 0.37 0.06 <0.0001 
FABP4 1.77 0.69 0.39 NS 
LepR 4.13 0.07 0.02 <0.0001 
SOD3 0.29 0.66 2.28 NS 
RANKL 0.35 0.20 0.56 NS 
OPG 2.44 0.25 0.10 0.0008 
RANK ND ND NA NA 
CXCL12 1554.00 26.19 0.02 <0.0001 
Cx43 31.55 24.51 0.78 NS 
HLCs 
RUNX2 0.35 0.33 0.95 NS 
SPARC 0.04 0.51 13.86 0.0003 
SFRP1 ND 0.002 NA NA 
FABP4 0.0145 0.1175 8.12 0.0409 
PPAR- 0.04 0.02 0.48 NS 
LepR 0.0023 0.0023 0.99 NS 
SOD3 ND 0.009 NA NA 
RANKL 0.35 0.19 0.54 NS 
OPG ND 0.09 NA NA 
RANK 0.10 0.07 0.71 NS 
CXCL12 0.03 0.06 2.21 NS 
Cx43 2.79 1.05 0.38 NS 
 
Top panel of genes include expression of MSC multipotentiality genes in MSCs and the 
bottom panel includes expression of HLCs . All expressions are relative to HPRT1, 
Mann-Whitney U test. * Medians in OA/ medians in old, NS: non-significant 
 
6.3.3 OA related differences in the expression of senescence, SASP and IFN 
pathway related genes in MSCs and HLCs 
An overall cluster analysis of all exploratory genes revealed some segregation of MSCs 


















































Figure 6.4 Cluster analysis of exploratory genes in OA samples in MSCs 
and HLCs 
 
Expression of IFNA1, IFNB1, IFN receptors, IRGs, genes associated with 
IFN1>BID>ROS pathway, senescence and other exploratory genes grouped by cluster 
analysis. Dendogram on the top indicate samples and dendogram on the right indicates 
genes . Colour key in shown at the bottom right of the figure. Grey squares indicate 




The median values for complete list of genes and differences in old healthy donors and 
OA patients is presented in Appendix 4, Tables 6.1 and 6.2 for gene expression in 
MSCs and HLCs, respectively. 
 
With respect to senescence and anti-ageing genes, the following results were obtained. 
Irrespective of the cell population, the anti-ageing gene Kl expression decreased by 
4.8-fold in MSCs and by 5.5-fold in HLCs in OA patients as compared to healthy old 
donors. MSCs from OA patients showed over 3-fold decline in Tp53 but no change in 
OA HLCs was observed. The expression of Sirt6 remained unchanged in both OA 
MSCs and HLCs. High level of donor variation was observed in the expression of Kl in 
OA patient samples in both, MSCs and in HLCs, and none of these trends were found 


















Figure 6.5 Expression of senescence and anti-ageing genes in MSCs and HLCs 
from healthy old donors and OA patients 
 
(A) Expression of Tp53, Sirt6 and Kl in MSCs. Grey dots indicate old donors and empty 
circles indicate OA patients. (B) Expression ofTp53, Sirt6 and Kl in HLCs. Healthy old 
donors and OA patients are indicated in grey dots and black empty circles, 
respectively. Horizontal line across data set indicates median values.  
 
When the expression of SASP-associated cytokines was analysed, IL6 displayed a 




increase in HLCs (not significant), these trends were consistent with its hypothesised 
changes in OA. IL7 showed a non-significant 5-fold decline in MSCs and no change in 
HLCs. IL8 did not reach statistical significance but showed opposite trends in MSCs 
and HLCs. While in MSC, it displayed nearly 8-fold increase in OA, in HLCs it had a 





















Figure 6.6 Expression of SASP-associated cytokines in MSCs and HLCs from 
healthy old donors and OA patients 
 
(A) Expression of IL6, IL7 and IL8 in MSCs, (B) Expression of IL6, IL7 and IL8 in HLCs. 
Healthy old donors and OA patients are indicated in grey dots and black empty circles, 
respectively. Horizontal line across data set indicates median values. p<0.05*, Mann-
Whitney U test. 
 
 
Overall, anti-ageing genes and senescence associated genes did not display any 
significant OA-related differences even though Kl declined in OA patients as displayed 
in both cell populations. SASP associated cytokine genes displayed significant 








Table 6.2 Differences in the expression of genes associated with IFN1 pathway, 
ROS, anti-ageing and senescence, in OA MSCs and HLCs as compared to 











IFNA1 9.15 2.23 0.24 NS 
IFNB1 1.72 0.27 0.16 NS 
IFNAR1 4.75 1.26 0.27 NS 
IFNAR2 5.76 1.36 0.24 0.041 
STING 4.88 1.25 0.26 NS 
IRF3 3.13 0.85 0.27 0.051 
STAT1 5.16 1.47 0.28 0.0221 
BID 0.11 0.47 4.27 NS 
MTCH2 1.27 0.47 0.37 NS 
Kl 0.48 0.1 0.21 NS 
Sirt6 0.4 0.3 0.75 NS 
Tp53 2.88 0.81 0.28 NS 
IL6 0.2 26.37 131.85 0.0101 
IL7 1.17 0.22 0.19 NS 
IL8 5.14 40.45 7.87 NS 
HLCs 
IFNA1 7.44 1.17 0.16 NS 
IFNB1 1.59 0.39 0.25 NS 
IFNAR1 0.48 0.65 1.35 NS 
IFNAR2 1.38 0.66 0.48 0.035 
STING 1.033 0.457 0.44 NS 
IRF3 0.66 0.43 0.65 NS 
STAT1 2.4 1.57 0.65 NS 
BID 1.032 0.62 0.60 NS 
MTCH2 0.79 0.34 0.43 NS 
Kl 0.011 0.002 0.18 NS 
Sirt6 0.15 0.1 0.67 NS 
Tp53 1.21 0.75 0.62 NS 
IL6 0.59 3.92 6.64 NS 
IL7 0.013 0.015 1.15 NS 
IL8  67.21  27.35 0.41   NS 
 
Top panel of genes include expression of MSC multipotentiality genes in MSCs and the 
bottom panel includes expression of HLCs . All expressions are relative to HPRT1, 
Mann-Whitney U test. * Medians in OA/ medians in old, NS: non-significant. 
 
Differences in IFNA1, IFNB1 and IFNA receptors were next analysed for understanding 
OA associated changes in relation to old age (Figure 6.5). In OA patients, IFNA1 
showed a non-significant decline (4-fold and 6-fold) in MSCs and HLCs, respectively. 




respectively. IFNAR1 showed a 3-fold decline in OA MSCs but its expression was 
unaltered in OA HLCs. IFNAR2 showed a statistically significant decline in both MSCs 







































Figure 6.7 Expression of IFNA, IFNB and IFNA receptor genes in MSCs and HLCs 
from healthy old donors and OA patients 
 (A) Expression of IFNA1 and IFNB1 (top panel) and IFNAR1 and IFNR2 (bottom 
panel) in MSCs (B) Expression of IFNA1 and IFNB1 (top panel) and IFNAR1 and 
IFNAR2 (bottom panel) in HLCs. Healthy old donors and OA patients are indicated in 
grey dots and black empty circles, respectively. Horizontal line across data set 
indicates median. p<0.05*, Mann-Whitney U test. 
 
Among the IRGs, a number of genes were found to be differentially expressed in both 




below shows some of the differentially expressed genes in MSCs. While most of the 
genes declined in OA patients, ISG20, LAMP3 and IFI27 were significantly higher in 
OA patients  MSCs. The medians, fold differences and statistical significance (if 























Figure 6.8 Genes expression of IRGs in OA MSCs compared to MSCs from 
healthy old donors  
Examples of differentially expressed IRGs in MSCs from OA donors compared to 
healthy old donors. Healthy old donors and OA patients are indicated in grey dots and 
black empty circles, respectively. Horizontal line across data set indicates median. 
p<0.05* and p<0.01**, Mann-Whitney U test. 
 
 
Figure 6.10 displays examples of genes that were differentially expressed in HLCs in 
OA patients as compared to healthy old donors. Interestingly, CASP1, ISG20 and 
LAIR1 were  differentially expressed in OA patients irrespective of the population 


























Figure 6.9 Genes expression of IRGs in OA HLCs compared to HLCs from 
healthy old donors  
Examples of differentially expressed IRGs in HLCs from OA donors compared to 
healthy old donors. Healthy old donors and OA patients are indicated in grey dots and 
black empty circles, respectively. Horizontal line across data set indicates median. 
p<0.05* and p<0.01**, Mann-Whitney U test. 
 
The genes associated with the IFN1>BID>ROS pathway were next investigated for any 
differences in OA patients as compared to healthy old donors. In MSCs, all the genes 
except BID displayed a decline in OA with STAT1 showing a significant decline 
(p=0.0221). However, in HLCs, the trends for decline were more subtle, even though a 



































Figure 6.10 Expression of genes associated with IFN1>BID>ROS pathway in 
MSCs and HLCs from healthy old donors and OA patients 
 
(A) Expression of STING, STAT1 and IRF3 (top panel) and BID, MTCH2 (bottom 
panel) in MSCs,  (B)  Expression of STING, STAT1 and IRF3 (top panel) and BID, 
MTCH2 (bottom panel) in HLCs. Healthy old donors and OA patients are indicated in 
grey dots and black empty circles, respectively. Horizontal line across data set 





In summary, section 6.3.3 investigated differences in exploratory gene expression 
including anti-ageing and IFN1>BID>ROS pathway genes, anti-ageing, SASP and 
cytokines, and identified novel molecules that displayed significant differences in their 
expression in OA MSCs. IFNAR2 declined significantly in OA MSCs along with a 
number of IRGs and STAT1, a downstream molecule through which IFNs induce the 
expression of IRGs. As expected, IL6 increased significantly in OA while anti-ageing 
gene Kl decreased by nearly 5-fold in OA patients. Altogether, these expression 
patterns indicated a possibility for a reduced IFN1 signalling in OA MSCs, which could 
further impact on their potency and senescence status. 
6.3.4 Biomarkers of age-related OA 
In the course of this study, a number of genes that displayed a trend towards age-
related differences, were also found to have a similar and aggravated trend in OA. 
While the expression of some of these genes was found to decline with both increasing 
age and OA, the others showed an increase in their expression. In MSCs, the statistical 
significance in these ‘aggravated’ genes was only observed for IL6 (Figure 6.12A), 
while more such genes were found in HLCs. In itself, this indicated that MSCs were 
more resistant to ageing and OA, compared to HLCs (Figure 6.12B). This section 
discusses the genes in both cell populations that have displayed distinct trends and 
statistical significance with respect to age-related differences that were further 
exacerbated in OA. 
 
The on transcript that displayed a distinct age-related increase followed by a further 
increase in OA MSCs was IL6 (p=0.0005), as shown in Figure 6.12A. Genes that 
displayed a age-related decrease followed by a further decrease in expression in OA 
HLCs included the anti-ageing gene Sirt6 (p=0.02), senescence associated Tp53 
(p<0.0001). Interestingly, IFNAR2 (p=0.0026) also displayed and age and OA-related 
decrease in HLCs, potentially suggesting an overall decline in the IFN1 cascade with 
advancing age, that is aggravated in OA. Thus, it was not surprising that the stimulator 
of IFN genes or STING was also found to display an age-and OA-related decline 




























Figure 6.11 Expression of genes that displayed age-related differences that were 
further exacerbated in OA 
 
 (A) Expression of IL6 in MSCs (B) Expression of RANKL, Sirt6, Tp53, IFNAR2, STING 
and MTCH2 in HLCs. Young donors, old donors and OA patients are indicated by black 
dots, grey dots and empty black circles, respectively. The black line indicates median 
values. *p<0.05, **p<0.01 and ****p<0.0001, Kruskal-wallis test with Dunn’s correction. 
 
Overall, this section outlines the potential markers of age-related OA reflecting the in 
vivo BM niche in uncultured BM MSCs and in HLCs. Further examination of these 
genes at both gene and protein level in a larger donor cohort would be extremely useful 
in translating these genes as biomarkers.  
 
6.3.5 Differences in surface marker expression in OA MSCs and HLCs 
compared to healthy old donors 
 
While none of the surface markers displayed any age-related changes in MSCs 
(Chapter 4, figure 4.14), CD106 and CD295 showed a significant decrease (4-fold, 




OA MSCs as compared to old donors MSCs. Expression of CD146 and Cx43 remained 
unchanged (Figure 6.13C and D). Interestingly, the decline in LepR both at the 
transcript level as well as in the protein level was found to be consistent and 
statistically significant, suggesting an imbalance between osteogenic and adipogenic 




















Figure 6.12 Surface marker expression in MSCs from healthy old donors and OA 
donors 
(A) CD106 (B) CD295 (C) CD146 and (D) Cx43 from old healthy donors and OA 
patients. Healthy old donors and OA patients are indicated in grey dots and black 
empty circles, respectively. Horizontal line across data indicate median values. *p<0.05 
and ***p<0.001, Mann-Whitney U test. 
 
 
Following comparisons in MSCs, surface marker expression was investigated in HLCs. 
CD106 and CD146 displayed a trend for increased expression in HLCs (2-fold in each) 
but the differences failed to reach significance. CD295 and Cx43 on the other hand, 
displayed a decline in expression in OA patients, but again failed to reach significance 





























Figure 6.13 Surface marker expression in HLCs from healthy old donors and OA 
donors 
(A) CD106 (B) CD295 (C) CD146 and (D) Cx43 from old healthy donors and OA 
patients. Healthy old donors and OA patients are indicated in grey dots and black 
empty circles, respectively. Horizontal line across data indicate median values. 
 
 
Overall, compared to healthy aged MSCs, MSCs from OA patients displayed a 
significant decline in PPAR-, LepR, OPG and CXCL12 expression. None of these 
changes could  be described as ‘aggravated ageing’ since all of these genes showed 
no age-related differences in healthy donor MSCs (section 4.4.3). LepR was also 
investigated at the protein level and a similar significant decline was confirmed in OA 
patients. This was also unique to OA since no age-related changes in LepR/CD295 
were found in healthy  old donors (section 4.3.5). Furthermore, like CD295, CD106 was 
another protein that displayed a very significant decline in MSCs from OA patients, 
which was likely to be associated with other local or systemic factors contributing to OA 
since no age-related differences in its expression were found in the previous chapter 
(section 4.3.5). 
 
In OA HLCs, anti-ageing genes Sirt6 and Kl, declined significantly and the expression 














































These genes were found to decline in healthy ageing as well. From these findings, it is 
tempting to speculate that in HLCs, age-related trends particularly in relation to IFN 
pathway, are further exacerbated in OA. But this is not the case for MSCs.  
Interestingly, the pro-inflammatory and SASP-associated cytokine IL6 transcript was 
found to increase by over 100-fold in OA MSCs and by 7-fold in OA HLCs. IL6 
expression also increased by 4-fold in healthy ageing in both MSCs and HLCs (section 
5.3.1). As IL6 was found to increase in healthy ageing and further aggravated in OA, in 
both MSCs and HLCs, it would be a good biomarker of age-related OA. 
 
6.4 Discussion 
The results from this chapter reveal very interesting alterations in MSCs from OA FH 
bone compared to healthy aged BM MSCs. Gene expression results indicated a 
decline in the adipogenic potential of MSCs from OA FHs, no alteration in the levels of 
osteogenic differentiation transcripts and a significant decline (nearly 10-fold) in the 
expression of OPG in MSCs from OA patients. A significant decline (60-fold) in the 
level of CXCL12 implicated in cell recruitment was also observed. Interestingly, there 
was no significant change in the transcript encoding an anti-oxidant enzyme SOD3 in 
OA MSCs compared to healthy old donors MSCs. The study of exploratory transcripts 
encoding cytokines revealed an increase in the level of IL6 transcript in OA, as 
expected from literature (461, 478). STAT1 declined in OA patients while no significant 
changes were observed in ageing and senescence associated genes (Kl, Sirt6, Tp53). 
Interestingly, the anti-ageing gene Kl decreased in OA patients by nearly 5-fold but 
statistical significance wasn’t achieved due to high donor variation in its expression 
levels. 
 
Transcripts associated with osteogenic differentiation potential showed no difference in 
OA MSCs compared to healthy old donor MSCs. A recent study from our group (Ilas et 
al., 2019) investigated the level of RUNX2 in BM MSCS from the FH of OA patients 
and found a significant increase in the expression of RUNX2 in MSCs from OA patients 
as compared to MSCs from healthy donors (69). Even though this was the most 
relevant study for comparison with the PhD project, the OA patients were not age-
matched with healthy donors in the Ilas et al., study. In this project, the genes 
associated with osteogenic differentiation showed no difference or non-significant 2-
fold increase (RUNX2) in OA MSCs as compared to healthy old MSCs. Future work 
with genes associated with osteogenic differentiation in OA must firstly consider the 




molecules at the protein level would further enhance the current understanding of OA 
progression. 
 
The expression of adipogenic transcripts in MSC population in this project suggested a 
decline in the fat forming capacity of MSCs from OA donors. This is in agreement with 
a previous study by Murphy et al. that have shown that the adipogenic potential of 
MSCs from OA donors is compromised. Interestingly, they also found a decline in the 
osteogenic potential of MSCs from OA donors which was not what was observed in this 
project. The variation could be potentially due to the fact that Murphy et al., used 
cultured cells as opposed to uncultured cells as in this project. Also, while they 
measured the differentiation potential of MSCs from OA donors in vitro, in this project, 
the cells were uncultured and hence better represented human OA conditions in vivo. 
Interestingly, another study from our group published in 2016 (183) found no defect in 
the adipogenic differentiation potential of culture-expanded MSCs either. These studies 
too tested the adipogenic potential of MSCs from hip OA donors in vitro under normal 
culture conditions, further highlighting the need to dissect any changes in OA MSCs 
prior plastic adhesion and culture. Overall, the expression of adipogenic transcripts 
were not found to be consistent with the hypothesis that there might be an exaggerated 
increase in OA, possibly due to other factors like lifestyle and obesity that are involved 
in age-related OA but were not accounted for in this project. 
 
Recently, a study from our group investigated the expression of MSC multipotentiality 
transcripts in MSCs from OA FH as compared to the MSCs in healthy donors (69). 
Interestingly, it showed a significant increase in the expression of OPG, RUNX2 and 
SPARC in patients with OA as compared to healthy donors. In this PhD project, the 
trend for RUNX2 expression was found to be consistent with the previous results from 
our group, but the level of SPARC expression was not. Even though the cells used 
were also uncultured CD45lowCD271+ cells, the patient cohorts in Ilas et al., study were 
not as well age-matched. The Ilas et al., study also used a larger panel of osteogenic 
transcripts. While expanding the number of transcripts for investigating multipotential 
functionalities of MSCs would be the way forward, low numbers of CD45lowCD271+ 
MSCs in aged donors  represent a significant limitation for future work. Using 
techniques like RNA seq to compare differentially expressed genes in OA as compared 
to healthy old donors would provide further insight into OA development. 
 
In this project, both RANKL and OPG displayed a decline in MSCs from OA patients as 
compared to healthy old donors. While the decline in OPG was significant, the 




involved in bone remodelling (discussed in Introduction, section 1.1.4 and in Chapter 4, 
section 4.1.1) and have been extensively investigated in OA. More relevant to this 
study, Bitenc Logar and colleagues in 2007 investigated the levels of RANKL, OPG  in 
the trabecular bone samples (uncultured) in OA patients (479). They found a significant 
decline in the levels of RANKL in the samples from OA patients compared to those with 
femoral neck fractures. While they used uncultured samples from donors, they did not 
isolate/purify any cell types for their experiments and studied mixed population of all 
the cell types present within the subchondral bone. The most recent study from our 
laboratory has shown higher OPG levels in OA CD45lowCD271+ MSCs compared to 
healthy OA MSCs whereas RANKL transcript levels were not altered (69). These data 
differ from the findings from this thesis where OPG was significantly lower in OA MSCs. 
This could be due to the fact that the age of healthy old donors and OA patients in Ilas 
et al., paper was not as closely age-matched and included healthy old donors in their 
40s as compared to this thesis where old donors were strictly over 59 years old. 
 
In another study, Upton and co-workers found a significant increase in the levels of 
both RANKL and OPG obtained from grade 2 OA patients compared to grade 0 OA 
using K/L system (480). However, Upton and co-workers had used articular cartilage 
and used IHC for their studies. Kwan et al showed a significant increase in the levels of 
OPG in OA patients cultured osteoblasts with high levels of prostaglandin E2 (PGE2) in 
comparison with OA patients with lower levels of PGE2, but not in comparison with 
healthy donors. In fact, in comparison with healthy donors, the level of OPG was lower 
in both the OA groups but did not show statistical significance. They observed no 
significant differences in the levels RANKL. Considering the MSCs are pre-osteoblasts 
cells, the results from Kwan et al., study are very comparable to that of the current 
project. However, they used cultured (P1) cells making the work in this PhD project 
novel due to the use of uncultured cells for better in vivo correlation of the disease 
progression in humans. 
 
This project also investigated RANKL and OPG in HLCs which showed no differences 
in OA patients for RANKL. OPG was not detected in HLCs from old donors and 
measurable in OA group suggesting a potential for increase. This project thoroughly 
investigated transcripts associated with bone remodelling in two pure BM cell 
populations for understanding bone remodelling processes in OA. This has not been 
done previously, making this project novel. 
 
Transcripts investigated for MSC stromal functions in this study in MSCs and HLCs 




significant decline observed in the expression of CXCL12 in MSCs from OA patients as 
compared to MSCs from healthy old donors. However, there was no difference 
observed in the expression of Cx43 in MSCs between OA patients and old donor 
groups. In HLCs, their differences observed were not significant. Cx43 has been shown 
to be increased in synovial cells OA patients (457) and recently, Cx43 has been 
suggested as a therapeutic target to halt OA progression (481). However, both of these 
studies were performed on cartilage and not on bone. 
 
CXCL12 has been previously investigated in OA owing to its role in chemotaxis and 
movement of MSCs and other BM cells and its close links with hematopoietic 
compartment within the BM niche. Previous investigations of CXCL12 in human OA 
patients remain limited and debatable. A study of MSCs from synovial joint of OA 
patients showed that the levels of CXCL12 were much lower in OA as compared to 
those without the disease (456). Conversely, another study suggested that CXCL12 
binding to its receptor CXCR4 contributed to the induction of cartilage degradation in 
OA (455). Even though a part of the study detected higher levels of CXCL12 in the OA 
patients, the model used here was cartilage explants from human OA patients. The 
accumulation of alternating results complicate the process of finalising the underlying 
mechanism that brings about the changes in the levels of CXCL12 in OA. However, 
with respect to OA, a study in 2017 identified CXCL12 as an important indicator of knee 
OA using microarray analysis (482). However, there was no difference in the 
expression of CXCL12 in HLCs in this project. Investigating CXCL12 at the protein 
level along with the gene, in more donors and comparison in different stages of OA 
would allow in better understanding of the gene with disease progression. 
 
LepR was also investigated in this thesis, both at the transcript and the protein level. 
Data from this chapter suggested a significant 55-fold decline in the expression of 
LepR transcript in OA MSCs as compared to healthy old donor MSCs. This trend was 
consistent with the surface marker expression of LepR (CD295) which also displayed a 
significant decline (3-fold) in MSCs from OA donors. This potentially indicated the 
impairment of bone-fat balance in OA bone. Interestingly, there was no difference 
observed in expression of LepR, both at the transcript and at the protein level, in the 
HLCs when compared between OA patients and healthy old donors. 
 
The hormone leptin has been found to have increased expression in the blood, plasma 
(483) and in the synovial fluid of OA patients and has also been shown to correlate 
positively with the severity of the disease (468, 484). In other studies, synovial Leptin 




women (484) as well shown to be directly proportional to BMI in OA patients (485).  A 
review in 2013 further suggested that the missing link between obesity and OA was the 
hormone Leptin (270). Interestingly, Leptin was also found to increase in synovial fluid 
of OA patients and positively correlate with the age of the OA patients (468). Leptin has 
also been associated with increased levels of bone forming markers in OA patients 
(486). This could potentially explain the loss of bone-fat balance in OA, whereby Leptin 
hormone potentially increases and expression of LepR decreases, as seen from data in 
this chapter. One study reported higher levels of both the hormone leptin and its 
receptor in OA, but this was investigated in the cartilage OA patients (454).  
 
Considering all of the above literature, it is clear that a lot of work has been performed 
on the role of Leptin in OA patients consistently reporting elevated levels of Leptin in 
OA patients. However, most of the studies have been focussed on synovial fluid, 
cartilage or serum levels. Expression levels of LepR via which the hormone Leptin 
functions has largely been overlooked and LepR in uncultured MSCs from OA donors 
has not been studied before. Lower levels of LepR in OA MSCs could potentially be a 
reaction to the higher levels of leptin in blood, which has already been suggested as a 
biomarker of the disease. Future work to understand differences in Leptin and its 
receptor in OA would ideally include blood and BM samples from OA patients to 
investigate them together in comparison with healthy old donors. Since there was no 
age-related difference in the expression of CD295 (Chapter4, section 4.3.8), the 
decline in CD295 observed in this chapter is clearly, specific to OA. 
 
Interestingly, there has been an increase in the number of studies associating OA with 
ROS and ageing (487). SOD3 expression in human cartilage is believed to decline in 
the later stages of OA (445). However, this project found a non-significant 2-fold 
increase in the level of SOD3 in OA MSCs as compared to healthy old donor MSCs, 
which was unexpected. The fact that the present study found minor age-related 
difference in ROS measurement and that was complemented by a lack of any major 
difference in SOD3 in BM MSCs (sections 4.3.3), is in line with the observation of no 
aggravated differences in SOD3 in OA MSCs.  This supports the notion that levels of 
ROS and anti-oxidant enzymes quantified in culture expanded MSCs (288) are likely to 
be in a state of induced oxidative stress and do not mirror the oxidative status of MSCs 
in vivo. 
 
Measurement of ROS alongside antioxidant enzymes genes (like Gx, SODs) in 
uncultured MSCs has not been performed before. However, the current study did not 




panel of number of anti-oxidant enzymes (including all the SODs, Gx, Ascorbic acid) 
and perform these measurement in larger number of donors. Culture expanded cells 
are automatically exposed to oxygen concentrations that are significantly higher than in 
the BM niche in vivo, inducing oxidative stress the moment they are cultured in 
laboratory conditions. This could also explain why data from this project (Section 5.3.1) 
did not observe any differences in the level of ROS in young and old donor MSCs 
either.  
 
With respect to the IFNA1, IFNB1 and IFNA receptors, all of these were found to be 
reduced in OA patients with IFNAR2 showing significant decline in both MSCs and 
HLCs. The presence of IFNA receptors has increasingly been associated with 
chondrocytes, synovial fibroblasts (488) and with activities their like mediating immune 
responses and operating various signalling networks within the bone (489). How the 
expression of IFN receptors change with progression of OA is a new field of research, 
but this can modulate binding with IFNs, and influence the immune signalling by 
downstream induction of various IRGs. A number of IRGs were found to be 
differentially expressed in both MSCs and HLCs from OA patients including LAIR1 
(decreased), CASP1 (decreased) and ISG20 (increased). LAIR1 is known as 
leukocyte-associated immunoglobulin-like receptor 1 that has previously been 
proposed as a marker of OA due to significantly higher expression in OA patients 
(490). In this project however, the expression was found to be significantly lower in 
both cell types of OA patients. The difference in trend with the aforementioned 
research could be due to the fact that their source was all cells from the synovial fluid. 
CASP1 or caspase1 has also been shown to be upregulated in OA patients when 
investigated in peripheral blood mononuclear cells (491) or more recently, from 
synovium (492). However, these studies were based on patients identified with knee 
OA and not hip OA, and also explored these molecules in immune cells rather than in 
MSCs. ISG20 very interestingly, unlike other genes in this chapter, indicated a 
significant increase in expression (irrespective of cell type) in OA patients. While there 
is not enough known about the involvement of this gene in OA, data from this project 
merits further investigation. 
 
Analysis of the results of the genes associated with IFN1>BID>ROS pathway revealed 
a non-significant decline in nearly all genes, except for STAT1, which showed a 
significant decline in MSCs from OA donors and a non-significant decline in HLCs from 
OA donors as compared to healthy old donors. A decline in STAT1 was aligned with 
the reduced expression of IFN receptor explained above. A study that compared 




found an overall increase in the level of STAT1 in all of the 3 types of arthritis from 
tissue samples at the protein level (493). Another study that compared STAT1 at the 
RNA and the protein level, found that STAT1 was significantly higher in RA as opposed 
to OA patient synovial tissue samples (494). The opposite trends in this project can be 
explained by different tissue sources and techniques. 
 
None of the anti-ageing genes or genes associated with senescence showed any 
significant differences in either of the cell types in OA, with Tp53 showing a non-
significant 3.5-fold decline in MSCs from OA patients. Previously, Tp53 downregulation 
has been associated with reduced chondrocyte apoptosis due to strain (460) and 
another study suggested that miR-34a in the human chondrocytes played a vital role in 
OA progression via the Sirt1/p53 signalling pathway, making it a potential therapeutic 
target for OA. Tp53 has also recently been labelled as one of the ‘key genes’ to be 
linked with OA, based on bioinformatics analysis (495).  
 
Not only has Sirt6 been suggested to prevent cellular senescence in chondrocytes 
(458), it has also been proposed as a potential therapeutic target for OA (459). Sirt6 
expression in this project showed no difference in OA MSCs or HLCs as compared to 
healthy old donors. Previous studies have indicated lower expression of Sirt6 not only 
in aged mice but also in mice and humans with OA, as compared to healthy controls 
(496). The study also claimed to protect mice from cartilage damage using Lenti-Sirt6 
intra-articular injection and to reduce chondrocyte senescence. Another study showed 
that inhibition of Sirt6 from human chondrocytes in vitro reduced proliferation, 
increased senescence, DNA damage and telomere dysfunction (497). While there was 
no age-related or OA-related difference found in MSCs or HLCs in Sirt6, Tp53 
demonstrated an age-related decline which was further aggravated in OA (section 
6.3.4) suggesting its role in ageing, senescence as well as in OA. Exploring Tp53 with 
p21 and p16 at gene and protein level in larger number of donors would be extremely 
useful in understanding the role of Tp53 in age-related diseases. 
 
Kl displayed a trend for decline (5-fold) in both MSCs and in HLCs in OA donors 
compared to healthy old donors. Previously, Kl  has been shown to be associated with 
female Caucasian patients with hand OA wherein they found that a genetic variant in 
the gene was related to increased vulnerability towards hand OA (498). They also 
suggested that this association was potentially stemming from bone rather than 
cartilage. Similarly, another study of Kl genetic variants found that this gene was 
closely related to knee OA in Greek population (499). Each of these investigations 




the single nucleotide polymorphism in the gene. Very recently, Tilly et al., found that Kl 
expression showed an age-related decline in articular cartilage (500). Although Kl 
expression increased in OA chondrocytes, KL-/- mice did not show any OA-related 
changes. They suggested that Kl potentially modulated pro-inflammatory cytokines in 
OA cartilage. Like Tp53, Kl too displayed an age-related decline in expression which 
was further aggravated in OA, even though the aggravated decline failed to reach 
statistical significance. 
 
Among the cytokines, IL6 showed a significant increase in its expression in MSCs and 
a non-significant increase in HLCs, in OA patients in this project. IL6 is among the most 
well examined cytokines associated with inflammation and ageing, as shown in 
discussion of Chapter 5. Thus it was not surprising to observe significantly higher levels 
of this cytokine transcript in OA. With respect to healthy ageing, there was a 4-fold 
increase in the expression of IL6 in both, MSCs and in HLCs. Previous studies have 
reported elevated levels of IL6 in OA patients, however, most of these studies have 
used blood/serum samples (501) or synovial fluids (461). Therefore, this was the first 
study to investigate IL6 in uncultured MSCs from OA patients and in two cell 
populations from healthy donors (MSCs and HLCs) simultaneously. IL7 is well-known 
cytokine to be secreted by BM MSCs (502). With respect to OA, this project found a 
trend for its decline in OA MSCs and no difference in HLCs. Data on the involvement of 
IL7 in OA is limited and to the best of my knowledge, has not yet been available on 
uncultured BM MSCs. Considering that IL7 plays an important role in cell proliferation 
and maturation of lymphoid cells along with having therapeutic potential as shown in a 
recent diabetic rat model (503), further investigations on IL7 would be interesting. 
 
Among the surface markers, CD106 and CD295 were found to be significantly lower in 
OA MSCs in this project. Previously, CD106/VCAM-1 measured using ELISA from 
blood of OA patients who underwent surgery (n=60) revealed a very significant 
increase as compared to patients who did not undergo surgery (n=852) (463). Based 
on the findings that VCAM-1 levels are elevated in severe OA from the previous study, 
a very recent study investigated the serum levels of VCAM-1 in patients with hip OA 
(n=100) (466). They found a non-significant 8% increase in the levels of VCAM in 
patients with hip OA, and concluded that VCAM-1 was not able to distinguish severe 
OA from age and sex-matched controls. Interestingly, both these studies have tables 
that indicate BMIs in patients with severe OA to be significantly higher as compared to 
their control, potentially indicating a disruption in their bone-fat balance. In HLCs, while 
there was no difference in CD106, the trend for CD295 stayed the same as in MSCs, it 




released protein as opposed to transcript in this study, explain the opposite results as 
compared to the findings in this thesis.  
 
Cx43 and CD146 did not show any differences in young and old donors (Section 4.3.4) 
and neither in MSCs from OA donors. They are expressed on uncultured MSCs and 
definitely play important functions, however, a larger cohort of donors must be used to 
understand the differences in the level of expression of Cx43 and CD146 in young and 
old donor MSCs as well as in OA. One study focussed on the protein interactions of 
Cx43 with other protein interactors in OA (504). They found over 100 proteins that were 
closely linked with Cx43. Gene ontology data from their OA donors suggested 
maximum interactors of Cx43 related to cell adhesion, nucleolus, calmodulin and 
cytoskeleton from chondrocytes in OA cartilage.  
 
In conclusion, there was a significant decline in adipogenic genes in OA MSCs along 
with a decline in OPG indicating towards increased bone resorption. IFNAR2 also 
declined significantly in OA MSCs which potentially led to the decline in several IRGs in 
OA. This indicated the role of IFNAR2 as a marker in OA. CD106 and CD295 declined 
significantly in BM MSCs suggesting a decline in immune-regulatory properties and 
loss of the bone-fat balance, suggesting these could be potential markers of OA. 
Senescence associated genes did not show any statistically significant differences but 
the age-related Tp53 and Sirt6 expression decline in HLCs was further aggravated in 
OA. Pro-inflammatory marker IL6 displayed an age-related increase in both MSCs and 
in HLCs which was further significantly aggravated in OA. Interestingly, IFNAR2, 
MTCH2 and STING which is the stimulator of IFN genes, both displayed an age-related 
decline followed by an exacerbated decline in OA HLCs. This indicates towards 
potential markers of age-related OA that need further exploration at protein level in a 
















Chapter 7 Discussion 
7.1 Key findings 
The aim of this project was to investigate bone resident MSCs in healthy ageing and in 
OA by means of enumeration and gene expression analysis. In most parts, donor-
matched HLCs were used as a control population. A decline in the number and 
proliferative capacity of MSCs was found in healthy ageing.  The genes selected to 
reflect MSC multifunctionality and selected surface markers did not display any 
significant differences in old donor MSCs compared to young donor MSCs, but 
surprisingly, some significant age-related differences, for example in the expression of 
RANKL, SPARC and LepR were observed in HLCs. MSCs and HLCs were 
investigated further for senescence, SASP and IFN1 pathway-related exploratory 
genes and once again, age-related differences were more evident in HLCs as 
compared to MSCs. Finally, investigations in OA suggested a significant decline in 
CXCL12, PPARand LepR expression in MSCs, which for LepR was confirmed at 
the surface protein level by flow cytometry. CD106 also showed a significant decline in 
MSCs from OA patients. Finally, a number of candidate genes (SPARC, Kl, IL6, and 
IL8) were found to display age-related differences in HLCs that were aggravated in OA 
patients, and IL6 showed the same trend in MSCs. These candidate genes should be 
further investigated as potential biomarkers of age-related OA and potentially targeted 
for future therapeutic approaches aimed at slowing down the progression of the 
disease. 
7.2 Clinical relevance  
This project showed a significant age-related decline in the number of BM MSCs 
measured by the classical CFU-F assay along with a significant decline in the 
proliferation potential of MSCs from older donors measured by colony area and 
integrated density (ID) analysis. To understand proliferative capacity of MSCs in 
relatively more ‘natural’ conditions, similar experiments were performed in human 
serum. Growing young donor MSCs in OS conditions resulted in significantly lower 
colony IDs as compared to when these MSCs were grown in YS conditions. The IDs of 
colonies from old donor MSCs were significantly higher when grown in YS when 
compared to OS. This suggested that old donor MSCs could be partially ‘rejuvenated’ 
in terms of their proliferation potential when grown in YS, highlighting the importance of 
cell extrinsic factors in the MSC in vivo niche. Thus, Chapter 3 results supported the 
SCE theory of ageing (section 1.1.1), however, a few of the old donors exhibited MSC 




towards a general decline in the number and proliferative capacities of MSCs in older 
population.  
 
However, the presence of old donors with a relatively good number of BM MSCs as 
compared to the other donors in their cohort, indicated that chronological age is a 
shared characteristic but biological age is personal and varies from donor to donor. 
From the clinician point of view, these data suggest that a higher volume of BMA needs 
to be aspirated from old donors to get a similar ‘dose’ of MSCs as compared to young 
donors. And even after a higher ‘dose’ of MSCs, the MSCs may need further 
stimulation and exposure to younger microenvironment in order to be used as a 
successful therapeutic (for fractures and other cell therapies). Rapid quantification of 
the number of CD45low CD271+ cells (111) from the BMA of the donors, MSC fitness 
and measurement in donor serum predicted by oxidation state (320) along with the 
level of pro-inflammatory cytokines like IL6 could help assess the biological age of the 
donor. This will potentially indicate the biological age of the donor cells to help predict 
the ‘dose’ of MSCs needed for a given patient. 
 
Using the CD45lowCD271+ phenotype to identify MSCs, this project showed a non-
significant age-related decline in their numbers. However, this decline has been shown 
to become significant when data from more donors (n=67) were analysed (505). 
Adipogenic bias has been suggested as the most accepted feature of ‘old’ donor 
MSCs, even though some reports of no changes in their differentiation potential, do 
exist. While the exact mechanism for this proposed shift remains unknown, presence of 
ROS in old and damaged cells has often been suggested to be the cause. In this 
project, no differences in the expression of selected osteogenic- and adipogenic-
lineage transcripts were found between young and old donors MSCs. Only some 
trends in the adipogenic bias were visible in old donor MSCs. In support of with this 
finding, when ROS and the level of anti-oxidant enzyme SOD3 were measured in 
MSCs, no significant difference between young and old donors were found. This 
indicated that scientists must be mindful when reporting on ‘age-related’ differences in 
MSCs, considering ‘in vitro’ ageing and ‘in vivo’ ageing may be driven by different 
mechanisms. 
 
Transcripts for bone remodelling and stromal functions also did not display any 
significant age-related differences in MSCs, even though both RANKL and OPG 
increased in old donor MSCs. Surface markers also demonstrated no changes in old 
donor MSCs or in HLCs. Interestingly, RANKL and SPARC both showed significant 




vivo are probably more subtle in comparison to the age-related changes in HLCs. This 
finding provided the first evidence that MSCs could be more resistant to age-related 
damages in vivo in comparison to HLCs, even though they may be exposed to the 
same levels of local cellular and intracellular insults such as ROS and DNA damage.  
 
Taking into account recent research suggesting potential links between DNA damage, 
senescence, ROS, IFN1 signalling and ageing in HSCs, the question if DNA damage, 
senescence, ROS and ageing could also be linked to cells of our interest, the MSCs, 
via IFN-signalling, formed the basis of next set of experiments in Chapter 5. This study 
is novel (to the best of my knowledge) to investigate a large number of genes on a 
broad donor age range on uncultured BM MSCs and HLCs using pure cell populations. 
This chapter revealed very interesting findings. Firstly, while senescence and SASP 
associated genes displayed trends towards increased damage in old donor MSCs, they 
did not reach statistical significance. Second, with respect to the expression of IFN1 
and related genes in MSC, some of them unexpectedly displayed very high expression 
in MSCs as compared to HLCs. Next, some novel genes were found to display age-
related differences in HLCs. Interestingly, in this investigation too, only one out of 96 
genes showed a significant decline in MSCs from older donors, further suggesting that 
age-related changes are relatively subtle in MSCs in vivo. However, genes associated 
with IFN1>BID>ROS pathway and senescence associated genes displayed significant 
changes in HLCs. This could be explained by the fact that MSCs are longer living cells 
and may have developed molecular mechanisms to combat ageing, which is not the 
case for HLCs that have shorter life-span. It will be interesting to investigate in the 
future if other long-living bone cells, such as osteocytes, have IFN1>BID>ROS  
signature similar to MSCs. 
 
Finally, investigations in MSCs from OA donors revealed a significant decline in the 
expression of adipogenic transcription factor PPAR-and stromal derived cytokine 
CXCL12 in MSCs. The surface marker CD106 also displayed a significant decline in 
OA donors as compared to healthy old donors and LepR showed a significant decline 
at both gene and protein levels. Many genes associated with IFN1>BID>ROS pathway, 
including IFNR2 and STAT1 were also down-regulated in OA MSCs. Again, OA HLCs 
demonstrated more profound OA-associated changes, some of which were in the same 
direction as noted for normal ageing in HLCs. IL6 was identified as the only gene which 
displayed an aggravated age-related change in both cell populations in OA. Thus, this 





7.3 The ‘bigger picture’ 
A number of genes investigated in this project have been shown by others to be 
associated with ageing/OA and/or other age-related diseases. For example, SPARC 
has been established as a key player in obesity and diabetes which are already been 
considered to be impacted by age (506). Makhluf and colleagues have previously 
shown an age-related decline in the expression of OPG in older OA donors, potentially 
connecting age with OA (507), however the study remained limited in terms of its 
patient cohort, given their youngest donor was 38 years old, when the decline in MSCs 
already take place, as shown in this thesis (Chapter 3) and the bone remodelling 
dynamics begin to shift (96). Another study on human femoral head BM investigated 
the levels of RANKL and OPG in OA patients and found an age-related decline in the 
levels of OPG. They also noticed variation in the levels of OPG in the young donors but 
the old donor cells consistently produced very low levels of OPG. The anti-ageing gene 
Sirt6 was shown to be significantly reduced in the articular chondrocytes of OA patients 
that displayed increased cellular senescence as compared to non OA patients (508). 
Higher levels of IL6 and IL8 was found to be secreted from the synovial of obese OA 
patients as compared to normal weight OA patients (478). 
 
In this context, my PhD has shown a decline in the expression of OPG, LepR, PPAR- 
and SPARC in MSCs from OA patients as compared to MSCs from old donors, 
suggesting a decline in osteogenic as well and adipogenic differentiation. IFNAR2 
declined significantly while IL6 was found to increase significantly indicative of higher 
levels of SASP associated with OA MSCs. With respect to age-related differences that 
were aggravated in OA, the pro-inflammatory cytokine IL6 displayed a significant 
increase in MSCs and the anti-ageing genes of Sirt6 and Kl displayed a decline  in 
HLCs.  
 
There has been an enormous rise in the number of publications aimed at the different 
aspects of OA in the last two decades on the research front which indicates towards 
the increased needs, availability of funding and thirst for knowledge among the medical 
and scientific community. However, very few of these publications have been aimed at 
prevention of the condition, by acting on the aspects of an individual’s life that can be 
controlled (diet, exercise, personal well-being). Healthcare systems globally should aim 
at early prevention of the disease for which early diagnosis is critical. This can be 
achieved by enhancing basic research towards early OA biomarkers to deliver more 
convenient diagnostic tools and better disease-modifying drugs. At the same time, it is 
equally important to spread awareness and educate people early on about the lifestyle 





The lack of strong and statistically significant age-related changes in uncultured BM 
MSCs in this project, as compared to the vast majority of literature outlining significant 
age-related differences in terms of MSC proliferation potential, ROS production and 
senescence in cultured MSCs strongly indicate towards two critical issues in 
experimental approach. First, a stronger emphasis should be directed towards the fact 
that culture expanded MSCs used in the majority of previous studies undergo in vitro 
ageing which is not the same as the cell ageing in vivo. In vitro culture forces MSCs to 
adapt to artificial conditions and enhances proliferation, which has an impact on their 
differentiation, ROS production and signalling mechanisms combating senescence. 
Thus, the molecular mechanisms of MSC ageing proposed, based on cultured MSCs 
are more likely to be applicable only to culture expanded MSCs and do not explain the 
mechanisms occurring in MSCs in vivo.  
 
Second, the concept of biological ageing as opposed to chronological ageing (both in 
vivo) needs to be better defined and considered in every research work that attempts to 
explore the complexity of ageing. Chronological age refers to the actual age of a donor 
while the biological age refers to the functionality of the organs (or cells) within the 
donor. Two or more people with the same chronological age can display difference in 
the ‘fitness’ of their organs indicating variation in their ‘biological age’. Obese teenagers 
have been reported to have higher bone age than their peers of same chronological 
age when quantified using physical examinations (509). DW Belsky and co-workers 
found that adults of the same age (38 years old) were growing old at different rates 
described as different ‘pace of ageing’ quantified by using physical functioning, 
cognitive functioning and perceptions of well-being (510). They also suggested that 
investigation of age-related differences in younger (<40 years old) donors may be most 
useful to identify factors that can be quantified as ‘early signs of ageing’. These findings 
bring our attention back to the various parts of thesis, for example large donor-
variations in both ‘young’ and ‘old’ donor groups, confirming that the biological age of a 
person is different to their chronological age and may be determined by diet, exercise, 
lifestyle and well-being.  
 
Biomedical research for ageing at the cellular level, often tends to investigate age-
related differences in phenotypes, genotypes, senescence and other cell functions 
using chronological ages and in vitro assays. With increasing evidence of the impact of 
extrinsic factors like nutrition, diet and lifestyle impacting an alarmingly large number of 
people globally, there is a dire need to shift the approach towards considering these 




may not be an option for all, having comprehensive knowledge of the donor’s nutrition 
intake, diet, lifestyle and well-being for at least up to 6 months prior to investigation will 
help connect the dots better. This is further emphasised by the WHO defining health as 
the ‘state of complete physical, mental and social wellbeing and not merely the 
absence of a disease’ (1). A growing body of evidence shows that good physical and 
mental health are essential for complete well-being of a person (511, 512), especially in 
the old age (513). While these factors were not accounted for in this thesis, they could 
potentially explain the donor variations that were observed across the experiments 
performed in this project. 
 
Increasingly, more and more online tests are easily available to help determine a 
person’s ‘actual age’ (i.e. biological age), based on diet, exercise, smoking, drinking, 
social and mental well-being, in less than 5 minutes (514, 515). Interestingly, the 
methodologies of these online tests are unclear, there is no known standard or 
normalisation and they regularly provide very different ‘actual age’ of the same person 
who answers questions to different tests. I am personally aged 7, 22 and 38 years old 
in three different online tests! As more researchers focus on ageing studies and 
investigation of age-related diseases like OA, the aim must shift towards considering 
diet, lifestyle and well-being for defining biological age, as well as to consider various 
scenarios and donor variations in their experimental design to make a study more 
comprehensive. This will aid better understanding towards early OA diagnosis and 
eventually sustainable treatment solutions. 
7.4 ‘Comprehensive’ research 
Even with the advancement of science, technology and our knowledge in healthcare 
and ageing, most of OA therapies are still aimed at alleviating the symptoms (pain relief 
for OA) rather than getting to the root of the problem, which is what causes the 
disease. Basic science plays a crucial role in studying cell behaviour, identifying the 
molecular pathways and mechanisms for a given condition. For research that may 
have clinical implications, it is vital that after optimising techniques, the research is 
encouraged to be performed on uncultured cells or using in vitro models (like 3D 
models using organ-on-a-chip or organoids) that can mimic the conditions in vivo. 
Acknowledgement of the fact that biomedical or healthcare research performed with 
human samples will inevitably display ‘donor variation’ in nearly every parameter being 
tested for any given experiment needs to be at the core of research investigating 
ageing and associated diseases like OA. Clinical trials may exclude a certain 




however, that might not be an option for other researchers that have access to a limited 
number of human samples. 
 
Thus, having more information about the diet, exercise, lifestyle and well-being state of 
the donors over at least the last 6 months will help researchers to link various factors 
that link ageing and OA. Ageing is inevitable and an increase in age-related diseases 
and disorders make ‘age’ an important factor in every research. To understand a 
specific disease or disorder, it is usually approached with a finite focus on the topic. 
This approach is essential to narrow down and identify molecules, factors and targets 
for potential therapy for a single disease. When it comes to multi-factorial conditions 
like ageing and OA, the research plan and experimental design should include a 
number of variables and parameters to represent much larger donor populations.  
 
For example, to investigate bone age and OA, sample collection should include not 
only bone samples but also matched sample of peripheral blood from the same donors. 
It would also include designing experiments to not only quantify a receptor (LepR) but 
also the hormone itself (Leptin) to better understand the signal transduction. The same 
should apply to IFN 1 type pathway mediators and SASP-associated molecules. To 
understand early signs of ageing and age-related differences, lifestyle data helping to 
define donor biological age would also provide essential information about potential 
causes (and potential targets) of age-related diseases. With multi-factorial conditions 
like ageing and OA a number of symptoms, parameters, genes and markers may 
overlap, increasing the complexity of the research work. Having more information will 
thus help to extrapolate markers or parameters that require further attention. 
7.5 Study novelty and contribution to the field 
The novelty of this project lies in the use of minimally-manipulated and uncultured 
human donor cells from a large number of donors and combination of a wide variety of 
genes. Biomedical research implementing the use of uncultured cells has strong 
implications and clinical relevance as it better reflects the behaviour and characteristics 
of cells in vivo. Over 50 donor samples were used for examining age-related changes 
in BM MSC numbers with minimum manipulation. Similar cohort-size investigations 
have been performed on cultured MSCs (97), but not on uncultured MSCs. This project 
was also the first of its kind to perform in depth investigation of over 100 genes in two 
uncultured and purified cell populations co-existing with the BM niche – MSCs and 
HLCs. Previous studies from our group have investigated 96 or 48 genes, but the 
cohort sizes were significantly smaller (8 donors (188) and 15 donors (516)), 





For the first time, this project evaluated colony sizes and densities to indicate MSC 
proliferation and heterogeneity in relation to donor age. Previous publications 
investigated different colony types based on sizes but not in relation to donor age (201, 
208) and colony density has never been quantified before. Also for the first time, this 
project studied IFN1 signature in human MSCs, previous studies have only focussed 
on HSCs or immune-lineage cells (335, 391, 392). For the first time, this project has 
shown considerable IRG and IFN1 receptor expression in MSCs, opening up a 
completely new research area on the role of IFN1 signalling in non-immune cells and 
MSCs in particular. At this stage, it can be only speculated that MSCs may use IFN1 
including their receptors and intracellular machinery to combat accumulating DNA 
damage and control senescence, future research is needed to further explore these 
possibilities. 
 
Apart from directing research towards expanding the existing horizon of knowledge on 
ageing and age-related risks that may eventually lead to OA, this project has also 
suggested considering both, chronological age and biological age in biomedical 
research. This project also highlighted the links between general health, ageing and 
risk of age-related OA at the MSCs level aimed at understanding the roles of MSCs in 
these processes. Discussions in each chapter outline the need for comprehensive 
research that must be performed in future to be able to pinpoint to specific factors and 
targets to better understand age-related OA. Finally, this project also provides first 
initial data that MSCs may be more resistant to ageing and damaging insults in vivo, 
compared to HLCs, thus making them a good choice for developing autologous cell 
based therapies. 
7.6 Drawbacks and study limitations 
Working with a rare population of cells without being able to expand them in culture has 
certain limitations. The low number of retrieved cells, particularly MSCs from older 
donors, was always a point of concern with respect to experimental design. As 
established in the beginning of the thesis, to understand ageing in vivo, it is important 
that the cells being used are not artificially aged in vitro. Apart from that, the high 
degree of donor-to-donor variations was something unexpected but was observed 
across all the experiments during the course of this PhD.  This meant that for many 
interesting findings, particularly in relation to gene expressions, the noted trends could 
not be confirmed statistically using the donor numbers available. However these pilot 
data provided important information on the magnitudes of differences and the 




study. These variations, even with tightly controlled within age groups suggested that 
chronological age may or may not be represent  the biological age of the person. Donor 
differences within the groups (young or old) could be explained by different donor’s 
BMIs, diet and other lifestyle factors, such information was not available for this study. 
Due to ethical approvals available, this project did not include matched blood samples, 
which could have allowed to quantify and compare levels of transcripts in BM cells with 
the corresponding proteins (like Leptin) in the circulation. Overall, only a limited number 
of molecules were investigated at both, the transcript and protein level. 
 
This project also did not perform any tests to evaluate and compare MSC differentiation 
or senescence status between young and old donors, which would be confirmatory to 
the presented gene expression data. Ideally, donor-matched comparisons could be 
done between in vitro cultured and in vivo MSCs. Looking back, quantification of genes 
and surface markers from the intermediate age group could have also been useful as 
well as having more information about the donors’ about lifestyle, medication and 
general well-being. As discussed above, lifestyle and well-being are increasingly being 
associated with age-related diseases and thus, this kind of information would be 
extremely useful in terms of understanding donors’ biological ages.  
7.7 Future Directions 
With the results obtained, it is clear that a larger cohort of patients is needed. However, 
with experiments performed in culture expanded MSCs, due to forced oxidative stress 
conditions, the results are often exaggerated. This can easily lead to scientists going 
ahead with animal studies and eventually to clinical trials, where over 50% of drugs 
have been known to fail (517, 518). It is ironical, that while this is the most exciting era 
for scientific research, biomedical and healthcare based technologies and the potential 
they hold for the future generation, it is also the era, where over 50% of all new drugs 
fail by the time they reach phase III clinical trials. It is also ironical, that even though, a 
human being lives the longest today we could have ever lived before, it also brings 
along with it the reduced quality of life after the age of 60 in most countries, globally. 
Not to forget, while there is a considerable increase in the access to different types of 
cuisines to people everywhere in the global era of networking and travel, 71% of the 
death every year is actually due to lifestyle disease which includes poor choices of diet 
and lifestyle (519).  
 
Taking this project forward would include investigation of the genes that have been 
indicated as potential ‘biomarkers’ (IL6, anti-ageing genes and IFNA receptors) down to 




(from early adulthood until old age). The last 6-months record about their diet 
(proportions of proteins, carbohydrates, fats, vitamins, minerals and water intake), 
lifestyle (drinking, smoking, exercises and medications) and well-being (questionnaires 
on personal motivation, family-friends-relationships and work life satisfaction) would be 
maintained. Further, classifying OA donors on the basis of the stage of the disease 
would be of critical importance. Comparing the levels of these indicative genes and 
proteins would aid our understanding of changes in these potential biomarkers with 
disease progression. Techniques like single cell RNA seq and the use of 3D models to 
mimic bone cells and the microenvironment (520) will further aid in investigations that 
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Appendix 1- List of donor cells used across the different arms of 
investigation in this thesis 
Table 1 Donor details for cells used in Chapter 3 
Donors Sex Age CFU-F 




PGBM002 M 19 Yes 
  PGBM003 F 63 Yes 
  PGBM004 M 56 Yes 
  PGBM005 F 37 Yes Yes 
 PGBM006 F 52 Yes 
  HOBM010 F 74 Yes 
  PGBM007 F 51 Yes 
  HOBM011 M 24 Yes Yes 
 PGBM008 M 28 Yes Yes 
 HOBM012 M 58 Yes 
  PGBM009 F 68 Yes Yes Yes 
PGBM010 F 73 Yes Yes 
 PGBM011 M 42 Yes 
  PGBM012 M 40 Yes 
  PGBM013 M 42 Yes 
  PGBM014 F 34 Yes 
 
Yes 
PGBM015 F 20 Yes 
 
Yes 
PGBM016 M 19 Yes Yes 
 PGBM017 M 46 Yes 
  PGBM018 F 72 Yes 
  PGBM019 F 72 Yes 
  KMBM020 F 46 Yes 
  JAO1 M 20 Yes 
  KMBM021 M 19 Yes Yes Yes 
HOBM013 M 58 Yes 
  PGBM020 M 49 Yes 
  KMBM027 F 23 Yes 
  PGBM021 M 22 Yes 
  PGBM022 F 49 Yes 
  PGBM023 F 67 Yes 
  PGBM024 M 42 Yes 
  PGBM025 F 38 Yes 
  PGBM026 F 69 Yes 
 
Yes 
PGBM027 F 89 Yes 
  PGBM028 F 76 Yes Yes Yes 





HOBM014 M 44 Yes 
  PGBM029 M 34 Yes 
  PGBM030 F 89 Yes 
  KMBM030 M 25 Yes Yes 
 JAO 25 F 55 Yes Yes Yes 
PGBM031 F 53 Yes 
 
Yes 
PGBM032 M 46 Yes 
  PGBM033 M 23 Yes 
  JAO039 M 26 Yes 
  PGBM034 F 36 Yes 
  HOBM018 M 78 Yes 
  PGBM036 M 54 Yes Yes 
 PGBM037 M 59 Yes Yes 
 PGBM038 F 64 Yes 
  PGBM039 M 29 Yes 
  PGBM040  F 37 Yes Yes Yes 
PGBM041 F 26 Yes 
 
Yes 
PGBM042 M 67 Yes 
  PGBM043 F 89 Yes 
  PGBM044 F 79 Yes 
      


















































Table 2 Donor details for cells used in Chapter 4 
 








PGBM005 F 37 Yes 
 
Yes 
  PGBM006 F 52 Yes 
 
Yes 
  HOBM010 F 74 Yes 
    PGBM007 F 51 Yes 
    HOBM011 M 24 Yes 
    PGBM008 M 28 Yes 
 
Yes 
  PGBM009 F 68 Yes 
    PGBM010 F 73 Yes 
 
Yes Yes Yes 
PGBM011 M 42 Yes 
    PGBM012 M 40 Yes 
    PGBM013 M 42 Yes 
    PGBM014 F 34 Yes 
    PGBM015 F 20 Yes 
    PGBM016 M 19 Yes 
 
Yes Yes Yes 
PGBM017 M 46 Yes 
    PGBM018 F 72 Yes 
    PGBM019 F 72 Yes 
    KMBM020 F 46 Yes 
    JAO1 M 20 Yes 
    KMBM021 M 19 Yes 
    HOBM013 M 58 Yes 
    PGBM020 M 49 Yes 
 
Yes Yes 
 KMBM027 F 23 Yes 
 
Yes Yes Yes 
PGBM021 M 22 Yes 
 
Yes Yes Yes 
PGBM022 F 49 Yes 
    PGBM023 F 67 Yes Yes Yes Yes Yes 
PGBM024 M 42 Yes 
    PGBM025 F 38 Yes Yes Yes Yes Yes 
PGBM026 F 69 Yes Yes Yes Yes Yes 
PGBM027 F 89 Yes Yes Yes Yes Yes 
PGBM028 F 76 Yes Yes Yes Yes Yes 
KMBM028 M 59 Yes 
    HOBM014 M 44 Yes 
    PGBM029 M 34 Yes Yes Yes Yes Yes 
PGBM030 F 89 
 
Yes Yes Yes Yes 
KMBM030 M 25 Yes Yes Yes Yes Yes 
JAO 25 F 55 Yes 
    PGBM031 F 53 Yes 
    PGBM033 M 23 
 
Yes Yes Yes Yes 
PGBM034 F 36 
 




PGBM037 M 59 Yes Yes Yes Yes Yes 
PGBM038 F 64 
  
Yes Yes Yes 
PGBM039 M 29 
 
Yes Yes Yes Yes 
PGBM042 M 67 Yes 
    PGBM047 M 65 
 
Yes 
   RCBM028 M 66 
  
Yes Yes Yes 
GCBM004 F 61 
  
Yes Yes Yes 
TRBM029 F 36 
  
Yes Yes Yes 
 
Age range: 19-89 years old, median: 47.5 years old 
 
 
Table 3 Donor details for cells used in Chapter 5 
 





PGBM005 F 37 Yes 
  PGBM006 F 52 Yes 
  PGBM008 M 28 Yes 
  PGBM010 F 73 Yes Yes Yes 
PGBM016 M 19 Yes Yes Yes 
PGBM020 M 49 Yes Yes 
 KMBM027 F 23 Yes Yes Yes 
PGBM021 M 22 Yes Yes Yes 
PGBM023 F 67 Yes Yes Yes 
PGBM025 F 38 Yes Yes Yes 
PGBM026 F 69 Yes Yes Yes 
PGBM027 F 89 Yes Yes Yes 
PGBM028 F 76 Yes Yes 
 PGBM029 M 34 Yes Yes 
 KMBM030 M 25 Yes Yes Yes 
PGBM033 M 23 Yes Yes Yes 
PGBM034 F 36 Yes Yes Yes 
PGBM037 M 59 Yes Yes Yes 
PGBM038 F 64 Yes Yes Yes 
PGBM039 M 29 Yes Yes Yes 
RCBM028 M 66 Yes Yes Yes 
GCBM004 F 61 Yes Yes Yes 
TRBM029 F 36 Yes Yes 
  









































DiFHOA003 M  74 Yes 
  DiFHOA008 F  81 Yes 
  DiFHOA014 F  56 Yes Yes Yes 
DiFHOA017 M  68 Yes Yes Yes 
DiFHOA018 F  83 Yes Yes 
 DiFHOA019 F  74 Yes Yes 
 DiFHOA021 F  72 Yes Yes 
 DiFHOA022 F  60 Yes Yes Yes 
DiFHOA024 F  79 Yes Yes Yes 
DiFHOA025 F  79 Yes Yes Yes 
DiFHOA026 M  68 Yes Yes Yes 
DiFHOA027 M  67 Yes Yes 
 DiFHOA029 M  82 Yes Yes Yes 
 
 




Appendix 2 – List of reagents, consumables, equipments, softwares, 
solutions and Taqman probes used throughout the thesis 
Table 1 List of reagents used throughout the thesis  
 
 
Tissue culture Company 
Ammonium Chloride Stem cells Technologies 
Anti-fibroblast beads MACS Miltenyi Biotec 




FCS Thermo Fisher 
Formaldehyde Sigma 
MACSelect LNGFR beads MACS Miltenyi Biotec 
Methylene blue Sigma  
PBS Sigma 
Penicillin/Streptomycin Thermo Fisher 
RosetteSep cocktail Stem Cells Technologies 
StemMACS MSC expansion medium MACS Miltenyi Biotec 
Trypan blue Sigma 
Trypsin Sigma 
  Flow cytometry/FACS Company 
7-AAD BD Pharmigen 
Blocking buffer Sigma 
BSA Sigma  
CD106 PE BD Pharmigen 
CD146 PE BD Pharmigen 
CD271 APC MACS Miltenyi Biotec 
CD271 PeVio770 MACS Miltenyi Biotec 
CD295 APC BD Pharmigen 
CD45 PE-Cy7 BD Pharmigen 
CD45 V450 BD Pharmigen 
IgG1 PE BD Pharmigen 
IgG2a APC BD Pharmigen 
IgG2b APC R & D systems 
IgG1 PE Vio 770 MACS Miltenyi Biotec 
CellROX (FITC) Thermo Fisher 
Connexin43 APC R & D systems 
Countbright absolute counting beads Life Technologies 
FCR MACS Miltenyi Biotec 






Assay loading buffer Fluidigm 
Elution solution Norgen Biotek 
Nuclease free water Thermo Fisher 
PA master mix Fluidigm 
RL Buffer (lysis buffer) Norgen Biotek 
RNAse away  Thermo Fisher 
Rt mastermix Fluidigm 
Sample loading buffer Fluidigm 
Single cell RNA purfication kit  Norgen Biotek 
Taqman Universal master mix Thermo Fisher 














































Table 2 List of consumables used throughout the thesis  
 
Tissue culture Company 
Cell strainer (70m) BD Falcon 
Cryo vials (1.8ml) Thermo Scientific 
EDTA tubes (4ml) VACUETTE, Griener Bio-one 
Falcon tubes (15 and 50 ml) Corning 
Mr Frosty Freezing container Thermo Scientific 
Petri dishes (60 and 100mm) Corning 
Pipette Tips (10, 200 and 1000l) Rainin 
Stripettes (5,10 and 25ml) Corning 
  Flow cytometry/FACS Company 
FACS tubes Corning 
Magnetic columns and plunger MACS Miltenyi Biotec 
Tubes with cell strainers BD 
  qPCR Company 
48.48 dynamic array IFC Fluidigm 
Collection tubes Norgen Biotek 
Control line fluid Fluidigm 
Eppendorfs (0.5-1.5ml) Eppendorf 
Flex SixTM gene expression IFC Fluidigm 
RNA elution tubes Norgen Biotek 































Table 3 List of equipments used throughout the thesis  
 
 
Tissue culture Company 
Centrifuge  Eppendorf 
Class II laminar flow biological safety 
cabinet Nuaire 
CO2 Incubator  Incusafe 
Freezer (-80°C) New Brunswick Scientific 
Haemocytometer Improved Neubauer, Hawksley 
Infinity 1 Camera Lumenera 
MACS separator MACS Miltenyi Biotec 
MACS stand MACS Miltenyi Biotec 
Microscope (Scanner) Infinity 1, L3200B 
Microscope (TC) Olympus CKX41 
Nanodrop Spectrophotometer Nanodrop 
Pipetteboy Integra 
Scanner Epson perfection 3590 photo 
Water bath Leica 
  Flow cytometry/FACS Company 
Influx 6 way cell sorter BD Biosciences 
LSRII flow cytometer BD Pharmigen 
Pipettes Gilson 
  qPCR Company 
Biomark HD system Fluidigm 
IFC controller HX Fluidigm 



























Table 4 List of softwares used throughout the thesis  
 
Softwares Company 
Cluster 3.0 Open source 
Data collection software Biomark 
FACS Diva 5.02 BD Biosciences 
FlowJo BD Biosciences 
GraphPad Prism (version 7.0a) GraphPad Software, Inc. 
ImageJ ImageJ 
Infinity analyze and capture Lumenera 
Real-time PCR analysis Biomark 









17.89g NH4Cl + 2g KCl + 400l  0.5M EDTA 
+200ml distilled Water, pH=8.0 
FACS buffer 
500ml PBS + 0.1%BSA + 0.01%Sodium Azide 
+ 200l of Na EDTA 
Formaldehyde (3.7%) 1ml of 37%formaldehyde + 9 ml PBS 
Freezing medium 10%DMSO + 45%FCS + 45%DMEM 
MACS buffer 500ml PBS+  0.1%BSA + EDTA (2ml) 
Methylene blue 
1%Methylene Blue in10mM borate buffer, 
pH=8.8 
Thawing medium DMEM+10%FCS + 80l DNAse for 50ml  

































Age-related changes in the number of CFU-Fs in males (top panel) and females 
(bottom panel) 
(A) Age-related change in the number of CFU-F per ml of BMA across entire donor age 
range in males and (B) in between age groups. (C) Age-related change in the number 
of CFU-F per ml of BMA across entire donor age range in females and (D) in between 
age groups.  Each dot indicates individual donor, black dots represent male donors and 
empty circles represent female donors. The black line on the left indicates the slope 
and the on the right, the median values. Spearman non-parametric test was performed 













Appendix 4 List of tables indicating expression of exploratory genes 
from Chapter 5 and 6 
All the data was normalised with HPRT1. p<0.05, p<0.01, p<0.001 and p<0.0001, 
Mann-Whitney U test. NA: not-applicable, NS: non-significant 
 
Table 5.1 Medians of expression of exploratory genes in all (young and old 









(MSCs/HLCs) p value 
ABCA1 1.17 0.24 4.88 0.0249 
ABCG1 ND 0.058 NA NA 
AICDA ND 0.009 NA NA 
BST2 12.06 4.97 2.43 0.0083 
CASP1 3.06 6.16 0.50 0.0205 
CCL8 0.22 0.072 3.03 0.0591 
CCND2 2.36 0.41 5.68 0.0013 
CEACAM 0.31 0.007 44.29 0.0021 
CHMP5 2.41 0.7 3.44 NS 
CXCL10 0.25 0.40 0.61 NS 
EPSTI1 1.59 0.57 2.79 0.0045 
EIF2AK2 3.81 0.95 3.98 0.0023 
FCGR1B 0.19 1.04 0.18 0.0031 
GBP1 3.4 1.375 2.47 0.078 
GUSB 2.66 3.39 0.78 NS 
HERC5 0.36 0.2 1.80 0.0188 
HPSE 0.09 0.73 0.13 0.0171 
IFI6 3.285 0.438 7.5 0.0145 
IFI16 1.66 0.81 2.06 0.0068 
IFI27 1.55 0.01 155.10 <0.0001 
IFI35 2.68 0.76 3.53 0.0387 
IFI44 3.1 1.01 3.07 0.0205 
IFI44L 1.50 0.31 4.86 0.008 
IFIH1 0.45 0.17 2.65 0.0106 
IFIT1 9.13 3.70 2.46 NS 
IFIT2 1.53 2.67 0.57 NS 
IFIT3 2.69 1.86 1.45 NS 
IFIT5 0.63 0.11 5.75 0.0284 
IFITM1 75.05 6.33 11.86 0.0005 
IFITM3 137.9 3.79 36.39 <0.0001 
IFNG ND ND NA NA 
IL7R 0.09 0.18 0.51 NS 
IRF2 2.48 1.83 1.36 0.0372 
IRF5 0.12 1.28 0.10 0.0157 
IRF7 4.73 4.97 0.95 NS 




ISG15 0.38 0.55 0.69 NS 
ISG20 0.39 1.12 0.35 NS 
LAIR1 0.43 1.4 0.31 0.0278 
LAMP3 ND ND NA NA 
LRP1 48.92 4.03 12.14 0.0007 
LSCR1 4.12 0.99 4.13 0.0068 
LY6E 24.58 2.4 10.24 <0.0001 
MSR1 0.11 0.20 0.53 NS 
MX1 2.889 1.71 1.69 NS 
NT5C3B 0.56 0.16 3.52 0.0018 
OAS1 0.61 0.13 4.66 NS 
OAS2 1.19 0.67 1.78 0.059 
OAS3 2.55 0.7 3.64 0.0121 
OASL 1.01 0.22 4.61 0.0284 
PHF11 1.79 0.98 1.82 0.0242 
PPIA 14.26 13.66 1.04 NS 
PRDM1 0.51 1.72 0.30 0.0148 
PRDM16 0.18 0.0017 105.29 0.042 
PRKRA 0.87 0.27 3.16 NS 
RGS1 0.621 32.29 0.02 0.0184 
RNF213 3.47 2.64 1.31 NS 
RSAD2 0.43 0.13 3.30 0.0169 
RTP4 0.96 0.08 12.00 0.0036 
SAMD9L 1.67 0.642 2.60 0.0387 
SCARB1 0.59 0.349 1.69 NS 
SERPING 22 0.09 233.30 0.0003 
SIGLEC1 0.13 0.38 0.34 0.0782 
SOCS1 2.55 0.46 5.55 0.0003 
SP100 6.78 3.86 1.76 0.049 
SPATS2L 3.50 0.40 8.66 0.0001 
TAP1 2.23 1.64 1.36 NS 
TGFB 2.93 5.35 0.55 0.0205 
TLR4 1.42 1.44 0.99 NS 
TNF 0.17 3.67 0.05 0.013 
TNFRSRP1 1.043 2.62 0.40 0.0512 
TRIM38 0.793 0.62 1.27 NS 
UBE2L6 11.86 4.5 2.64 0.0083 
UNC93B 2.08 2.75 0.76 NS 
USP18 0.35 0.02 17.50 <0.0001 


















Table 5.2 Medians of expression of exploratory genes between young and old 









(old/young) p value 
ABCA1 1.11 2.78 2.51 NS 
ABCG1 ND ND NA NA 
AICDA ND ND NA NA 
BST2 12.06 14.6 1.21 NS 
CASP1 3.23 3.05 0.94 NS 
CCL8 0.21 0.26 1.22 NS 
CCND2 2.36 3.57 1.52 NS 
CEACAM 0.1 0.35 3.50 NS 
CHMP5 3.10 1.66 0.54 NS 
CXCL10 0.56 0.16 0.29 NS 
EPSTI1 1.59 1.69 1.06 NS 
EIF2AK2 3.48 3.8 1.09 NS 
FCGR1B 0.05 0.27 5.00 NS 
GBP1 3.173 3.4 1.07 NS 
GUSB 2.98 2.33 0.78 NS 
HERC5 0.53 0.34 0.64 NS 
HPSE 0.11 0.08 0.80 NS 
IFI6 4.36 2.57 0.59 NS 
IFI16 1.54 1.76 1.14 NS 
IFI27 1.26 2.06 1.63 NS 
IFI35 2.68 2.11 0.79 NS 
IFI44 3.83 2.71 0.71 NS 
IFI44L 1.54 1.42 0.92 NS 
IFIH1 0.45 0.43 0.96 NS 
IFIT1 7.04 10.06 1.43 NS 
IFIT2 1.33 1.68 1.26 NS 
IFIT3 1.78 3.4 1.91 NS 
IFIT5 0.63 0.55 0.87 NS 
IFITM1 75.05 81.38 1.08 NS 
IFITM3 139.4 111.9 0.80 NS 
IFNG ND ND NA NA 
IL7R 0.22 0.05 0.24 NS 
IRF2 2.48 2.23 0.90 NS 
IRF5 0.11 0.42 3.91 NS 
IRF7 4.73 4.13 0.87 NS 
IRF9 1.70 1.35 0.79 NS 
ISG15 0.42 0.28 0.67 NS 
ISG20 0.51 0.35 0.69 NS 
LAIR1 0.8 0.43 0.54 NS 




LRP1 50.97 38.69 0.76 NS 
LSCR1 4.11 6.41 1.56 NS 
LY6E 24.58 21.34 0.87 NS 
MSR1 0.12 0.05 0.45 NS 
MX1 2.89 2.9 1.00 NS 
NT5C3B 0.47 0.67 1.41 NS 
OAS1 0.68 0.58 0.85 NS 
OAS2 1.52 0.88 0.58 NS 
OAS3 2.72 1.79 0.66 NS 
OASL 1.09 0.82 0.75 NS 
PHF11 2.10 1.76 0.84 NS 
PPIA 15.94 12.03 0.75 NS 
PRDM1 0.21 0.66 3.14 NS 
PRDM16 0.29 0.17 0.6 NS 
PRKRA 0.79 1.1 1.39 NS 
RGS1 0.62 6.11 9.85 NS 
RNF213 4.52 1.88 0.42 0.0411 
RSAD2 0.394 0.47 1.19 NS 
RTP4 0.96 0.71 0.74 NS 
SAMD9L 1.83 0.90 0.50 NS 
SCARB1 0.80 0.20 0.25 NS 
SERPING 21.95 22.85 1.04 NS 
SIGLEC1 0.20 0.13 0.65 NS 
SOCS1 3.79 2.13 0.56 NS 
SP100 6.75 6.78 1.00 NS 
SPATS2L 4.09 3.38 0.83 NS 
TAP1 2.11 2.53 1.20 NS 
TGFB 3.35 2.59 0.77 NS 
TLR4 1.2 2.16 1.80 NS 
TNF 1.58 0.155 0.10 NS 
TNFRSRP1 1.37 0.76 0.55 NS 
TRIM38 0.80 0.73 0.91 NS 
UBE2L6 11.26 12.94 1.15 NS 
UNC93B 2 2.21 1.105 NS 
USP18 0.31 0.36 1.16 NS 























Table 5.3 Medians of expression of exploratory genes between young and old 









(old/young) p value 
ABCA1 0.53 0.16 0.30 NS 
ABCG1 0.07 0.03 0.43 0.0649 
AICDA 0.009 0.01 1.11 NS 
BST2 6.29 3.24 0.51 NS 
CASP1 7.18 4.77 0.66 NS 
CCL8 0.09 0.03 0.42 NS 
CCND2 0.85 0.291 0.34 NS 
CEACAM 0.008 0.003 0.38 0.0667 
CHMP5 0.87 0.63 0.72 NS 
CXCL10 0.58 0.18 0.31 0.0667 
EPSTI1 0.58 0.51 0.88 NS 
EIF2AK2 0.80 1.05 1.30 NS 
FCGR1B 1.05 1.55 1.48 NS 
GBP1 1.67 1.33 0.80 NS 
GUSB 4.49 2.57 0.57 NS 
HERC5 0.22 0.18 0.82 NS 
HPSE 0.73 0.66 0.91 NS 
IFI6 0.87 0.76 0.87 NS 
IFI16 0.31 0.55 1.77 NS 
IFI27 0.014 0.008 0.57 NS 
IFI35 0.93 0.50 0.54 0.0649 
IFI44 1.01 0.87 0.86 NS 
IFI44L 0.31 0.33 1.06 NS 
IFIH1 0.19 0.16 0.84 NS 
IFIT1 2.17 5.73 2.64 NS 
IFIT2 2.51 2.76 1.10 NS 
IFIT3 1.76 1.86 1.06 NS 
IFIT5 0.12 0.058 0.47 0.0411 
IFITM1 18.32 2.22 0.12 NS 
IFITM3 7.15 3.45 0.48 NS 
IFNG ND ND NA NA 
IL7R 0.49 0.09 0.20 0.026 
IRF2 2.09 1.11 0.53 0.0043 
IRF5 1.59 1.08 0.68 NS 
IRF7 6.37 4.97 0.78 NS 
IRF9 1.52 0.62 0.41 0.026 
ISG15 0.4 0.6 1.50 NS 
ISG20 1.18 0.83 0.70 NS 




LAMP3 ND ND NA NA 
LRP1 4.65 2.73 0.59 NS 
LSCR1 1.29 0.65 0.50 NS 
LY6E 2.91 1.8 0.62 NS 
MSR1 0.177 0.318 1.80 NS 
MX1 1.71 2.13 1.25 NS 
NT5C3B 0.23 0.09 0.41 NS 
OAS1 0.35 0.05 0.15 NS 
OAS2 0.69 0.22 0.32 NS 
OAS3 0.9 0.49 0.54 NS 
OASL 0.22 0.26 1.18 NS 
PHF11 0.77 1.20 1.55 NS 
PPIA 16.08 12.35 0.77 NS 
PRDM1 2.35 1.4 0.60 NS 
PRDM16 0.0012 ND NA NA 
PRKRA 0.97 0.2 0.21 0.0152 
RGS1 28.47 32.29 1.13 NS 
RNF213 3.01 1.75 0.58 NS 
RSAD2 0.13 0.12 0.92 NS 
RTP4 0.15 0.05 0.33 0.0152 
SAMD9L 0.86 0.47 0.55 NS 
SCARB1 0.431 0.131 0.30 0.0087 
SERPING 0.10 0.08 0.80 NS 
SIGLEC1 0.38 0.35 0.92 NS 
SOCS1 0.72 0.33 0.46 NS 
SP100 4.43 3.27 0.74 NS 
SPATS2L 0.47 0.37 0.79 NS 
TAP1 1.429 1.65 1.15 NS 
TGFB 6.42 4.64 0.72 NS 
TLR4 1.87 0.92 0.49 NS 
TNF 2.98 3.66 1.23 NS 
TNFRSRP1 2.69 2.62 0.97 NS 
TRIM38 0.58 0.68 1.17 NS 
UBE2L6 5.04 4.26 NS NS 
UNC93B 2.9 2.31 0.80 NS 
USP18 0.027 0.025 0.93 NS 






















Table 6.1 Medians of expression of exploratory genes between old donors and 











ABCA1 2.78 2.88 1.04 NS 
ABCG1 0.02 0.21 12.35 NS 
AICDA ND ND NA NA 
BST2 14.60 1.36 0.09 0.0047 
CASP1 3.04 0.53 0.17 0.0012 
CCL8 0.25 0.12 0.48 NS 
CCND2 3.57 2.43 0.68 NS 
CEACAM 0.35 0.02 0.06 0.0221 
CHMP5 1.66 1.78 1.07 NS 
CXCL10 0.16 0.63 3.94 NS 
EPSTI1 1.69 0.31 0.18 0.035 
EIF2AK2 3.81 1.72 0.45 NS 
FCGR1B 0.27 0.00 0.01 0.0476 
GBP1 3.40 3.30 0.97 NS 
GUSB 2.34 0.67 0.29 0.035 
HERC5 0.34 0.20 0.59 NS 
HPSE 0.08 0.06 0.75 NS 
IFI6 2.57 1.45 0.56 NS 
IFI16 1.76 1.16 0.66 NS 
IFI27 2.15 0.82 0.38 0.014 
IFI35 2.11 1.29 0.61 NS 
IFI44 2.71 0.60 0.22 0.0047 
IFI44L 1.43 0.35 0.25 0.0047 
IFIH1 0.42 0.28 0.67 NS 
IFIT1 10.06 3.90 0.39 NS 
IFIT2 1.68 0.64 0.38 NS 
IFIT3 3.40 0.51 0.15 0.014 
IFIT5 0.55 0.26 0.47 NS 
IFITM1 81.38 8.52 0.10 0.014 
IFITM3 111.90 11.60 0.10 0.014 
IFNG ND ND NA NA 
IL7R 0.05 0.19 3.66 NS 
IRF2 2.23 1.11 0.50 NS 
IRF5 0.42 0.01 0.02 NS 
IRF7 4.13 2.48 0.60 NS 
IRF9 1.35 0.88 0.65 NS 
ISG15 0.28 1.56 5.57 NS 
ISG20 0.35 1.17 3.34 0.0424 




LAMP3 ND ND NA NA 
LRP1 38.69 8.00 0.21 0.0221 
LSCR1 6.41 2.04 0.32 NS 
LY6E 21.34 4.07 0.19 0.0152 
MSR1 0.06 0.11 2.00 NS 
MX1 2.90 1.66 0.57 NS 
NT5C3B 0.67 0.37 0.55 NS 
OAS1 0.58 0.23 0.39 NS 
OAS2 0.88 0.30 0.34 NS 
OAS3 1.80 0.54 0.30 0.014 
OASL 0.82 0.79 0.96 NS 
PHF11 1.76 0.81 0.46 NS 
PPIA 12.03 9.65 0.80 NS 
PRDM1 0.66 0.71 1.08 NS 
PRDM16 0.17 0.11 0.65 NS 
PRKRA 1.10 0.82 0.74 NS 
RGS1 6.12 0.18 0.03 NS 
RNF213 1.88 4.07 2.16 NS 
RSAD2 0.47 0.33 0.70 NS 
RTP4 0.71 0.12 0.17 0.0221 
SAMD9L 0.91 0.58 0.64 NS 
SCARB1 0.20 0.24 1.20 NS 
SERPING 22.85 8.80 0.39 0.0513 
SIGLEC1 0.13 0.01 0.06 NS 
SOCS1 2.13 0.76 0.36 NS 
SP100 6.78 2.99 0.44 NS 
SPATS2L 3.82 2.12 0.55 NS 
TAP1 2.53 1.27 0.50 0.0513 
TGFB 2.59 2.90 1.12 NS 
TLR4 2.16 0.88 0.41 NS 
TNF 0.16 0.60 3.88 NS 
TNFRSRP1 0.76 0.65 0.86 NS 
TRIM38 0.73 0.83 1.14 NS 
UBE2L6 12.94 2.08 0.16 0.014 
UNC93B 2.21 2.37 1.07 NS 
USP18 0.36 0.06 0.17 0.0082 

















Table 6.2 Medians of expression of exploratory genes between old donors and 











ABCA1 0.17 0.59 3.51 0.035 
ABCG1 0.03 0.17 5.28 0.0012 
AICDA 0.01 0.00 0.06 NS 
BST2 3.24 1.44 0.44 0.035 
CASP1 4.77 1.01 0.21 0.0023 
CCL8 0.04 0.02 0.61 NS 
CCND2 0.29 2.29 7.90 0.0022 
CEACAM 0.00 0.01 2.00 NS 
CHMP5 0.60 0.21 0.34 NS 
CXCL10 0.19 0.11 0.58 NS 
EPSTI1 0.51 0.34 0.67 NS 
EIF2AK2 1.05 0.96 0.92 NS 
FCGR1B 1.55 0.07 0.04 0.0012 
GBP1 1.34 0.85 0.63 NS 
GUSB 2.57 0.72 0.28 0.0047 
HERC5 0.18 0.22 1.22 NS 
HPSE 0.66 0.16 0.24 NS 
IFI6 0.55 0.48 0.87 NS 
IFI16 0.76 0.56 0.74 NS 
IFI27 0.01 0.07 8.75 0.0051 
IFI35 0.51 0.29 0.57 NS 
IFI44 0.87 0.37 0.43 NS 
IFI44L 0.33 0.16 0.48 NS 
IFIH1 0.17 0.20 1.20 NS 
IFIT1 5.73 1.50 0.26 0.0734 
IFIT2 2.76 0.49 0.18 0.0513 
IFIT3 1.86 0.76 0.41 NS 
IFIT5 0.06 0.13 2.19 NS 
IFITM1 2.22 9.11 4.10 0.0734 
IFITM3 3.45 2.47 0.72 NS 
IFNG 0.07 1.29 17.42 0.0177 
IL7R 0.09 2.89 32.11 0.0012 
IRF2 1.11 0.65 0.59 NS 
IRF5 1.08 0.14 0.13 0.0012 
IRF7 4.98 3.19 0.64 NS 
IRF9 0.63 0.35 0.56 NS 
ISG15 0.59 0.47 0.80 NS 
ISG20 0.83 5.08 6.12 0.0012 
LAIR1 1.40 0.61 0.44 0.014 
LAMP3 0.01 0.49 40.67 0.0023 
LRP1 2.73 0.31 0.11 NS 
LSCR1 0.65 0.81 1.25 NS 




MSR1 0.31 0.18 0.58 NS 
MX1 2.13 1.68 0.79 NS 
NT5C3B 0.09 0.07 0.78 NS 
OAS1 0.05 0.02 0.44 NS 
OAS2 0.22 0.44 2.00 NS 
OAS3 0.49 0.65 1.33 NS 
OASL 0.26 0.74 2.85 0.035 
PHF11 1.21 0.86 0.71 NS 
PPIA 12.35 7.68 0.62 NS 
PRDM1 1.40 3.60 2.57 0.0221 
PRDM16 ND ND NA NA 
PRKRA 0.20 0.21 1.05 NS 
RGS1 32.29 21.98 0.68 NS 
RNF213 1.75 2.23 1.27 NS 
RSAD2 0.12 0.32 2.63 NS 
RTP4 0.05 0.03 0.58 NS 
SAMD9L 0.47 0.31 0.66 NS 
SCARB1 0.13 0.05 0.38 NS 
SERPING 0.09 0.09 1.00 NS 
SIGLEC1 0.35 0.09 0.25 0.0087 
SOCS1 0.33 1.03 3.11 NS 
SP100 3.28 2.50 0.76 NS 
SPATS2L 0.37 0.32 0.85 NS 
TAP1 1.65 1.81 1.10 NS 
TGFB 4.64 13.23 2.85 0.014 
TLR4 0.92 0.16 0.17 0.0513 
TNF 3.66 2.16 0.59 NS 
TNFRSRP1 2.62 4.96 1.89 NS 
TRIM38 0.68 0.24 0.35 NS 
UBE2L6 4.26 1.58 0.37 0.035 
UNC93B 2.32 0.51 0.22 0.0012 
USP18 0.03 0.03 1.12 NS 
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